



# **Mozambique**

## **Country Operational Plan**

### **FY 2015**



## Budget Summary Reports

### Summary of Planned Funding by Agency and Funding Source

| Agency   | Funding Source |             |           | Funding Source Total | Applied Pipeline |
|----------|----------------|-------------|-----------|----------------------|------------------|
|          | GAP            | GHP-State   | GHP-USAID |                      |                  |
| DOD      |                | 4,487,251   |           | 4,487,251            | 0                |
| HHS/CDC  | 3,075,000      | 173,876,238 |           | 176,951,238          | 0                |
| HHS/HRSA |                | 3,758,333   |           | 3,758,333            | 0                |
| PC       |                | 3,098,458   |           | 3,098,458            | 0                |
| State    |                | 1,695,590   |           | 1,695,590            | 0                |
| State/AF |                | 2,350,000   |           | 2,350,000            | 0                |
| USAID    |                | 138,182,632 |           | 138,182,632          | 6,552,407        |
| Total    | 3,075,000      | 327,448,502 | 0         | 330,523,502          | 6,552,407        |

### Summary of Planned Funding by Budget Code and Agency

| Budget Code | Agency  |           |            |           |           |           |            | On Hold Amount | Total       |
|-------------|---------|-----------|------------|-----------|-----------|-----------|------------|----------------|-------------|
|             | State   | DOD       | HHS/CDC    | HHS/HRSA  | PC        | State/AF  | USAID      |                |             |
| CIRC        |         | 2,545,461 | 19,791,313 | 350,000   |           |           | 4,522,583  | 0              | 27,209,357  |
| HBHC        | 228,624 | 398,102   | 16,686,578 |           | 47,210    | 260,000   | 17,336,651 | 0              | 34,957,165  |
| HKID        | 135,386 |           | 531,143    | 450,000   | 158,255   | 360,000   | 20,846,568 | 0              | 22,481,352  |
| HLAB        |         |           | 5,799,169  | 200,000   |           | 1,600,000 | 0          | 0              | 7,599,169   |
| HMBL        |         |           | 741,907    |           |           |           |            | 0              | 741,907     |
| HMIN        |         | 0         |            |           |           |           |            | 0              | 0           |
| HTXD        |         |           | 57,096     |           |           |           | 31,500,000 | 0              | 31,557,096  |
| HTXS        | 31,930  | 1,388,087 | 70,471,995 | 1,278,333 | 11,922    |           | 35,229,339 | 0              | 108,411,606 |
| HVAB        | 6,385   |           |            |           |           | 50,000    | 0          | 0              | 56,385      |
| HVCT        | 12,771  | 0         | 11,951,724 | 230,000   |           |           | 3,062,717  | 0              | 15,257,212  |
| HVMS        | 906,272 | 102,746   | 8,787,164  |           | 2,548,800 |           | 1,347,593  | 0              | 13,692,575  |
| HVOP        | 144,326 | 0         | 1,906,911  |           | 332,271   | 50,000    | 1,905,293  | 0              | 4,338,801   |



|      |           |           |             |           |           |           |             |   |             |
|------|-----------|-----------|-------------|-----------|-----------|-----------|-------------|---|-------------|
| HVSI | 127,723   | 0         | 5,361,848   |           |           |           | 1,806,000   | 0 | 7,295,571   |
| HVTB | 19,157    | 52,855    | 4,730,232   |           |           |           | 1,677,239   | 0 | 6,479,483   |
| MTCT | 6,385     |           | 12,796,730  | 230,000   |           |           | 5,337,042   | 0 | 18,370,157  |
| OHSS | 12,771    | 0         | 3,437,639   | 100,000   |           | 30,000    | 10,941,121  | 0 | 14,521,531  |
| PDCS | 31,930    |           | 3,488,073   |           |           |           | 792,947     | 0 | 4,312,950   |
| PDTX | 31,930    |           | 10,411,716  | 920,000   |           |           | 1,877,539   | 0 | 13,241,185  |
|      | 1,695,590 | 4,487,251 | 176,951,238 | 3,758,333 | 3,098,458 | 2,350,000 | 138,182,632 | 0 | 330,523,502 |



## Technical Areas

### Technical Area Summary

#### Technical Area: Care

| Budget Code                                  | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HBHC   | 34,002,268                 | 0              |
| HKID   | 22,268,568                 | 0              |
| HVTB   | 6,254,743                  | 0              |
| PDCS   | 4,135,676                  | 0              |
| <b>Total Technical Area Planned Funding:</b> | <b>66,661,255</b>          | <b>0</b>       |

#### Technical Area: Governance and Systems

| Budget Code                                  | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HLAB   | 7,350,000                  | 0              |
| HVSI   | 6,326,896                  | 0              |
| OHSS   | 14,301,121                 | 0              |
| <b>Total Technical Area Planned Funding:</b> | <b>27,978,017</b>          | <b>0</b>       |

#### Technical Area: Prevention

| Budget Code                         | Budget Code Planned Amount | On Hold Amount |
|-------------------------------------|----------------------------|----------------|
| CIRC                                | 26,882,063                 | 0              |
| HMBL                                | 690,000                    | 0              |
| HMIN                                | 0                          | 0              |
| HVAB                                | 50,000                     | 0              |
| HVCT                                | 15,062,756                 | 0              |
| HVOP                                | 4,036,143                  | 0              |
| MTCT                                | 18,197,663                 | 0              |
| <b>Total Technical Area Planned</b> | <b>64,918,625</b>          | <b>0</b>       |



|                 |  |  |
|-----------------|--|--|
| <b>Funding:</b> |  |  |
|-----------------|--|--|

**Technical Area: Treatment**

| <b>Budget Code</b>                           | <b>Budget Code Planned Amount</b> | <b>On Hold Amount</b> |
|--|-----------------------------------|-----------------------|
| HTXD   | 31,500,000                        | 0                     |
| HTXS   | 105,691,085                       | 0                     |
| PDTX   | 13,058,721                        | 0                     |
| <b>Total Technical Area Planned Funding:</b> | <b>150,249,806</b>                | <b>0</b>              |

## Technical Area Summary Indicators and Targets

| Indicator Number | Label   | 2015    | 2016    |
|------------------|---|---------|---------|
| PMTCT_STAT_DSD   | PMTCT_STAT_DSD<br>Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD) | 100 %   |         |
|                  | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                                    | 887,747 | 568,939 |
|                  | Number of new ANC and L&D clients   | 887,747 | 541,861 |
|                  | By: Known positives at entry  | 19,554  | 17,472  |
|                  | By: Number of new positives identified  | 47,874  | 42,765  |
|                  | Sum of Positives Status disaggregates   | 67,428  | 60,237  |
|                  | Required only for DREAMS Countries - By Number of new positives: <15  |         |         |
|                  | Required only for DREAMS Countries - By Number of new positives: 15-19  |         |         |
|                  | Required only for DREAMS Countries - By Number of new positives: 20-24  |         |         |
|                  | Required only for DREAMS Countries - By Number of new positives: 25+  |         |         |

|               |  |         |         |
|---------------|--|---------|---------|
|               | Required only for DREAMS Countries - By Number of known positives: <15   |         |         |
|               | Required only for DREAMS Countries - By Number of known positives: 15-19   |         |         |
|               | Required only for DREAMS Countries - By Number of known positives: 20-24   |         |         |
|               | Required only for DREAMS Countries - By Number of known positives: 25+   |         |         |
|               | Required only for DREAMS Countries - Denominator: <15  |         |         |
|               | Required only for DREAMS Countries - Denominator: <15-19   |         |         |
|               | Required only for DREAMS Countries - Denominator: 20-24  |         |         |
|               | Required only for DREAMS Countries - Denominator: 25+  |         |         |
| PMTCT_STAT_TA | PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA) | 100 %   |         |
|               | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                               | 194,170 | 309,275 |

|  |  |         |         |
|--|--|---------|---------|
|  | Number of new ANC and L&D clients                              | 194,170 | 296,642 |
|  | By: Known positives at entry                                   | 3,354   | 1,597   |
|  | By: Number of new positives identified                         | 8,209   | 3,928   |
|  | Sum of Positives Status disaggregates                          | 11,563  | 5,525   |
|  | Required only for DREAMS countries - By known positives: <15   |         |         |
|  | Required only for DREAMS countries - By known positives: 15-19 |         |         |
|  | Required only for DREAMS countries - By known positives: 20-24 |         |         |
|  | Required only for DREAMS countries - By known positives: 25+   |         |         |
|  | Required only for DREAMS countries - By new positives: <15     |         |         |
|  | Required only for DREAMS countries - By new positives: 15-19   |         |         |
|  | Required only for DREAMS countries - By new positives: 20-24   |         |         |
|  | Required only for DREAMS countries - By new positives: 25+     |         |         |
|  | Required only for DREAMS countries - Denominator: <15          |         |         |
|  | Required only for DREAMS countries - Denominator:              |         |         |



|               |  |        |        |
|---------------|--|--------|--------|
|               | 15-19  |        |        |
|               | Required only for DREAMS countries - Denominator: 20-24  |        |        |
|               | Required only for DREAMS countries - Denominator: 25+  |        |        |
| PMTCT_ARV_DSD | PMTCT_ARV_DSD<br>Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD) | 98 %   |        |
|               | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery                             | 66,292 | 60,237 |
|               | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)  | 67,429 | 60,237 |
|               | Life-long ART (including Option B+)  | 64,964 |        |
|               | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 44,102 | 36,150 |
|               | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 18,902 | 24,087 |
|               |  |        |        |

|              |  |        |        |
|--------------|--|--------|--------|
|              | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)   |        |        |
|              | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 1,326  |        |
|              | Single-dose nevirapine (with or without tail)  |        | 0      |
|              | Sum of Regimen Type disaggregates  | 66,290 | 0      |
|              | Sum of New and Current disaggregates   | 63,004 | 60,237 |
| PMTCT_ARV_TA | PMTCT_ARV_TA<br>Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA) | 97 %   |        |
|              | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery                           | 11,236 | 13,790 |
|              | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)  | 11,562 | 5,525  |

|             |   |        |        |
|-------------|---|--------|--------|
|             | Life-long ART (including Option B+)   | 8,625  |        |
|             | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy   | 7,413  | 8,265  |
|             | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy  | 3,176  | 5,525  |
|             | Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)                        | 2,614  |        |
|             | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)  |        |        |
|             | Single-dose nevirapine (with or without tail)   |        | 0      |
|             | Sum of Regimen Type disaggregates   | 11,239 | 0      |
|             | Sum of New and Current disaggregates  | 10,589 | 13,790 |
| VMMC_AE_DSD | Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs) |        | 2,445  |
|             | By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)                               |        |        |
|             | Sub-Disag: Surgical   |        |        |

|  |  |  |  |
|--|--|--|--|
|  | intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)                     |  |  |
|  | Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)   |  |  |
|  | By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)   |  |  |
|  | Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s) |  |  |
|  | Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)   |  |  |
|  | By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)  |  |  |
|  | Sub-Disag: By Medical  |  |  |

|               |   |         |         |
|---------------|---|---------|---------|
|               | device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s) |         |         |
|               | Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more severe medical device-related AE(s)                         |         |         |
| VMMC_CIRC_DSD | Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period                          | 296,298 | 271,537 |
|               | By Age: <1  |         | 0       |
|               | By Age: 1-9   |         | 0       |
|               | By Age: 10-14   | 118,520 | 81,461  |
|               | By Age: 15-19   | 88,889  | 81,461  |
|               | By Age: 20-24   | 59,260  | 67,885  |
|               | By Age: 25-29   |         | 27,155  |
|               | By Age: 30-49   |         | 13,581  |
|               | By Age: 50+   | 5,925   | 0       |
|               | Sum of age disaggregates  | 296,298 | 230,807 |
|               | By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)  |         | 3,505   |
|               | By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)   |         | 267,927 |

|             |   |         |         |
|-------------|---|---------|---------|
|             | By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site   |         | 111     |
|             | By circumcision technique: Surgical VMMC  |         | 271,537 |
|             | By circumcision technique: Device-based VMMC  |         | 0       |
|             | By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery                          |         | 244,382 |
|             | By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery                                  |         | 27,155  |
| PP_PREV_DSD | PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD) | n/a     |         |
|             | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.                      | 139,813 |         |
|             | Total number of people in the target population   |         |         |

|            |  |         |         |
|------------|--|---------|---------|
|            | Age/sex: 10-14 Male  | 10,904  |         |
|            | Age/sex: 15-19 Male  | 16,779  |         |
|            | Age/sex: 20-24 Male  | 8,528   |         |
|            | Age/sex: 25-49 Male  | 7,411   |         |
|            | Age/sex: 50+ Male  | 981     |         |
|            | Age/sex: 10-14 Female  | 27,263  |         |
|            | Age/sex: 15-19 Female  | 45,300  |         |
|            | Age/sex: 20-24 Female  | 20,270  |         |
|            | Age/sex: 25-49 Female  | 2,377   |         |
|            | Age/sex: 50+ Female  |         |         |
|            | Sum of Age/Sex disaggregates   | 139,813 |         |
|            |  |         |         |
| PP_PREV_TA | PP_PREV_TA Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (TA-only) | n/a     |         |
|            | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.                         |         | 131,436 |
|            | Total number of people in the target population  |         |         |
|            | Age/sex: 10-14 Male  |         | 10,253  |
|            | Age/sex: 15-19 Male  |         | 15,773  |
|            | Age/sex: 20-24 Male  |         | 8,020   |
|            | Age/sex: 25-49 Male  |         | 6,966   |
|            | Age/sex: 50+ Male  |         | 918     |
|            | Age/sex: 10-14 Female  |         | 25,631  |
|            | Age/sex: 15-19 Female  |         | 42,584  |

|             |   |        |         |
|-------------|---|--------|---------|
|             | Age/sex: 20-24 Female   |        | 19,059  |
|             | Age/sex: 25-49 Female   |        | 2,237   |
|             | Age/sex: 50+ Female   |        | 0       |
|             | Sum of Age/Sex disaggregates  |        | 131,441 |
| KP_PREV_DSD | KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)   | n/a    |         |
|             | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required   | 36,057 | 38,965  |
|             | Total estimated number of key population in the catchment area  |        |         |
|             | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 27,848 | 25,501  |
|             | By key population type: Males who inject drugs ( Male PWID) (Numerator:   | 135    |         |
|             |   |        |         |



|  |   |       |        |
|--|---|-------|--------|
|  | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)  |       |        |
|  | By key population type:<br>Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)      | 15    |        |
|  | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 8,059 | 13,464 |
|  | By key population type:<br>MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the                         |       |        |

|             |   |           |           |
|-------------|---|-----------|-----------|
|             | minimum standards required)   |           |           |
|             | By key population type:<br>Female sex workers (FSW)<br>(Denominator: Total<br>estimated number of key<br>population in the catchment<br>area)                           |           |           |
|             | By key population type:<br>Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)                             |           |           |
|             | By key population type:<br>Females who inject drugs (Female PWID)<br>(Denominator: Total<br>estimated number of key<br>population in the catchment<br>area)             |           |           |
|             | By key population type: Men<br>who have sex with<br>men/Transgender (MSM/TG)<br>(Denominator: Total<br>estimated number of key<br>population in the catchment<br>area)  |           |           |
|             | By key population type:<br>MSM/TG who are male sex<br>workers (subset MSM/TG)<br>(Denominator: Total<br>estimated number of key<br>population in the catchment<br>area) |           |           |
| HTC_TST_DSD | Number of individuals who<br>received T&C services for  | 3,691,212 | 3,472,781 |

|  |   |  |           |
|--|---|--|-----------|
|  | HIV and received their test results during the past 12 months |  |           |
|  | By Test Result: Negative                                      |  | 2,931,811 |
|  | By Test Result: Positive                                      |  | 540,970   |
|  | Sum of Test Result disaggregates                              |  | 3,472,781 |
|  | Test Result by Age and Sex: Positive: <1 Male                 |  |           |
|  | Test Result by Age and Sex: Positive: 1-4 Male                |  |           |
|  | Test Result by Age and Sex: Positive: 5-9 Male                |  |           |
|  | Test Result by Age and Sex: Positive: 10-14 Male              |  |           |
|  | Test Result by Age and Sex: Positive: 15-19 Male              |  |           |
|  | Test Result by Age and Sex: Positive: 20-24 Male              |  |           |
|  | Test Result by Age and Sex: Positive: 25-49 Male              |  |           |
|  | Test Result by Age and Sex: Positive: 50+ Male                |  |           |
|  | Test Result by Age and Sex: Positive: <1 Female               |  |           |
|  | Test Result by Age and Sex: Positive: 1-4 Female              |  |           |
|  | Test Result by Age and Sex: Positive: 5-9 Female              |  |           |
|  | Test Result by Age and Sex: Positive: 10-14 Female            |  |           |
|  | Test Result by Age and Sex: Positive: 15-19 Female            |  |           |
|  | Test Result by Age and Sex:                                   |  |           |

|  |                             |  |  |
|--|-----------------------------|--|--|
|  | Positive: 20-24 Female      |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Positive: 25-49 Female      |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Positive: 50+ Female        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: <1 Male           |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 1-4 Male          |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 5-9 Male          |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 10-14 Male        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 15-19 Male        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 20-24 Male        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 25-49 Male        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 50+ Male          |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: <1 Female         |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 1-4 Female        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 5-9 Female        |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 10-14 Female      |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 15-19 Female      |  |  |
|  | Test Result by Age and Sex: |  |  |
|  | Negative: 20-24 Female      |  |  |
|  | Test Result by Age and Sex: |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Negative: 25-49 Female   |  |  |
|  | Test Result by Age and Sex:<br>Negative: 50+ Female                    |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Male       |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Male       |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Female     |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Female     |  |  |
|  | Sum of Aggregated Age/Sex<br><15                                       |  |  |
|  | Sum of Aggregated Age/Sex<br>15+                                       |  |  |
|  | Sum of Aggregated Age/Sex<br>disaggregates                             |  |  |
|  | Service Delivery Point by<br>Result: Antenatal Clinic - All<br>results |  |  |
|  | Service Delivery Point by<br>Result: Antenatal Clinic -<br>Positive    |  |  |
|  | Service Delivery Point by<br>Result: Antenatal Clinic -<br>Negative    |  |  |
|  | Service Delivery Point by<br>Result: Labor & delivery - All<br>results |  |  |
|  | Service Delivery Point by<br>Result: Labor & delivery -                |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Positive   |  |  |
|  | Service Delivery Point by<br>Result: Labor & delivery -<br>Negative                    |  |  |
|  | Service Delivery Point by<br>Result: Under 5 Clinic – All<br>results                   |  |  |
|  | Service Delivery Point by<br>Result: Under 5 Clinic -<br>Positive                      |  |  |
|  | Service Delivery Point by<br>Result: Under 5 Clinic -<br>Negative                      |  |  |
|  | Service Delivery Point by<br>Result: Maternal and Child<br>Health Clinic – All Results |  |  |
|  | Service Delivery Point by<br>Result: Maternal and Child<br>Health Clinic - Positive    |  |  |
|  | Service Delivery Point by<br>Result: Maternal and Child<br>Health Clinic - Negative    |  |  |
|  | Service Delivery Point by<br>Result: Tuberculosis – All<br>results                     |  |  |
|  | Service Delivery Point by<br>Result: Tuberculosis -<br>Positive                        |  |  |
|  | Service Delivery Point by<br>Result: Tuberculosis -<br>Negative                        |  |  |
|  | Service Delivery Point by<br>Result: Sexually Transmitted<br>Infections – All Results  |  |  |
|  | Service Delivery Point by  |  |  |

|  |   |  |  |
|--|---|--|--|
|  | Result: Sexually Transmitted Infections - Positive                                  |  |  |
|  | Service Delivery Point by Result: Sexually Transmitted Infections - Negative        |  |  |
|  | Service Delivery Point by Result: Outpatient Department – All Results               |  |  |
|  | Service Delivery Point by Result: Outpatient Department - Positive                  |  |  |
|  | Service Delivery Point by Result: Outpatient Department - Negative                  |  |  |
|  | Service Delivery Point by Result: Inpatient – All Results                           |  |  |
|  | Service Delivery Point by Result: Inpatient - Positive                              |  |  |
|  | Service Delivery Point by Result: Inpatient - Negative                              |  |  |
|  | Service Delivery Point by Result: HIV care and treatment clinic – All Results       |  |  |
|  | Service Delivery Point by Result: HIV care and treatment clinic - Positive          |  |  |
|  | Service Delivery Point by Result: HIV care and treatment clinic - Negative          |  |  |
|  | Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results |  |  |
|  | Service Delivery Point by   |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Result: Voluntary Medical Male Circumcision - Positive                                       |  |  |
|  | Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative             |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results  |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive     |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative     |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive    |  |  |
|  | Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative    |  |  |
|  | Service Delivery Point by Result: Mobile – All Results                                       |  |  |
|  | Service Delivery Point by Result: Mobile - Positive  |  |  |
|  | Service Delivery Point by Result: Mobile - Negative  |  |  |



|            |   |         |         |
|------------|---|---------|---------|
|            | Service Delivery Point by Result: Home-based – All Results  |         |         |
|            | Service Delivery Point by Result: Home-based - Positive   |         |         |
|            | Service Delivery Point by Result: Home-based - Negative   |         |         |
|            | Service Delivery Point by Result: Other – All Results   |         |         |
|            | Service Delivery Point by Result: Other - Positive  |         |         |
|            | Service Delivery Point by Result: Other - Negative  |         |         |
| HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 490,326 | 803,295 |
|            | By Test Result: Negative  |         | 680,965 |
|            | By Test Result: Positive  |         | 122,330 |
|            | Sum of Test Result disaggregates  |         | 803,295 |
|            | Test Result by Age and Sex: Positive: <1 Male   |         |         |
|            | Test Result by Age and Sex: Positive: 1-4 Male  |         |         |
|            | Test Result by Age and Sex: Positive: 5-9 Male  |         |         |
|            | Test Result by Age and Sex: Positive: 10-14 Male  |         |         |
|            | Test Result by Age and Sex: Positive: 15-19 Male  |         |         |
|            |   |         |         |

|  |   |  |  |
|--|---|--|--|
|  | Test Result by Age and Sex:<br>Positive: 20-24 Male   |  |  |
|  | Test Result by Age and Sex:<br>Positive: 25-49 Male   |  |  |
|  | Test Result by Age and Sex:<br>Positive: 50+ Male     |  |  |
|  | Test Result by Age and Sex:<br>Positive: <1 Female    |  |  |
|  | Test Result by Age and Sex:<br>Positive: 1-4 Female   |  |  |
|  | Test Result by Age and Sex:<br>Positive: 5-9 Female   |  |  |
|  | Test Result by Age and Sex:<br>Positive: 10-14 Female |  |  |
|  | Test Result by Age and Sex:<br>Positive: 15-19 Female |  |  |
|  | Test Result by Age and Sex:<br>Positive: 20-24 Female |  |  |
|  | Test Result by Age and Sex:<br>Positive: 25-49 Female |  |  |
|  | Test Result by Age and Sex:<br>Positive: 50+ Female   |  |  |
|  | Test Result by Age and Sex:<br>Negative: <1 Male      |  |  |
|  | Test Result by Age and Sex:<br>Negative: 1-4 Male     |  |  |
|  | Test Result by Age and Sex:<br>Negative: 5-9 Male     |  |  |
|  | Test Result by Age and Sex:<br>Negative: 10-14 Male   |  |  |
|  | Test Result by Age and Sex:<br>Negative: 15-19 Male   |  |  |
|  | Test Result by Age and Sex:<br>Negative: 20-24 Male   |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Test Result by Age and Sex:<br>Negative: 25-49 Male                |  |  |
|  | Test Result by Age and Sex:<br>Negative: 50+ Male                  |  |  |
|  | Test Result by Age and Sex:<br>Negative: <1 Female                 |  |  |
|  | Test Result by Age and Sex:<br>Negative: 1-4 Female                |  |  |
|  | Test Result by Age and Sex:<br>Negative: 5-9 Female                |  |  |
|  | Test Result by Age and Sex:<br>Negative: 10-14 Female              |  |  |
|  | Test Result by Age and Sex:<br>Negative: 15-19 Female              |  |  |
|  | Test Result by Age and Sex:<br>Negative: 20-24 Female              |  |  |
|  | Test Result by Age and Sex:<br>Negative: 25-49 Female              |  |  |
|  | Test Result by Age and Sex:<br>Negative: 50+ Female                |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Male   |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Male   |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Female |  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Female |  |  |
|  | Sum of Aggregated Age/Sex<br><15                                   |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Sum of Aggregated Age/Sex 15+  |  |  |
|  | Sum of Aggregated Age/Sex disaggregates  |  |  |
|  | Service Delivery Point by Result: Antenatal Clinic - All results                 |  |  |
|  | Service Delivery Point by Result: Antenatal Clinic - Positive                    |  |  |
|  | Service Delivery Point by Result: Antenatal Clinic - Negative                    |  |  |
|  | Service Delivery Point by Result: Labor & delivery - All results                 |  |  |
|  | Service Delivery Point by Result: Labor & delivery - Positive                    |  |  |
|  | Service Delivery Point by Result: Labor & delivery - Negative                    |  |  |
|  | Service Delivery Point by Result: Under 5 Clinic – All results                   |  |  |
|  | Service Delivery Point by Result: Under 5 Clinic - Positive                      |  |  |
|  | Service Delivery Point by Result: Under 5 Clinic - Negative                      |  |  |
|  | Service Delivery Point by Result: Maternal and Child Health Clinic – All Results |  |  |
|  | Service Delivery Point by  |  |  |
|  |  |  |  |

|  |   |  |  |
|--|---|--|--|
|  | Result: Maternal and Child Health Clinic - Positive                             |  |  |
|  | Service Delivery Point by Result: Maternal and Child Health Clinic - Negative   |  |  |
|  | Service Delivery Point by Result: Tuberculosis – All results                    |  |  |
|  | Service Delivery Point by Result: Tuberculosis - Positive                       |  |  |
|  | Service Delivery Point by Result: Tuberculosis - Negative                       |  |  |
|  | Service Delivery Point by Result: Sexually Transmitted Infections – All Results |  |  |
|  | Service Delivery Point by Result: Sexually Transmitted Infections - Positive    |  |  |
|  | Service Delivery Point by Result: Sexually Transmitted Infections - Negative    |  |  |
|  | Service Delivery Point by Result: Outpatient Department – All Results           |  |  |
|  | Service Delivery Point by Result: Outpatient Department - Positive              |  |  |
|  | Service Delivery Point by Result: Outpatient Department - Negative              |  |  |
|  | Service Delivery Point by Result: Inpatient – All Results                       |  |  |

|  |  |  |  |
|--|--|--|--|
|  | Service Delivery Point by<br>Result: Inpatient - Positive  |  |  |
|  | Service Delivery Point by<br>Result: Inpatient - Negative  |  |  |
|  | Service Delivery Point by<br>Result: HIV care and<br>treatment clinic – All Results                  |  |  |
|  | Service Delivery Point by<br>Result: HIV care and<br>treatment clinic - Positive                     |  |  |
|  | Service Delivery Point by<br>Result: HIV care and<br>treatment clinic - Negative                     |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Medical<br>Male Circumcision – All<br>Results         |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Medical<br>Male Circumcision - Positive               |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Medical<br>Male Circumcision - Negative               |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (co-located) – All<br>Results |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (co-located) -<br>Positive    |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (co-located) -<br>Negative    |  |  |

|  |   |  |  |
|--|---|--|--|
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (standalone) - All         |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (standalone) -<br>Positive |  |  |
|  | Service Delivery Point by<br>Result: Voluntary Counseling<br>& Testing (standalone) -<br>Negative |  |  |
|  | Service Delivery Point by<br>Result: Mobile – All Results   |  |  |
|  | Service Delivery Point by<br>Result: Mobile - Positive  |  |  |
|  | Service Delivery Point by<br>Result: Mobile - Negative  |  |  |
|  | Service Delivery Point by<br>Result: Home-based – All<br>Results                                  |  |  |
|  | Service Delivery Point by<br>Result: Home-based -<br>Positive                                     |  |  |
|  | Service Delivery Point by<br>Result: Home-based -<br>Negative                                     |  |  |
|  | Service Delivery Point by<br>Result: Other – All Results  |  |  |
|  | Service Delivery Point by<br>Result: Other - Positive   |  |  |
|  | Service Delivery Point by<br>Result: Other - Negative   |  |  |
|  | Test Result by Aggregated<br>Age and Sex: Negative <15<br>Male                                    |  |  |

|             |   |     |        |
|-------------|---|-----|--------|
|             | Test Result by Aggregated Age and Sex: Negative 15+ Male  |     |        |
|             | Test Result by Aggregated Age and Sex: Negative <15 Female  |     |        |
|             | Test Result by Aggregated Age and Sex: Negative 15+ Female  |     |        |
|             | Test Result by Aggregated Age and Sex: Positive <15 Male  |     |        |
|             | Test Result by Aggregated Age and Sex: Positive 15+ Male  |     |        |
|             | Test Result by Aggregated Age and Sex: Positive <15 Female  |     |        |
|             | Test Result by Aggregated Age and Sex: Positive 15+ Female  |     |        |
| TB_STAT_DSD | TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.              | n/a |        |
|             | Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. |     | 54,845 |
|             | Total number of registered new and relapsed TB cases, during the reporting period.                      |     | 55,398 |
|             | Sex: Male   |     |        |
|             | Sex: Female   |     |        |



|              |   |       |        |
|--------------|---|-------|--------|
|              | Age: <1   |       |        |
|              | Age: 1-4  |       |        |
|              | Age: 5-9  |       |        |
|              | Age: 10-14  |       |        |
|              | Age 15-19   |       |        |
|              | Age: 20+  |       |        |
|              | Status: Positive  |       | 22,491 |
|              | Status: Negative  |       | 8,232  |
| TB_STAT_TA   | TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.               | n/a   |        |
|              | Number of registered new and relapsed TB cases with documented HIV status, during the reporting period. |       | 17,627 |
|              | Total number of registered new and relapsed TB cases, during the reporting period.                      |       | 17,804 |
|              | Age 15-19   |       |        |
|              | Age: <1   |       |        |
|              | Age: 1-4  |       |        |
|              | Age: 10-14  |       |        |
|              | Age: 20+  |       |        |
|              | Age: 5-9  |       |        |
|              | Sex: Female   |       |        |
|              | Sex: Male   |       |        |
|              | Status: Negative  |       | 2,645  |
|              | Status: Positive  |       | 7,230  |
| GEND_GBV_DSD | Number of people receiving post-GBV care  | 3,040 | 16,290 |
|              | Age/Sex: <10 Male   |       |        |

|               |   |       |        |
|---------------|---|-------|--------|
|               | Age/Sex: 10-14 Male   |       |        |
|               | Age/Sex: 15-17 Male   |       |        |
|               | Age/Sex: 18-24 Male   |       |        |
|               | Age/Sex: 25+ Male   |       |        |
|               | Age/Sex: <10 Female   |       |        |
|               | Age/Sex: 10-14 Female   |       |        |
|               | Age/Sex: 15-17 Female   |       |        |
|               | Age/Sex: 18-24 Female   |       |        |
|               | Age/Sex: 25+ Female   |       |        |
|               | Sum of Age/Sex Disaggregates  |       |        |
|               | By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)                        |       | 8,144  |
|               | By type of service: Sexual Violence (Post-Rape Care)  |       | 8,144  |
|               | By PEP service provision (related to sexual violence services provided)                             |       |        |
| GEND_NORM_DSD | Number of people completing an intervention pertaining to gender norms, that meets minimum criteria | 2,650 | 40,045 |
|               | Age/Sex: <10 Male   |       |        |
|               | Age/Sex: 10-14 Male   |       |        |
|               | Age/Sex: 15-19 Male   |       |        |
|               | Age/Sex: 20-24 Male   |       |        |
|               | Age/Sex: 25+ Male   |       |        |
|               | Age/Sex: <10 Female   |       |        |
|               | Age/Sex: 10-14 Female   |       |        |
|               | Age/Sex: 15-19 Female   |       |        |
|               | Age/Sex: 20-24 Female   |       |        |
|               | Age/Sex: 25+ Female   |       |        |

|              |   |         |         |
|--------------|---|---------|---------|
|              | By Age: 0-9   |         |         |
|              | By Age: 10-14   |         |         |
|              | By Age: 15-19   |         |         |
|              | By Age: 20-24   |         |         |
|              | By Age: 25+   |         |         |
|              | Sum of Age disaggregates  |         |         |
| OVC_ACC_DSD  | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services            | 57,592  | 43,435  |
|              | Age/Sex: <1 Male  |         | 262     |
|              | Age/Sex: 1-4 Male   |         | 2,691   |
|              | Age/Sex: 5-9 Male   |         | 4,826   |
|              | Age/Sex: 10-14 Male   |         | 6,038   |
|              | Age/Sex: 15-17 Male   |         | 2,691   |
|              | Age/Sex: 18-24 Male   |         | 4,257   |
|              | Age/Sex: 25+ Male   |         | 0       |
|              | Age/Sex: <1 Female  |         | 476     |
|              | Age/Sex: 1-4 Female   |         | 2,517   |
|              | Age/Sex: 5-9 Female   |         | 4,475   |
|              | Age/Sex: 10-14 Female   |         | 8,165   |
|              | Age/Sex: 15-17 Female   |         | 2,736   |
|              | Age/Sex: 18+ Female   |         |         |
|              | Age/Sex: 18-24 Female   |         | 4,301   |
|              | Age/Sex: 25+ Female   |         | 0       |
|              | Sum of Age/Sex disaggregates  |         | 43,435  |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 230,365 | 219,654 |

|  |   |  |         |
|--|---|--|---------|
|  | Age/Sex: <1 Male  |  | 1,315   |
|  | Age/Sex: 1-4 Male   |  | 13,619  |
|  | Age/Sex: 5-9 Male   |  | 24,378  |
|  | Age/Sex: 10-14 Male   |  | 30,533  |
|  | Age/Sex: 15-17 Male   |  | 13,619  |
|  | By: Age/sex: Male 18-24   |  | 21,526  |
|  | By: Age/sex: Male 25+   |  | 0       |
|  | Age/Sex: <1 Female  |  | 2,417   |
|  | Age/Sex: 1-4 Female   |  | 12,737  |
|  | Age/Sex: 5-9 Female   |  | 22,622  |
|  | Age/Sex: 10-14 Female   |  | 41,296  |
|  | Age/Sex: 15-17 Female   |  | 13,840  |
|  | By: Age/sex: 18-24 Female   |  | 21,745  |
|  | By: Age/sex: 25+ Female   |  | 0       |
|  | Sum of Age/Sex<br>disaggregates   |  | 176,376 |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female <1    |  |         |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female 1-4   |  |         |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female 5-9   |  |         |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female 10-14 |  |         |
|  | Required only for DREAMS<br>countries - By service, age   |  |         |

|  |   |  |  |
|--|---|--|--|
|  | and sex: Education Support<br>Female 15-17  |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female 18-24 |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Female 25+   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male <1      |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male 1-4     |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male 5-9     |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male 10-14   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male 15-17   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Education Support<br>Male 18-24   |  |  |
|  | Required only for DREAMS  |  |  |

|  |   |  |  |
|--|---|--|--|
|  | countries - By service, age and sex: Education Support Male 25+   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1    |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1      |  |  |

|  |   |  |  |
|--|---|--|--|
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection Female <1             |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4            |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection                       |  |  |

|  |   |  |  |
|--|---|--|--|
|  | Female 5-9  |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Female 10-14 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Female 15-17 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Female 18-24 |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Female 25+   |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Male <1      |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Male 1-4     |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Male 5-9     |  |  |
|  | Required only for DREAMS countries - By service, age and sex: Social Protection<br>Male 10-14   |  |  |
|  | Required only for DREAMS countries - By service, age  |  |  |



|  |  |  |  |
|--|--|--|--|
|  | and sex: Social Protection<br>Male 15-17   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Social Protection<br>Male 18-24        |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Social Protection<br>Male 25+          |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female <1    |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female 1-4   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female 5-9   |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female 10-14 |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female 15-17 |  |  |
|  | Required only for DREAMS<br>countries - By service, age<br>and sex: Economic<br>Strengthening Female 18-24 |  |  |
|  | Required only for DREAMS   |  |  |

|               |  |           |           |
|---------------|--|-----------|-----------|
|               | countries - By service, age and sex: Economic Strengthening Female 25+                                     |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1               |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4              |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9              |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14            |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17            |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24            |           |           |
|               | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+              |           |           |
| CARE_CURR_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting | 1,001,283 | 1,051,394 |

|  |  |         |  |
|--|--|---------|--|
|  | period: clinical assessment<br>(WHO staging) OR CD4<br>count OR viral load |         |  |
|  | Age/sex: <1 Male   |         |  |
|  | Age/sex: 1-4 Male  |         |  |
|  | Age/sex: 5-9 Male  |         |  |
|  | Age/sex: 10-14 Male  |         |  |
|  | Age/sex: 15-19 Male  |         |  |
|  | Age/sex: 20-24 Male  |         |  |
|  | Age/sex: 25-49 Male  |         |  |
|  | Age/sex: 50+ Male  |         |  |
|  | Age/sex: <1 Female   |         |  |
|  | Age/sex: 1-4 Female  |         |  |
|  | Age/sex: 5-9 Female  |         |  |
|  | Age/sex: 10-14 Female  |         |  |
|  | Age/sex: 15-19 Female  |         |  |
|  | Age/sex: 20-24 Female  |         |  |
|  | Age/sex: 25-49 Female  |         |  |
|  | Age/sex: 50+ Female  |         |  |
|  | Sun of Age/Sex<br>disaggregates  |         |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Male           | 40,050  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Male           | 390,503 |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: <15 Female         | 40,050  |  |
|  | Aggregated Age/sex - USE<br>WITH HQ PERMISSION<br>ONLY: 15+ Female         | 530,681 |  |

|              |   |           |         |
|--------------|---|-----------|---------|
|              | Sum of Aggregated Age/Sex disaggregates   | 1,001,284 |         |
| CARE_CURR_TA | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 76,084    | 154,440 |
|              | Age/sex: <1 Male  |           |         |
|              | Age/sex: 1-4 Male   |           |         |
|              | Age/sex: 5-9 Male   |           |         |
|              | Age/sex: 10-14 Male   |           |         |
|              | Age/sex: 15-19 Male   |           |         |
|              | Age/sex: 20-24 Male   |           |         |
|              | Age/sex: 25-49 Male   |           |         |
|              | Age/sex: 50+ Male   |           |         |
|              | Age/sex: <1 Female  |           |         |
|              | Age/sex: 1-4 Female   |           |         |
|              | Age/sex: 5-9 Female   |           |         |
|              | Age/sex: 10-14 Female   |           |         |
|              | Age/sex: 15-19 Female   |           |         |
|              | Age/sex: 20-24 Female   |           |         |
|              | Age/sex: 25-49 Female   |           |         |
|              | Age/sex: 50+ Female   |           |         |
|              | Sum of Age/Sex disaggregates  |           |         |
|              | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 3,043     |         |
|              | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 29,674    |         |

|              |   |         |         |
|--------------|---|---------|---------|
|              | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 3,043   |         |
|              | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 40,323  |         |
|              | Sum of Aggregated Age/Sex disaggregates   | 76,083  |         |
| CARE_NEW_DSD | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 442,448 | 429,623 |
|              | Age/sex: <1 Male  |         |         |
|              | Age/sex: 1-4 Male   |         |         |
|              | Age/sex: 5-9 Male   |         |         |
|              | Age/sex: 10-14 Male   |         |         |
|              | Age/sex: 15-19 Male   |         |         |
|              | Age/sex: 20-24 Male   |         |         |
|              | Age/sex: 25-49 Male   |         |         |
|              | Age/sex: 50+ Male   |         |         |
|              | Age/sex: <1 Female  |         |         |
|              | Age/sex: 1-4 Female   |         |         |
|              | Age/sex: 5-9 Female   |         |         |
|              | Age/sex: 10-14 Female   |         |         |
|              | Age/sex: 15-19 Female   |         |         |
|              | Age/sex: 20-24 Female   |         |         |
|              | Age/sex: 25-49 Female   |         |         |
|              | Age/sex: 50+ Female   |         |         |
|              | Sum of Age/sex  |         |         |

|             |   |         |        |
|-------------|---|---------|--------|
|             | disaggregates   |         |        |
|             | Aggregated Age/sex: <15 Male  | 17,696  |        |
|             | Aggregated Age/sex: 15+ Male  | 172,553 |        |
|             | Aggregated Age/sex: <15 Female  | 17,696  |        |
|             | Aggregated Age/sex: 15+ Female  | 234,497 |        |
|             | Sum of Aggregated Age/sex disaggregates   | 442,442 |        |
| CARE_NEW_TA | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |         | 87,899 |
|             | Age/sex: <1 Female  |         |        |
|             | Age/sex: 1-4 Female   |         |        |
|             | Age/sex: 5-9 Female   |         |        |
|             | Age/sex: 10-14 Female   |         |        |
|             | Age/sex: 15-19 Female   |         |        |
|             | Age/sex: 20-24 Female   |         |        |
|             | Age/sex: 25-49 Female   |         |        |
|             | Age/sex: 50+ Female   |         |        |
|             | Age/sex: <1 Male  |         |        |
|             | Age/sex: 1-4 Male   |         |        |
|             | Age/sex: 5-9 Male   |         |        |
|             | Age/sex: 10-14 Male   |         |        |
|             | Age/sex: 15-19 Male   |         |        |
|             | Age/sex: 20-24 Male   |         |        |

|             |   |         |         |
|-------------|---|---------|---------|
|             | Age/sex: 25-49 Male   |         |         |
|             | Age/sex: 50+ Male   |         |         |
|             | Aggregated Age/sex: <15 Female  |         |         |
|             | Aggregated Age/sex: <15 Male  |         |         |
|             | Aggregated Age/sex: 15+ Female  |         |         |
|             | Aggregated Age/sex: 15+ Male  |         |         |
|             | Sum of Aggregated Age/sex disaggregates   | 442,442 |         |
|             | Sum of age/sex disaggregates  |         |         |
| FN_THER_DSD | FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food                | 50 %    |         |
|             | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period. | 75,098  | 94,628  |
|             | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.                              | 150,192 | 126,162 |
|             | Age: <1   |         |         |
|             | Age: 1-4  |         |         |
|             | Age: 5-14   |         |         |
|             | Age: 15-17  |         |         |
|             | Age: 18+  |         |         |
|             | Sum of Age disaggregates  |         |         |
|             |   |         |         |

|            |   |     |        |
|------------|---|-----|--------|
|            | Aggregated Age: <18   |     |        |
|            | Aggregated Age: 18+   |     |        |
|            | Sum of Aggregated Age disaggregates   |     |        |
|            | By Pregnancy/Postpartum Status: Pregnant  |     |        |
|            | By Pregnancy/Postpartum Status: Postpartum  |     |        |
| FN_THER_TA | FN_THER_TA Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food                 | n/a |        |
|            | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period. |     | 13,897 |
|            | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.                              |     | 18,535 |
|            | Age: <1   |     |        |
|            | Age: 1-4  |     |        |
|            | Age: 5-14   |     |        |
|            | Age: 15-17  |     |        |
|            | Age: 18+  |     |        |
|            | Sum of Age disaggregates  |     |        |
|            | Aggregated Age - USE WITH HQ PERMISSION ONLY: <18   |     |        |
|            | Aggregated Age - USE WITH HQ PERMISSION ONLY: 18+   |     |        |
|            |   |     |        |
|            |   |     |        |
|            |   |     |        |



|            |   |     |         |
|------------|---|-----|---------|
|            | By Pregnancy/Postpartum Status: Pregnant  |     |         |
|            | By Pregnancy/Postpartum Status: Postpartum  |     |         |
|            | Sum of Aggregated Age disaggregates   |     |         |
| TB_IPT_DSD | TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)   | n/a |         |
|            | The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period  |     | 240,581 |
|            | Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |     |         |
|            | Age: <1   |     |         |
|            | Age: 1-4  |     |         |
|            | Age: 5-9  |     |         |
|            | Age: 10-14  |     |         |
|            | Age: 15-19  |     |         |
|            | Age: 20+  |     |         |
|            | Sum of Age disaggregates  |     |         |
|            | Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15  |     |         |
|            | Age (Aggregated)- USE   |     |         |

|           |   |     |         |
|-----------|---|-----|---------|
|           | WITH HQ PERMISSION ONLY: 15+  |     |         |
|           | Sex: Male   |     | 84,207  |
|           | Sex: Female   |     | 156,374 |
| TB_IPT_TA | TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)  | n/a |         |
|           | The number of PLHIV newly enrolled in HIV care who start IPT during the reporting period  |     | 49,222  |
|           | Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load |     |         |
|           | Age: <1   |     |         |
|           | Age: 1-4  |     |         |
|           | Age: 5-9  |     |         |
|           | Age: 10-14  |     |         |
|           | Age: 15-19  |     |         |
|           | Age: 20+  |     |         |
|           | Sum of Age disaggregates  |     |         |
|           | Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15  |     |         |
|           | Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+  |     |         |

|            |  |        |        |
|------------|--|--------|--------|
|            | Sex: Male  |        | 17,228 |
|            | Sex: Female  |        | 31,994 |
| TB_ART_DSD | TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment  | 85 %   |        |
|            | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 23,704 | 29,741 |
|            | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period                | 27,885 | 33,046 |
|            | Age: <1  |        |        |
|            | Age: 1-4   |        |        |
|            | Age: 5-9   |        |        |
|            | Age: 10-14   |        |        |
|            | Age: 15-19   |        |        |
|            | Age: 20+   |        |        |
|            | Sum of Age disaggregates   |        |        |
|            | Male   |        |        |
|            | Female   |        |        |
|            | Sum of Sex disaggregates   |        |        |
|            | Newly tested   |        |        |
|            | Known HIV-positive   |        |        |
|            | Sum of Test Status disaggregates   |        |        |
|            | Aggregated Age: <15  |        |        |
|            | Aggregated Age: 15+  |        |        |

|           |  |     |       |
|-----------|--|-----|-------|
|           | Sum of Aggregated Age disaggregates  |     |       |
|           | Timeliness: Art initiation <8 weeks of start of TB treatment   |     |       |
|           | Timeliness: Art initiation >8 weeks of start of TB treatment   |     |       |
| TB_ART_TA | TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment   | n/a |       |
|           | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period |     | 6,136 |
|           | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period                |     | 6,817 |
|           | Age: <1  |     |       |
|           | Age: 1-4   |     |       |
|           | Age: 5-9   |     |       |
|           | Age: 10-14   |     |       |
|           | Age: 15-19   |     |       |
|           | Age: 20+   |     |       |
|           | Sum of Age disaggregates   |     |       |
|           | Aggregated Age: <15  |     |       |
|           | Aggregated Age: 15+  |     |       |
|           | Sum of Aggregated Age  |     |       |

|               |   |           |           |
|---------------|---|-----------|-----------|
|               | disaggregates   |           |           |
|               | Male  |           |           |
|               | Female  |           |           |
|               | Sum of Sex disaggregates  |           |           |
|               | Known HIV-positive  |           |           |
|               | Newly tested  |           |           |
|               | Sum of Test Status<br>disaggregates   |           |           |
|               | Timeliness: Art initiation <8<br>weeks of start of TB<br>treatment  |           |           |
|               | Timeliness: Art initiation >8<br>weeks of start of TB<br>treatment  |           |           |
| TB_SCREEN_DSD | TB_SCREEN_DSD<br>Percentage of PLHIV who<br>were screened for TB<br>symptoms at the last clinical<br>visit to an HIV care facility<br>during the reporting period.                                | 96 %      |           |
|               | The number of PLHIV who<br>were screened for TB<br>symptoms at the last clinical<br>visit to an HIV care facility<br>during the reporting period  | 961,231   |           |
|               | Number of HIV positive<br>adults and children who<br>received at least one of the<br>following during the reporting<br>period: clinical assessment<br>(WHO staging) OR CD4<br>count OR viral load | 1,001,283 | 1,051,394 |
|               | Age: <1   |           |           |
|               | Age: 1-4  |           |           |
|               | Age: 5-9  |           |           |
|               |   |           |           |

|              |   |        |         |
|--------------|---|--------|---------|
|              | Age: 10-14  |        |         |
|              | Age: 15-19  |        |         |
|              | Age: 20+  |        |         |
|              | Sum of Age disaggregates  |        |         |
|              | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15   |        |         |
|              | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+   |        |         |
|              | Sum of Aggregated Age disaggregates   |        |         |
|              | Sex: Male   |        |         |
|              | Sex: Female   |        |         |
|              | Sum of Sex disaggregates  |        |         |
| TB_SCREEN_TA | TB_SCREEN_TA<br>Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.                           | n/a    |         |
|              | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  |        |         |
|              | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 76,084 | 154,440 |
|              | Age: <1   |        |         |
|              | Age: 1-4  |        |         |

|               |  |        |        |
|---------------|--|--------|--------|
|               | Age: 5-9   |        |        |
|               | Age: 10-14   |        |        |
|               | Age: 15-19   |        |        |
|               | Age: 20+   |        |        |
|               | Sum of Age disaggregates   |        |        |
|               | Aggregated Age - USE WITH HQ PERMISSION ONLY: <15  |        |        |
|               | Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+  |        |        |
|               | Sum of Aggregated Age disaggregates  |        |        |
|               | Sex: Female  |        |        |
|               | Sex: Male  |        |        |
|               | Sum of Sex disaggregates   |        |        |
| PMTCT_EID_DSD | PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)      | 95 %   |        |
|               | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period                                 | 74,672 | 48,920 |
|               | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 78,992 |        |
|               | By infants who received a virologic test within 2 months of birth  |        |        |

|              |  |     |        |
|--------------|--|-----|--------|
|              | By infants who received their first virologic HIV test between 2 and 12 months of age  |     |        |
|              | Sum of Infant Age disaggregates  |     |        |
|              | By infants with a positive virologic test result within 12 months of birth   |     |        |
|              | Number of infants with a positive virological test result within 2 months of birth   |     |        |
|              | Number of infants with a positive virological test result within 12 months of birth  |     |        |
| PMTCT_EID_TA | PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)        | n/a |        |
|              | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period                                 |     | 13,288 |
|              | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) |     |        |
|              | By infants who received a virologic test within 2 months of birth  |     |        |
|              | By infants who received their first virologic HIV test between 2 and 12 months of  |     |        |



|               |   |  |         |
|---------------|---|--|---------|
|               | age   |  |         |
|               | Sum of Infant Age disaggregates   |  |         |
|               | By infants with a positive virologic test result within 12 months of birth                                    |  |         |
|               | Number of infants with a positive virological test result within 2 months of birth                            |  |         |
|               | Number of infants with a positive virological test result within 12 months of birth                           |  |         |
| CARE_COMM_DSD | Number of HIV-infected adults and children receiving care and support services outside of the health facility |  | 262,942 |
|               | Age/Sex: <1 Male  |  |         |
|               | Age/Sex: 1-4 Male   |  |         |
|               | Age/Sex: 5-9 Male   |  |         |
|               | Age/Sex: 10-14 Male   |  |         |
|               | Age/Sex: 15-19 Male   |  |         |
|               | Age/Sex: 20-24 Male   |  |         |
|               | Age/Sex: 25-49 Male   |  |         |
|               | Age/Sex: 50+ Male   |  |         |
|               | Age/Sex: <1 Female  |  |         |
|               | Age/Sex: 1-4 Female   |  |         |
|               | Age/Sex: 5-9 Female   |  |         |
|               | Age/Sex: 10-14 Female   |  |         |
|               | Age/Sex: 15-19 Female   |  |         |
|               | Age/Sex: 20-24 Female   |  |         |
|               | Age/Sex: 25-49 Female   |  |         |
|               | Age/Sex: 50+ Female   |  |         |
| CARE_COMM_TA  | Number of HIV-infected  |  | 38,611  |

|             |  |         |         |
|-------------|--|---------|---------|
|             | adults and children receiving care and support services outside of the health facility |         |         |
|             | Age/Sex: <1 Female   |         |         |
|             | Age/Sex: <1 Male   |         |         |
|             | Age/Sex: 1-4 Female  |         |         |
|             | Age/Sex: 1-4 Male  |         |         |
|             | Age/Sex: 10-14 Female  |         |         |
|             | Age/Sex: 10-14 Male  |         |         |
|             | Age/Sex: 15-19 Female  |         |         |
|             | Age/Sex: 15-19 Male  |         |         |
|             | Age/Sex: 20-24 Female  |         |         |
|             | Age/Sex: 20-24 Male  |         |         |
|             | Age/Sex: 25-49 Female  |         |         |
|             | Age/Sex: 25-49 Male  |         |         |
|             | Age/Sex: 5-9 Female  |         |         |
|             | Age/Sex: 5-9 Male  |         |         |
|             | Age/Sex: 50+ Female  |         |         |
|             | Age/Sex: 50+ Male  |         |         |
| TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART)                   | 603,184 | 735,982 |
|             | Age/Sex: <1 Male   | 11,016  | 6,871   |
|             | Age/Sex: 1-4 Male  | 16,522  | 15,628  |
|             | Age/Sex: 5-14 Male   | 11,016  | 11,032  |
|             | Age/Sex: 15-19 Male  |         |         |
|             | Age/Sex: 20+ Male  |         |         |
|             | Age/Sex: <1 Female   | 12,588  | 6,871   |
|             | Age/Sex: 1-4 Female  | 16,522  | 15,628  |
|             | Age/Sex: 5-14 Female   | 11,016  | 11,032  |
|             | Age/Sex: 15-19 Female  |         |         |
|             | Age/Sex: 20+ Female  |         |         |

|            |  |         |         |
|------------|--|---------|---------|
|            | Aggregated Age/Sex: <1 Male  | 11,016  |         |
|            | Aggregated Age/Sex: <1 Female  | 12,588  |         |
|            | Aggregated Age/Sex: 15+ Male   | 152,107 |         |
|            | Aggregated Age/Sex: 1-14 Female                                      |         |         |
|            | Aggregated Age/Sex: 15+ Female                                       | 372,402 |         |
|            | Sum of Aggregated Age/Sex <15  | 78,672  |         |
|            | Sum of Aggregated Age/Sex 15+  | 524,509 |         |
|            | Sum of Aggregated Age/Sex disaggregates                              | 603,181 |         |
|            | Aggregated Age/Sex: 1-14 Male  |         |         |
|            | Sum of Aggregated Age/Sex (<1 and 1-14) <15                          | 23,604  |         |
| TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 45,833  | 108,106 |
|            | Age/Sex: <1 Male   | 836     | 1,330   |
|            | Age/Sex: 1-4 Male  | 1,256   | 3,036   |
|            | Age/Sex: 5-14 Male   | 836     | 2,137   |
|            | Age/Sex: 15-19 Male  |         |         |
|            | Age/Sex: 20+ Male  |         |         |
|            | Age/Sex: <1 Female   | 955     | 1,330   |
|            | Age/Sex: 1-4 Female  | 1,256   | 3,036   |
|            | Age/Sex: 5-14 Female   | 836     | 2,137   |
|            | Age/Sex: 15-19 Female  |         |         |
|            | Age/Sex: 20+ Female  |         |         |

|            |  |         |         |
|------------|--|---------|---------|
|            | Sum of Age/Sex disaggregations   | 5,975   | 13,006  |
|            | Aggregated Age/Sex: <1 Male  | 836     |         |
|            | Aggregated Age/Sex: <1 Female  | 955     |         |
|            | Aggregated Age/Sex: 1-14 Male  |         |         |
|            | Aggregated Age/Sex: 15+ Male   | 11,558  |         |
|            | Aggregated Age/Sex: 1-14 Female  |         |         |
|            | Aggregated Age/Sex: 15+ Female   | 28,296  |         |
|            | Sum of Aggregated Age/Sex <15  | 5,980   |         |
|            | Sum of Aggregated Age/Sex 15+  | 39,854  |         |
|            | Sum of Aggregated Age/Sex disaggregates                                      | 45,834  |         |
|            | Sum of Aggregated Age/Sex (<1 and 1-14) <15                                  | 1,791   |         |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 219,431 | 311,700 |
|            | By Age/Sex: <1 Male  |         |         |
|            | By Age/Sex: 1-4 Male   |         | 5,768   |
|            | By Age/Sex: 5-9 Male   |         |         |
|            | By Age/Sex: 10-14 Male   |         |         |
|            | By Age/Sex: 15-19 Male   |         |         |
|            | By Age/Sex: 20-24 Male   |         |         |
|            | By Age/Sex: 25-49 Male   |         |         |
|            | By Age/Sex: 50+ Male   |         |         |
|            | By Age/Sex: <1 Female  |         |         |

|           |  |         |         |
|-----------|--|---------|---------|
|           | By Age/Sex: 1-4 Female   |         | 5,768   |
|           | By Age/Sex: 5-9 Female   |         |         |
|           | By Age/Sex: 10-14 Female   |         |         |
|           | By Age/Sex: 15-19 Female   |         |         |
|           | By Age/Sex: 20-24 Female   |         |         |
|           | By Age/Sex: 25-49 Female   |         |         |
|           | By Age/Sex: 50+ Female   |         |         |
|           | Sum of Age/Sex disaggregates   |         | 11,536  |
|           | Aggregated Grouping by Age: <1 Male  | 5,439   | 2,536   |
|           | Aggregated Grouping by Age/Sex: 1-14 Male                                    |         | 9,824   |
|           | Aggregated Grouping by Age/Sex: 15+ Male                                     | 55,337  | 100,427 |
|           | Aggregated Grouping by Age/Sex: <1 Female                                    | 6,012   | 2,536   |
|           | Aggregated Grouping by Age/Sex: 15+ Female                                   | 135,475 | 186,498 |
|           | Sum of Aggregated Age/Sex disaggregates                                      | 219,436 | 286,925 |
|           | Pregnancy status   | 44,102  | 36,150  |
|           | Breastfeeding status   | 28,622  |         |
|           | Aggregated Grouping by Age/Sex: 1-14 Female                                  |         | 9,824   |
| TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) |         | 42,326  |
|           | By Age/Sex: <1 Male  |         |         |
|           | By Age/Sex: 1-4 Male   |         | 1,256   |
|           | By Age/Sex: 5-9 Male   |         |         |
|           | By Age/Sex: 10-14 Male   |         |         |
|           | By Age/Sex: 15-19 Male   |         |         |

|            |  |      |        |
|------------|--|------|--------|
|            | By Age/Sex: 20-24 Male   |      |        |
|            | By Age/Sex: 25-49 Male   |      |        |
|            | By Age/Sex: 50+ Male   |      |        |
|            | By Age/Sex: <1 Female  |      |        |
|            | By Age/Sex: 1-4 Female   |      | 1,256  |
|            | By Age/Sex: 5-9 Female   |      |        |
|            | By Age/Sex: 10-14 Female   |      |        |
|            | By Age/Sex: 15-19 Female   |      |        |
|            | By Age/Sex: 20-24 Female   |      |        |
|            | By Age/Sex: 25-49 Female   |      |        |
|            | By Age/Sex: 50+ Female   |      |        |
|            | Sum of Age/Sex disaggregates   |      | 2,512  |
|            | Aggregated Grouping by Age: <1 Male  |      | 555    |
|            | Aggregated Grouping by Age/Sex: 1-14 Male  |      | 2,147  |
|            | Aggregated Grouping by Age/Sex: 15+ Male   |      | 12,922 |
|            | Aggregated Grouping by Age: <1 Female  |      | 555    |
|            | Aggregated Grouping by Age/Sex: 1-14 Female  |      | 2,147  |
|            | Aggregated Grouping by Age/Sex: 15+ Female   |      | 24,005 |
|            | Sum of Aggregated Age/Sex disaggregates  |      | 36,927 |
|            | Pregnancy status   |      | 8,265  |
|            | Breastfeeding status   |      |        |
| TX_RET_DSD | TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of | 85 % |        |

|  |   |         |         |
|--|---|---------|---------|
|  | antiretroviral therapy  |         |         |
|  | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 110,428 | 121,857 |
|  | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 129,915 | 165,357 |
|  | Age/Sex: <5 Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |         |         |
|  | Age/Sex: 5-14 Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |         |         |
|  | Age/Sex: 15-19 Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)  |         |         |
|  | Age/Sex: 20+ Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)  |         |         |

|  |  |  |  |
|--|--|--|--|
|  | ART)   |  |  |
|  | Age/Sex: <5 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)  |  |  |
|  | Age/Sex: 5-14 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)  |  |  |
|  | Age/Sex: 15-19 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |  |  |
|  | Age/Sex: 20+ Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |  |  |
|  | Age/Sex: <5 Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |  |  |
|  | Age/Sex: 5-14 Male   |  |  |



|  |   |  |  |
|--|---|--|--|
|  | (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)                        |  |  |
|  | Age/Sex: 15-19 Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |  |  |
|  | Age/Sex: 20+ Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)   |  |  |
|  | Age/Sex: <5 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have   |  |  |

|  |   |  |  |
|--|---|--|--|
|  | died, those who have stopped ART, and those lost to follow-up)  |  |  |
|  | Age/Sex: 5-14 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  |  |  |
|  | Age/Sex: 15-19 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |  |  |
|  | Age/Sex: 20+ Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)   |  |  |
|  | Numerator by Status:<br>Pregnant  |  |  |
|  | Numerator by Status:  |  |  |

|           |   |     |        |
|-----------|---|-----|--------|
|           | Breastfeeding   |     |        |
|           | Denominator by Status:<br>Pregnant  |     |        |
|           | Denominator by Status:<br>Breastfeeding   |     |        |
| TX_RET_TA | TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy  | n/a |        |
|           | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  |     | 28,907 |
|           | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up |     | 39,848 |
|           | Age/Sex: <5 Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |     |        |
|           | Age/Sex: 5-14 Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |     |        |
|           | Age/Sex: 15-19 Male   |     |        |

|  |  |  |  |
|--|--|--|--|
|  | (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)                          |  |  |
|  | Age/Sex: 20+ Male<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)     |  |  |
|  | Age/Sex: <5 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)    |  |  |
|  | Age/Sex: 5-14 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)  |  |  |
|  | Age/Sex: 15-19 Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) |  |  |
|  | Age/Sex: 20+ Female<br>(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)   |  |  |
|  | Age/Sex: <5 Male   |  |  |

|  |   |  |  |
|--|---|--|--|
|  | (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)                        |  |  |
|  | Age/Sex: 5-14 Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  |  |  |
|  | Age/Sex: 15-19 Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |  |  |
|  | Age/Sex: 20+ Male<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have  |  |  |

|  |   |  |  |
|--|---|--|--|
|  | died, those who have stopped ART, and those lost to follow-up)  |  |  |
|  | Age/Sex: <5 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)    |  |  |
|  | Age/Sex: 5-14 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)  |  |  |
|  | Age/Sex: 15-19 Female<br>(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |  |  |
|  | Age/Sex: 20+ Female<br>(Denominator: Total number of adults and children who  |  |  |

|              |  |     |        |
|--------------|--|-----|--------|
|              | initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |     |        |
|              | Numerator by Status: Pregnant  |     |        |
|              | Numerator by Status: Breastfeeding   |     |        |
|              | Denominator by Status: Pregnant  |     |        |
|              | Denominator by Status: Breastfeeding   |     |        |
| TX_VIRAL_DSD | TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART   | n/a |        |
|              | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months                                 |     | 61,068 |
|              | Number of adults and children on ART at least 6 months whose medical records were reviewed   |     | 87,236 |
|              | Age/Sex: <1 Male   |     |        |
|              | Age/Sex: 1-4 Male  |     |        |
|              | Age/Sex: 5-14 Male   |     |        |
|              | Age/Sex: 15-19 Male  |     |        |
|              | Age/Sex: 20+ Male  |     |        |
|              | Age/Sex: <1 Female   |     |        |
|              | Age/Sex: 1-4 Female  |     |        |

|             |   |     |        |
|-------------|---|-----|--------|
|             | Age/Sex: 5-14 Female  |     |        |
|             | Age/Sex: 15-19 Female   |     |        |
|             | Age/Sex: 20+ Female   |     |        |
|             | Results Category:<br>Undetectable   |     |        |
|             | Results Category: Detectable  |     |        |
| TX_VIRAL_TA | TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART                             | n/a |        |
|             | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months. |     | 13,585 |
|             | Number of adults and children on ART at least 6 months whose medical records were reviewed.   |     | 19,402 |
|             | Age/Sex: <1 Male  |     |        |
|             | Age/Sex: 1-4 Male   |     |        |
|             | Age/Sex: 5-14 Male  |     |        |
|             | Age/Sex: 15-19 Male   |     |        |
|             | Age/Sex: 20+Male  |     |        |
|             | Age/Sex: <1 Female  |     |        |
|             | Age/Ses: 1-4 Female   |     |        |
|             | Age/Sex: 5-14 Female  |     |        |
|             | Age/Sex: 15-19 Female   |     |        |
|             | Age/Sex: 20+ Female   |     |        |
|             | Result Category:<br>Undetectable  |     |        |
|             | Result Category: Detectable   |     |        |
| LAB_ACC_TA  | Number of PEPFAR-supported testing  |     | 90     |



|             |  |     |       |
|-------------|--|-----|-------|
|             | facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation |     |       |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests   | 460 |       |
|             | By clinical laboratories   |     | 110   |
|             | By Point-of-care testing sites   |     | 665   |
| LAB_CAP_TA  | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests   |     |       |
|             | By clinical laboratories   |     | 235   |
|             | By Point-of-care testing sites   |     | 1,759 |
| LAB_PT_TA   | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program                    |     |       |
|             | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program   |     | 242   |
|             | CD4: Number of laboratories that participate in this PT  |     | 261   |

|  |   |  |       |
|--|---|--|-------|
|  | program   |  |       |
|  | CD4: Number of laboratories that perform this testing   |  | 294   |
|  | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program         |  | 28    |
|  | Early infant diagnostics: Number of laboratories that participate in this PT program  |  | 32    |
|  | Early infant diagnostics: Number of laboratories that perform this testing  |  | 48    |
|  | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program |  | 286   |
|  | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program                                    |  | 338   |
|  | HIV serologic/diagnostic testing: Number of laboratories that perform this testing  |  | 2,973 |
|  | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program                   |  | 7     |
|  | HIV viral load: Number of   |  | 31    |

|  |  |  |     |
|--|--|--|-----|
|  | laboratories that participate in this PT program   |  |     |
|  | HIV viral load: Number of laboratories that perform this testing   |  | 31  |
|  | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program |  | 153 |
|  | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program                                    |  | 132 |
|  | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing  |  | 486 |
|  | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program  |  | 34  |
|  | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program                                     |  | 36  |
|  | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing   |  | 47  |
|  | TB diagnostics (Culture/DST): Number of  |  | 5   |

|                 |   |     |        |
|-----------------|---|-----|--------|
|                 | laboratories that achieve acceptable successful passing criteria in this PT program   |     |        |
|                 | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program  |     | 8      |
|                 | TB diagnostics (Culture/DST): Number of laboratories that perform this testing  |     | 8      |
| TX_UNDETECT_DSD | TX_UNDETECT_DSD<br>Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)                                 | n/a |        |
|                 | Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml |     | 91,600 |
|                 | Number of viral load tests performed from adults and children on ART within the current reporting period                            |     | 61,068 |
|                 | Age/Sex: <1 Male  |     |        |
|                 | Age/Sex: 1-4 Male   |     | 50     |
|                 | Age/Sex: 5-14 Male  |     |        |
|                 | Age/Sex: 15-19 Male   |     |        |
|                 | Age/Sex: 20+ Male   |     |        |
|                 | Age/Sex: <1 Female  |     | 50     |
|                 | Age/Sex: 1-4 Female   |     |        |
|                 | Age/Sex: 5-14 Female  |     |        |
|                 | Age/Sex: 15-19 Female   |     |        |

|                |   |     |        |
|----------------|---|-----|--------|
|                | Age/Sex: 20+ Female   |     |        |
|                | Pregnant  |     |        |
|                | Breastfeeding   |     |        |
|                | Test indication: Routine monitoring   |     |        |
|                | Test indication: Targeted monitoring  |     |        |
| TX_UNDETECT_TA | TX_UNDETECT_TA<br>Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)                                  | n/a |        |
|                | Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml |     | 21,200 |
|                | Number of viral load tests performed from adults and children on ART within the current reporting period                            |     | 13,585 |
|                | Age/Sex: <1 Female  |     |        |
|                | Age/Sex: <1 Male  |     |        |
|                | Age/Sex: 1-4 Female   |     |        |
|                | Age/Sex: 1-4 Male   |     |        |
|                | Age/Sex: 15-19 Female   |     |        |
|                | Age/Sex: 15-19 Male   |     |        |
|                | Age/Sex: 20+ Female   |     |        |
|                | Age/Sex: 20+ Male   |     |        |
|                | Age/Sex: 5-14 Female  |     |        |
|                | Age/Sex: 5-14 Male  |     |        |
|                | Breastfeeding   |     |        |
|                | Pregnant  |     |        |
|                | Test indication: Routine  |     |        |

|                |   |       |       |
|----------------|---|-------|-------|
|                | monitoring  |       |       |
|                | Test indication: Targeted monitoring  |       |       |
| HRH_PRE        | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre      | 2,027 | 681   |
|                | By Graduates: Doctors   | 64    |       |
|                | By Graduates: Nurses  | 1,336 | 341   |
|                | By Graduates: Midwives  |       |       |
|                | By Graduates: Social service workers  | 90    | 120   |
|                | By Graduates: Laboratory professionals  | 82    | 80    |
|                | By Graduates: Other   | 455   | 345   |
|                | Sum of Graduates disaggreagtes  | 2,027 | 886   |
| FPINT_SITE_DSD | FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services | 80 %  |       |
|                | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 885   | 1,327 |

|               |  |       |       |
|---------------|--|-------|-------|
|               | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment  | 1,106 | 1,327 |
|               | Service delivery type: Care and Support  |       | 388   |
|               | Service delivery type: Treatment   |       | 388   |
|               | Service delivery type: PMTCT   |       | 551   |
|               | Sum of Service delivery type (Care, Tx and PMTCT) disaggregates  |       |       |
| FPINT_SITE_TA | FPINT_SITE_TA Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services | n/a   |       |
|               | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services   |       | 339   |
|               | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment  |       | 339   |
|               | Service delivery type: Care and Support  |       | 112   |
|               | Service delivery type: Treatment   |       | 112   |



|  |   |  |     |
|--|---|--|-----|
|  | Service delivery type:<br>PMTCT                                       |  | 115 |
|  | Sum of Service Delivery<br>Type (Care, Tx and PMTCT)<br>disaggregates |  | 339 |



## Partners and Implementing Mechanisms

### Partner List

| Mech ID | Partner Name  | Organization Type  | Agency  | Funding Source | Planned Funding |
|---------|---|--------------------|---|----------------|-----------------|
| 7314    | University Research Corporation, LLC                                    | Private Contractor | U.S. Agency for International Development   | GHP-State      | 0               |
| 7315    | FHI 360   | NGO                | U.S. Agency for International Development   | GHP-State      | 0               |
| 7326    | Partnership for Supply Chain Management                                 | Private Contractor | U.S. Agency for International Development   | GHP-State      | 61,178,456      |
| 7328    | University of North Carolina at Chapel Hill, Carolina Population Center | University         | U.S. Agency for International Development   | GHP-State      | 300,000         |
| 7466    | TEBA Development  | NGO                | U.S. Agency for International Development   | GHP-State      | 0               |
| 9564    | American Society of Clinical Pathology                                  | NGO                | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State      | 1,020,000       |
| 9568    | American Society for Microbiology                                       | Private Contractor | U.S. Department of Health and Human Services/Centers                                    | GHP-State      | 725,000         |



|      |  |                                |   |           |            |
|------|--|--------------------------------|---|-----------|------------|
|      |  |                                | for Disease Control and Prevention  |           |            |
| 9570 | U.S. Department of State                               | Other USG Agency               | U.S. Department of State/Bureau of African Affairs  | GHP-State | 375,000    |
| 9725 | American International Health Alliance Twinning Center | NGO                            | U.S. Department of Health and Human Services/Health Resources and Services Administration | GHP-State | 450,000    |
| 9811 | Vanderbilt University                                  | University                     | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 18,095,253 |
| 9818 | Association of Public Health Laboratories              | NGO                            | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 1,600,000  |
| 9856 | Ministry of Health, Mozambique                         | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 440,000    |
| 9858 | Ministry of Women and                                  | Host Country Government        | U.S. Department of Health and   | GHP-State | 0          |



|       |                                      |                    |   |           |            |
|-------|--------------------------------------|--------------------|---|-----------|------------|
|       | Social Action, Mozambique            | Agency             | Human Services/Centers for Disease Control and Prevention                               |           |            |
| 9900  | FHI 360                              | NGO                | U.S. Agency for International Development   | GHP-State | 2,415,307  |
| 10135 | Abt Associates                       | Private Contractor | U.S. Agency for International Development   | GHP-State | 0          |
| 10962 | University of Connecticut            | University         | U.S. Department of Defense  | GHP-State | 173,093    |
| 10971 | U.S. Department of Defense (Defense) | Other USG Agency   | U.S. Department of Defense  | GHP-State | 0          |
| 11463 | U.S. Peace Corps                     | Other USG Agency   | U.S. Peace Corps  | GHP-State | 420,905    |
| 11580 | JHPIEGO                              | University         | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 26,022,759 |
| 12147 | JHPIEGO                              | University         | U.S. Agency for International Development   | GHP-State | 0          |
| 12148 | Pathfinder International             | NGO                | U.S. Agency for International Development   | GHP-State | 0          |
| 12149 | World Vision International           | FBO                | U.S. Agency for International Development   | GHP-State | 1,938,437  |
| 12150 | Management                           | NGO                | U.S. Agency for   | GHP-State | 1,000,000  |



|       |   |                      |   |           |           |
|-------|---|----------------------|---|-----------|-----------|
|       | Sciences for Health                         |                      | International Development   |           |           |
| 12152 | FHI 360                                     | NGO                  | U.S. Agency for International Development   | GHP-State | 0         |
| 12159 | United Nations Development Programme        | Multi-lateral Agency | U.S. Agency for International Development   | GHP-State | 0         |
| 12165 | Health Alliance International               | NGO                  | U.S. Agency for International Development   | GHP-State | 250,000   |
| 12167 | Clinical and Laboratory Standards Institute | NGO                  | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0         |
| 12168 | Pathfinder International                    | NGO                  | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 2,362,132 |
| 12169 | Samaritans Purse                            | FBO                  | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0         |
| 12619 | American Association of Blood Banks         | NGO                  | U.S. Department of Health and Human Services/Centers                                    | GHP-State | 250,000   |



|       |  |                                |   |           |           |
|-------|--|--------------------------------|---|-----------|-----------|
|       |  |                                | for Disease Control and Prevention  |           |           |
| 12624 | Fundacao Universitaria Jose Bonifacio          | NGO                            | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0         |
| 12648 | United States Pharmacopeia                     | Private Contractor             | U.S. Agency for International Development   | GHP-State | 300,000   |
| 12665 | Provincial Directorate of Health, Cabo Delgado | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 389,300   |
| 12681 | JEMBI  | Private Contractor             | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,430,896 |
| 12702 | University of California at San Francisco      | University                     | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,850,000 |
| 12998 | Provincial Directorate of                      | Host Country Government        | U.S. Department of Health and   | GHP-State | 97,325    |



**PEPFAR**

U.S. President's Emergency Plan for AIDS Relief

|       |   |                                |   |           |            |
|-------|---|--------------------------------|---|-----------|------------|
|       | Health, Maputo                                      | Agency                         | Human Services/Centers for Disease Control and Prevention                               |           |            |
| 13022 | FHI 360   | NGO                            | U.S. Agency for International Development   | GHP-State | 38,555,013 |
| 13065 | Columbia University Mailman School of Public Health | University                     | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,000,000  |
| 13160 | Provincial Directorate of Health, Zambezia          | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 875,926    |
| 13194 | University of California at San Francisco           | University                     | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0          |
| 13206 | Elizabeth Glaser Pediatric AIDS Foundation          | NGO                            | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0          |



|       |  |                    |   |           |           |
|-------|--|--------------------|---|-----------|-----------|
| 13212 | New York AIDS Institute                                    | Other USG Agency   | U.S. Department of Health and Human Services/Health Resources and Services Administration | GHP-State | 0         |
| 13214 | Deloitte Consulting Limited                                | Private Contractor | U.S. Agency for International Development   | GHP-State | 0         |
| 13255 | FHI 360  | NGO                | U.S. Agency for International Development   | GHP-State | 0         |
| 13271 | Johns Hopkins University Bloomberg School of Public Health | University         | U.S. Agency for International Development   | GHP-State | 0         |
| 13275 | Columbia University Mailman School of Public Health        | University         | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 0         |
| 13313 | Regional Procurement Support Office/Frankfurt              | Other USG Agency   | U.S. Department of State/Bureau of African Affairs  | GHP-State | 1,600,000 |
| 13413 | International Youth Foundation                             | NGO                | U.S. Agency for International Development   | GHP-State | 0         |
| 13510 | Global Health Communications                               | NGO                | U.S. Department of Health and Human Services/Centers for Disease                          | GHP-State | 0         |



**PEPFAR**

U.S. President's Emergency Plan for AIDS Relief

|       |   |            |   |           |            |
|-------|---|------------|---|-----------|------------|
|       |   |            | Control and Prevention  |           |            |
| 13583 | Columbia University Mailman School of Public Health | University | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 27,667,525 |
| 13654 | Catholic University of Mozambique                   | University | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 300,000    |
| 13661 | Barcelona Centre for International Health           | NGO        | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 540,000    |
| 13668 | Fundacao ARIEL Contra a SIDA Pediatrica             | NGO        | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 25,768,800 |
| 13776 | Center for Collaboration in Health                  | NGO        | U.S. Department of Health and Human Services/Centers for Disease Control and            | GHP-State | 18,699,218 |



|       |  |                                |   |           |           |
|-------|--|--------------------------------|---|-----------|-----------|
|       |  |                                | Prevention  |           |           |
| 13782 | International Center for Reproductive Health, Mozambique         | NGO                            | U.S. Agency for International Development   | GHP-State | 0         |
| 13784 | Instituto Nacional de Saúde                                      | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 3,965,000 |
| 14597 | DevResults   | Private Contractor             | U.S. Agency for International Development   | GHP-State | 76,000    |
| 14598 | Futures Group  | Private Contractor             | U.S. Agency for International Development   | GHP-State | 240,000   |
| 14639 | New Partner  | TBD                            | U.S. Agency for International Development   | GHP-State | 400,000   |
| 14652 | Columbia University Mailman School of Public Health              | University                     | U.S. Agency for International Development   | GHP-State | 200,000   |
| 14670 | Foundation for Community Development, Mozambique                 | NGO                            | U.S. Agency for International Development   | GHP-State | 1,063,551 |
| 14719 | U.S. Department of Health and Human Services/Centers for Disease | Implementing Agency            | U.S. Department of Health and Human Services/Centers for Disease                        | GHP-State | 500,000   |



|       |   |                      |   |           |            |
|-------|---|----------------------|---|-----------|------------|
|       | Control and Prevention (HHS/CDC)                |                      | Control and Prevention  |           |            |
| 14732 | FHI 360   | NGO                  | U.S. Agency for International Development   | GHP-State | 350,000    |
| 14739 | TBD   | TBD                  | Redacted  | Redacted  | Redacted   |
| 14748 | United Nations Children's Fund                  | Multi-lateral Agency | U.S. Agency for International Development   | GHP-State | 1,060,000  |
| 14751 | Gorongosa National Park                         | TBD                  | U.S. Agency for International Development   | GHP-State | 0          |
| 14789 | Elizabeth Glaser Pediatric AIDS Foundation      | NGO                  | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 22,563,096 |
| 14792 | ISCISA- Superior Institution of Health Sciences | University           | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 400,000    |
| 14794 | Mozambique Blood Donor Association              | NGO                  | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0          |
| 14806 | U.S. Department                                 | Other USG            | U.S. Department   | GHP-State | 375,000    |



|       |   |                                |   |           |           |
|-------|---|--------------------------------|---|-----------|-----------|
|       | of State                                    | Agency                         | of State/Bureau of African Affairs  |           |           |
| 14807 | Population Services International           | NGO                            | U.S. Department of Defense  | GHP-State | 0         |
| 14822 | University of Washington                    | University                     | U.S. Department of Health and Human Services/Health Resources and Services Administration | GHP-State | 3,208,333 |
| 16052 | University of California at San Francisco   | University                     | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 900,000   |
| 16671 | Foundation for Innovative New Diagnostics   | NGO                            | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 755,000   |
| 16802 | Provincial Directorate of Health, Inhambane | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 97,325    |
| 16879 | World Food Program                          | Multi-lateral Agency           | U.S. Agency for International Development   | GHP-State | 4,252,526 |



|       |  |                                |   |           |           |
|-------|--|--------------------------------|---|-----------|-----------|
| 16998 | Provincial Directorate of Health, Gaza   | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 439,300   |
| 16999 | Provincial Directorate of Health, Nampula  | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 97,325    |
| 17044 | Ministry of Health, Mozambique   | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,374,000 |
| 17169 | John Snow Inc (JSI)  | Implementing Agency            | U.S. Agency for International Development   | GHP-State | 875,000   |
| 17171 | N'WETI - Comunicação para Saúde  | NGO                            | U.S. Agency for International Development   | GHP-State | 1,104,424 |
| 17259 | JEMBI  | Private Contractor             | U.S. Agency for International Development   | GHP-State | 0         |
| 17260 | REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã | NGO                            | U.S. Agency for International Development   | GHP-State | 502,004   |

|       |   |            |   |           |           |
|-------|---|------------|---|-----------|-----------|
| 17261 | Associacao Nacional dos Enfermeiros de Mocambique (ANEMO) | NGO        | U.S. Agency for International Development   | GHP-State | 0         |
| 17567 | National Alliance of State and Territorial AIDS Directors | NGO        | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention   | GHP-State | 890,370   |
| 17571 | Columbia University Mailman School of Public Health       | University | U.S. Department of Health and Human Services/Health Resources and Services Administration | GHP-State | 100,000   |
| 17591 | TBD   | TBD        | Redacted  | Redacted  | Redacted  |
| 17652 | University of California                                  | University | U.S. Agency for International Development   | GHP-State | 250,000   |
| 17723 | JHPIEGO   | University | U.S. Department of Defense  | GHP-State | 2,462,147 |
| 18099 | FHI 360   | NGO        | U.S. Agency for International Development   | GHP-State | 1,555,770 |
| 18100 | TBD   | TBD        | Redacted  | Redacted  | Redacted  |
| 18101 | JHPIEGO   | University | U.S. Agency for International Development   | GHP-State | 500,000   |
| 18102 | TBD   | TBD        | Redacted  | Redacted  | Redacted  |
| 18103 | TBD   | TBD        | Redacted  | Redacted  | Redacted  |
| 18104 | TBD   | TBD        | Redacted  | Redacted  | Redacted  |

|       |             |                    |   |           |          |
|-------|-------------|--------------------|---|-----------|----------|
| 18108 | TBD         | TBD                | Redacted  | Redacted  | Redacted |
| 18110 | New Partner | TBD                | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 100,000  |
| 18112 | TBD         | TBD                | Redacted  | Redacted  | Redacted |
| 18120 | TBD         | TBD                | Redacted  | Redacted  | Redacted |
| 18121 | ICF Macro   | Private Contractor | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 410,000  |
| 18122 | TBD         | TBD                | Redacted  | Redacted  | Redacted |
| 18123 | TBD         | TBD                | Redacted  | Redacted  | Redacted |



## Implementing Mechanism(s)

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 7314</b>                                | <b>Mechanism Name: ASSIST (Applying Science to Strengthen and Improve Systems)</b> |
| Funding Agency: USAID                                    | Procurement Type: Contract   |
| Prime Partner Name: University Research Corporation, LLC |  |
| Agreement Start Date: Redacted                           | Agreement End Date: Redacted   |
| TBD: No  | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A               |  |
| G2G: No  | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                           |  |
|---------------------------|--|
| <b>Mechanism ID: 7314</b> |  |
|---------------------------|--|

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism Name:</b>     | <b>ASSIST (Applying Science to Strengthen and Improve Systems)</b> |                       |                       |
| <b>Prime Partner Name:</b> | <b>University Research Corporation, LLC</b>                        |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC   | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID   | 0                     | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 7315</b>                  | <b>Mechanism Name: FANTA III</b>        |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement |
| Prime Partner Name: FHI 360                |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted            |
| TBD: No                                    | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:                        |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 7315        |                |                |
|----------------------------|-------------|----------------|----------------|
| <b>Mechanism Name:</b>     | FANTA III   |                |                |
| <b>Prime Partner Name:</b> | FHI 360     |                |                |
| Strategic Area             | Budget Code | Planned Amount | On Hold Amount |
| Care                       | HKID        | 0              | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 7326</b>                                   | <b>Mechanism Name: Supply Chain Management Systems (SCMS)</b> |
| Funding Agency: USAID                                       | Procurement Type: Contract                                    |
| Prime Partner Name: Partnership for Supply Chain Management |   |
| Agreement Start Date: Redacted                              | Agreement End Date: Redacted                                  |
| TBD: No   | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A                  |   |
| G2G: No   | Managing Agency:  |

| <b>Total All Funding Sources: 61,178,456</b> |                |
|--|----------------|
| <b>Applied Pipeline Amount: 0</b>            |                |
| Funding Source                               | Funding Amount |
| GHP-State                                    | 61,178,456     |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                           |         |
|---------------------------|---------|
| Motor Vehicles: Purchased | 135,000 |
|---------------------------|---------|

## Key Issues

(No data provided.)

## Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 7326                                    |                       |                       |
| <b>Mechanism Name:</b>     | Supply Chain Management Systems (SCMS)  |                       |                       |
| <b>Prime Partner Name:</b> | Partnership for Supply Chain Management |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                                    | 3,300,000             | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HVTB                                    | 800,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HVSI                                    | 650,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | OHSS                                    | 8,141,121             | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | CIRC                                    | 230,000               | 0                     |

| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Treatment      | HTXD        | 31,500,000     | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | HTXS        | 16,516,306     | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | PDTX        | 41,029         | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| LAB_CAP_DSD      | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 86   |      |
| LAB_CAP_DSD      | By site support type: Direct Service Delivery (DSD)  | 86   |      |
| LAB_CAP_DSD      | Sum of Site Support Type disaggregates   | 86   |      |
| LAB_CAP_TA       | Sum of Site Support Type disaggregates   | 86   |      |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 7328</b>   | <b>Mechanism Name: Measure Impact Evaluation of OVC program - MEASURE IV</b> |
| Funding Agency: USAID   | Procurement Type: Contract   |
| Prime Partner Name: University of North Carolina at Chapel Hill, Carolina Population Center |  |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted   |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A  |  |
| G2G: No   | Managing Agency:   |
| <b>Total All Funding Sources: 300,000</b>   |  |
| <b>Applied Pipeline Amount: 0</b>   |  |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 300,000        |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b> 7328<br><b>Mechanism Name:</b> Measure Impact Evaluation of OVC program - MEASURE IV<br><b>Prime Partner Name:</b> University of North Carolina at Chapel Hill, Carolina Population Center |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HKID        | 300,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID:</b> 7466                   | <b>Mechanism Name:</b> Community Based Responses to HIV/AIDS in Mine-sending Areas in Mozambique |
| <b>Funding Agency:</b> USAID                | <b>Procurement Type:</b> Cooperative Agreement   |
| <b>Prime Partner Name:</b> TEBA Development |  |



|  |                              |
|--|------------------------------|
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 7466   |                       |                       |
| <b>Mechanism Name:</b>     | Community Based Responses to HIV/AIDS in Mine-sending Areas in |                       |                       |
| <b>Prime Partner Name:</b> | Mozambique   |                       |                       |
|                            | TEBA Development   |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC   | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID   | 0                     | 0                     |

| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Care           | PDCS        | 0              | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015  | 2016 |
|------------------|--|-------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 0     |      |
| PP_PREV_DSD      | Total number of people in the target population  | 0     |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 0     |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 0     |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 0     |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 0     |      |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 0     |      |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 0     |      |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 0     |      |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 0     |      |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 0     |      |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 0     |      |
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results during the past 12 months                                      | 0     |      |
| OVC_ACC_DSD      | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services   | 1,018 |      |
| OVC_SERV_DSD     | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS  | 4,074 |      |
| OVC_SERV_DSD     | Sex: Male  | 2,037 |      |



|                |   |       |  |
|----------------|---|-------|--|
| OVC_SERV_DSD   | Sex: Female   | 2,037 |  |
| OVC_SERV_DSD   | Sum of Sex disaggregates  | 4,074 |  |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment | 0     |  |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 9564</b>                                  | <b>Mechanism Name: ASCP</b>             |
| Funding Agency: HHS/CDC                                    | Procurement Type: Cooperative Agreement |
| Prime Partner Name: American Society of Clinical Pathology |   |
| Agreement Start Date: Redacted                             | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                 |   |
| G2G: No  | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,020,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,020,000             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 9564                                   |                       |                       |
| <b>Mechanism Name:</b>     | ASCP                                   |                       |                       |
| <b>Prime Partner Name:</b> | American Society of Clinical Pathology |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HLAB                                   | 1,020,000             | 0                     |

### Implementing Mechanism Indicator Information

| Indicator Number | Label                             | 2015 | 2016 | Planning Budget Targets |
|------------------|-----------------------------------|------|------|-------------------------|
| LAB_ACC_TA       | Sum of Support Type disaggregates | 19   |      | Redacted                |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 9568</b>                             | <b>Mechanism Name: ASM-Technical assistance for microbiology capacity building</b> |
| Funding Agency: HHS/CDC                               | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: American Society for Microbiology |  |
| Agreement Start Date: Redacted                        | Agreement End Date: Redacted   |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A            |  |
| G2G: No   | Managing Agency:   |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 725,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 725,000               |

### Sub Partner Name(s)

(No data provided.)



## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 9568<br><b>Mechanism Name:</b> ASM-Technical assistance for microbiology capacity building<br><b>Prime Partner Name:</b> American Society for Microbiology |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HVTB        | 125,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems  | HLAB        | 500,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Treatment   | HTXS        | 100,000        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| LAB_CAP_DSD      | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 3    |      | Redacted                |

|             |  |   |  |          |
|-------------|--|---|--|----------|
| LAB_CAP_DSD | By site support type: Technical Assistance-only (TA) | 3 |  | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates               | 3 |  | Redacted |
| LAB_CAP_TA  | Sum of Site Support Type disaggregates               | 3 |  | Redacted |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 9570</b>                    | <b>Mechanism Name: PAS Small Grants</b> |
| Funding Agency: State/AF                     | Procurement Type: Grant                 |
| Prime Partner Name: U.S. Department of State |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted            |
| TBD: No                                      | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A   |   |
| G2G: No                                      | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 375,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 375,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | <b>9570</b>                     |                |                |
|----------------------------|---------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | <b>PAS Small Grants</b>         |                |                |
| <b>Prime Partner Name:</b> | <b>U.S. Department of State</b> |                |                |
| Strategic Area             | Budget Code                     | Planned Amount | On Hold Amount |
| Care                       | HBHC                            | 210,000        | 0              |
| Strategic Area             | Budget Code                     | Planned Amount | On Hold Amount |
| Care                       | HKID                            | 100,000        | 0              |
| Strategic Area             | Budget Code                     | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS                            | 15,000         | 0              |
| Strategic Area             | Budget Code                     | Planned Amount | On Hold Amount |
| Prevention                 | HVOP                            | 50,000         | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015   | 2016 |
|------------------|--|--------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 42,271 |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 3,297  |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 5,073  |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 2,579  |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 2,240  |      |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 296    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 8,243  |      |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 13,696 |      |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 6,129  |      |



|             |                              |        |  |
|-------------|------------------------------|--------|--|
| PP_PREV_DSD | Age/sex: 25-49 Female        | 719    |  |
| PP_PREV_DSD | Sum of Age/Sex disaggregates | 42,272 |  |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 9725</b>  | <b>Mechanism Name: Disclosure counseling training for social service providers supporting parents, children and adolescents</b> |
| Funding Agency: HHS/HRSA   | Procurement Type: Cooperative Agreement   |
| Prime Partner Name: American International Health Alliance Twinning Center |   |
| Agreement Start Date: Redacted   | Agreement End Date: Redacted  |
| TBD: No  | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A                                 |   |
| G2G: No  | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 450,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 450,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                           |
|---------------------------|
| <b>Mechanism ID:</b> 9725 |
|---------------------------|



|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism Name:</b>     | Disclosure counseling training for social service providers supporting                      |                       |                       |
| <b>Prime Partner Name:</b> | parents, children and adolescents<br>American International Health Alliance Twinning Center |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID  | 450,000               | 0                     |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 9811</b>                  | <b>Mechanism Name: Friends in Global Health</b> |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement         |
| Prime Partner Name: Vanderbilt University  |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                    |
| TBD: No                                    | New Mechanism: No                               |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:                                |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 18,095,253</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 18,095,253            |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                           |         |
|---------------------------|---------|
| Motor Vehicles: Purchased | 671,170 |
|---------------------------|---------|

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 9811<br><b>Mechanism Name:</b> Friends in Global Health<br><b>Prime Partner Name:</b> Vanderbilt University |             |                |                |
|--|-------------|----------------|----------------|
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | HBHC        | 2,631,610      | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | HVTB        | 388,677        | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | PDCS        | 552,600        | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Prevention   | HVCT        | 1,120,278      | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Prevention   | MTCT        | 1,861,565      | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Treatment  | HTXS        | 10,271,756     | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Treatment  | PDTX        | 1,268,767      | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label | 2015 | 2016 | Planning |
|------------------|-------|------|------|----------|
|------------------|-------|------|------|----------|

|                   |  |       |       | <b>Budget Targets</b> |
|-------------------|--|-------|-------|-----------------------|
| PMTCT_ARV_DS<br>D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 7,950 | 5,217 | Redacted              |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 8,086 | 5,217 | Redacted              |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 7,791 |       | Redacted              |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 5,385 | 3,130 | Redacted              |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 2,308 | 2,087 | Redacted              |
| PMTCT_ARV_DS<br>D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 159   |       | Redacted              |
| PMTCT_ARV_DS<br>D | Single-dose nevirapine (with or without tail)  | 0     | 0     | Redacted              |
| PMTCT_ARV_DS<br>D | Sum of Regimen Type disaggregates  | 7,950 | 0     | Redacted              |
| PMTCT_ARV_DS<br>D | Sum of New and Current disaggregates   | 7,693 | 5,217 | Redacted              |
| PMTCT_ARV_TA      | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 826   | 607   | Redacted              |
| PMTCT_ARV_TA      | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 841   | 243   | Redacted              |

|                    |  |         |         |          |
|--------------------|--|---------|---------|----------|
| PMTCT_ARV_TA       | Life-long ART (including Option B+)  | 703     |         | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy                              | 560     | 364     | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy                         | 240     | 243     | Redacted |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)                                 | 124     |         | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates  | 827     | 0       | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates   | 800     | 607     | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 100,685 | 60,546  | Redacted |
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients  | 100,685 | 57,662  | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry   | 2,345   | 1,514   | Redacted |
| PMTCT_STAT_DS<br>D | By: Number of new positives identified   | 5,741   | 3,703   | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates  | 8,086   | 5,217   | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 10,468  | 14,337  | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients  | 10,468  | 13,550  | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry   | 244     | 70      | Redacted |
| PMTCT_STAT_TA      | By: Number of new positives identified   | 597     | 173     | Redacted |
| PMTCT_STAT_TA      | Sum of Positives Status disaggregates  | 841     | 243     | Redacted |
| HTC_TST_DSD        | Number of individuals who received T&C services for HIV and received their   | 272,569 | 420,004 | Redacted |



|                   |   |        |         |          |
|-------------------|---|--------|---------|----------|
|                   | test results during the past 12 months  |        |         |          |
| HTC_TST_TA        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 18,789 | 30,229  | Redacted |
| GEND_GBV_DSD      | Number of people receiving post-GBV care  | 40     | 926     | Redacted |
| CARE_CURR_DS<br>D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 77,332 | 100,461 | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 3,093  |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 30,160 |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 3,093  |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 40,986 |         | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex disaggregates   | 77,332 |         | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 1,625  | 5,374   | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 65     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 634    |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 65     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 861    |         | Redacted |

|               |   |        |        |          |
|---------------|---|--------|--------|----------|
| CARE_CURR_TA  | Sum of Aggregated Age/Sex disaggregates   | 1,625  |        | Redacted |
| CARE_NEW_DSD  | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 40,451 | 38,329 | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male  | 1,618  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male  | 15,776 |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female  | 1,618  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female  | 21,439 |        | Redacted |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates   | 40,451 |        | Redacted |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates   | 40,451 |        | Redacted |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.   | 5,800  | 9,044  | Redacted |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.  | 11,600 | 12,053 | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period  | 1,699  | 2,076  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period   | 1,999  | 2,307  | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period  | 8,513  | 2,663  | Redacted |

|               |  |        |        |          |
|---------------|--|--------|--------|----------|
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 8,927  |        | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 46,586 | 70,320 | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 851    | 428    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 1,276  | 976    | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 851    | 689    | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 11,748 |        | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 972    | 428    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 1,276  | 976    | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 851    | 689    | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 28,762 |        | Redacted |
| TX_CURR_DSD   | Sum of age/sex disaggregates   | 6,077  | 4,186  | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Male  | 851    |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Female  | 972    |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Male   | 3,038  |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Male   | 11,748 |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Female   | 3,038  |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Female   | 28,762 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex <15  | 6,076  |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex 15+  | 40,510 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex disaggregates  | 46,586 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex (<1 and 1-14) <15  | 1,823  |        | Redacted |
| TX_CURR_TA    | Number of adults and children receiving antiretroviral therapy (ART)   | 979    | 3,762  | Redacted |
| TX_CURR_TA    | Age/Sex: <1 Male   | 18     | 58     | Redacted |
| TX_CURR_TA    | Age/Sex: 1-4 Male  | 27     | 135    | Redacted |
| TX_CURR_TA    | Age/Sex: 5-14 Male   | 18     | 95     | Redacted |
| TX_CURR_TA    | Age/Sex: 15+ Male  | 247    |        | Redacted |

|            |  |        |        |          |
|------------|--|--------|--------|----------|
| TX_CURR_TA | Age/Sex: <1 Female   | 20     | 58     | Redacted |
| TX_CURR_TA | Age/Sex: 1-4 Female  | 27     | 135    | Redacted |
| TX_CURR_TA | Age/Sex: 5-14 Female   | 18     | 95     | Redacted |
| TX_CURR_TA | Age/Sex: 15+ Female  | 604    |        | Redacted |
| TX_CURR_TA | Sum of Age/Sex disaggregations   | 128    | 576    | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Male  | 18     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Female  | 20     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Male   | 64     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Male   | 247    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Female   | 64     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Female   | 604    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex <15  | 128    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex 15+  | 851    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates                                      | 979    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex (<1 and 1-14) <15                                  | 38     |        | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 17,764 | 47,716 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male  | 446    |        | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female  | 487    |        | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates   | 933    | 956    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male  | 446    | 213    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male                                     | 1,159  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male                                     | 4,480  | 15,984 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female                                    | 487    | 213    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female                                   | 1,159  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female                                   | 10,967 | 29,681 | Redacted |

|                |   |        |        |          |
|----------------|---|--------|--------|----------|
| TX_NEW_DSD     | Sum of Aggregated Age/Sex disaggregates   | 17,765 | 45,665 | Redacted |
| TX_NEW_DSD     | Pregnancy status  | 5,385  | 3,130  | Redacted |
| TX_NEW_DSD     | Breastfeeding status  | 2,317  |        | Redacted |
| TX_RET_DSD     | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 7,425  | 11,713 | Redacted |
| TX_RET_DSD     | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 8,735  | 17,955 | Redacted |
| LAB_CAP_DSD    | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 49     |        | Redacted |
| LAB_CAP_DSD    | By site support type: Technical Assistance-only (TA)  | 49     |        | Redacted |
| LAB_CAP_DSD    | Sum of Site Support Type disaggregates  | 49     |        | Redacted |
| LAB_CAP_TA     | Sum of Site Support Type disaggregates  | 49     |        | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 80     | 172    | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 219    | 172    | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services         | 80     |        | Redacted |

|                |   |        |         |          |
|----------------|---|--------|---------|----------|
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 80     |         | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 219    |         | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 219    |         | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 80     |         | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 80     |         | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 219    |         | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 80     |         | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 80     |         | Redacted |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 74,239 |         | Redacted |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 77,332 | 100,461 | Redacted |
| TB_SCREEN_TA   | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 1,625  | 5,374   | Redacted |

### Implementing Mechanism Details

|                           |   |
|---------------------------|---|
| <b>Mechanism ID: 9818</b> | <b>Mechanism Name: APHL</b>             |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |



|   |                              |
|---|------------------------------|
| Prime Partner Name: Association of Public Health Laboratories |                              |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted |
| TBD: No   | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A                    |                              |
| G2G: No   | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,600,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,600,000             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 9818                                      |                       |                       |
| <b>Mechanism Name:</b>     | APHL                                      |                       |                       |
| <b>Prime Partner Name:</b> | Association of Public Health Laboratories |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HLAB                                      | 1,600,000             | 0                     |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| LAB_ACC_TA       | Sum of Support Type disaggregates  | 10   |      | Redacted                |
| LAB_CAP_DSD      | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 9    |      | Redacted                |
| LAB_CAP_DSD      | By site support type: Direct Service Delivery (DSD)  | 9    |      | Redacted                |
| LAB_CAP_DSD      | Sum of Site Support Type disaggregates   | 9    |      | Redacted                |
| LAB_CAP_TA       | Sum of Site Support Type disaggregates   | 9    |      | Redacted                |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 9856</b>                          | <b>Mechanism Name: MISAU BS</b>         |
| Funding Agency: HHS/CDC                            | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Ministry of Health, Mozambique |   |
| Agreement Start Date: Redacted                     | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A         |   |
| G2G: Yes   | Managing Agency: HHS/CDC                |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 440,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 440,000               |

### Sub Partner Name(s)

(No data provided.)





## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 9856                           |                |                |
|----------------------------|--------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | MISAU BS                       |                |                |
| <b>Prime Partner Name:</b> | Ministry of Health, Mozambique |                |                |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Prevention                 | HMBL                           | 440,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 9858</b>   | <b>Mechanism Name: MMAS - Rapid Strengthening and Expansion of Integrated Social Services for People Infected and Affected by HIV/AIDS in the Republic of Mozambique</b> |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Ministry of Women and Social Action, Mozambique |  |
| Agreement Start Date: Redacted                                      | Agreement End Date: Redacted   |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A                          |  |
| G2G: Yes  | Managing Agency: HHS/CDC   |
| <b>Total All Funding Sources: 0</b>                                 |  |



|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Applied Pipeline Amount: 0</b> |                       |
|                                   |                       |
| <b>Funding Source</b>             | <b>Funding Amount</b> |
| GHP-State                         | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 9858   |                       |                       |
| <b>Mechanism Name:</b>     | MMAS - Rapid Strengthening and Expansion of Integrated Social Services for People Infected and Affected by HIV/AIDS in the Republic of |                       |                       |
| <b>Prime Partner Name:</b> | Mozambique   |                       |                       |
|                            | Ministry of Women and Social Action, Mozambique  |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC   | 0                     | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                           |  |
|---------------------------|--|
| <b>Mechanism ID: 9900</b> | <b>Mechanism Name: Capable Partners Program (CAP) II</b> |
|---------------------------|--|



|  |   |
|--|---|
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement |
| Prime Partner Name: FHI 360                |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted            |
| TBD: No                                    | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 2,415,307</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 2,415,307             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                         |   |
|-------------------------|---|
| Condom programming      | 101,694   |
| Gender: GBV             | 1,000,000   |
| Focus Area:             | GBV Prevention  |
| Sub Area:               | Implementation  |
| Sub Area:               | Capacity building   |
| Sub Area:               | Monitoring and Evaluation   |
| Focus Area:             | Post GBV Care   |
| Sub Area:               | Implementation  |
| Gender: Gender Equality | 1,000,000   |
| Focus Area:             | Changing harmful gender norms and promoting positive gender norms         |
| Sub Area:               | Capacity building   |
| Focus Area:             | Promoting gender-related policies and laws that increase legal protection |
| Sub Area:               | Implementation  |



|             |   |
|-------------|---|
| Sub Area:   | Capacity building                                     |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area:   | Implementation  |
| Sub Area:   | Capacity building                                     |

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 9900<br><b>Mechanism Name:</b> Capable Partners Program (CAP) II<br><b>Prime Partner Name:</b> FHI 360 |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HBHC        | 961,952        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HKID        | 1,128,530      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | HVCT        | 219,621        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | HVOP        | 105,204        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label                               | 2015   | 2016 |
|------------------|-------------------------------------|--------|------|
| PP_PREV_DSD      | Number of the target population who | 10,753 |      |

|              |   |        |       |
|--------------|---|--------|-------|
|              | completed a standardized HIV prevention intervention including the minimum components during the reporting period.  |        |       |
| PP_PREV_DSD  | Age/sex: 10-14 Male   | 839    |       |
| PP_PREV_DSD  | Age/sex: 15-19 Male   | 1,291  |       |
| PP_PREV_DSD  | Age/sex: 20-24 Male   | 656    |       |
| PP_PREV_DSD  | Age/sex: 25-49 Male   | 571    |       |
| PP_PREV_DSD  | Age/sex: 50+ Male   | 75     |       |
| PP_PREV_DSD  | Age/sex: 10-14 Female   | 2,095  |       |
| PP_PREV_DSD  | Age/sex: 15-19 Female   | 3,484  |       |
| PP_PREV_DSD  | Age/sex: 20-24 Female   | 1,559  |       |
| PP_PREV_DSD  | Age/sex: 25-49 Female   | 183    |       |
| PP_PREV_DSD  | Age/sex: 50+ Female   | 0      |       |
| PP_PREV_DSD  | Sum of Age/Sex disaggregates  | 10,753 |       |
| KP_PREV_DSD  | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required   | 100    |       |
| KP_PREV_DSD  | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 100    |       |
| HTC_TST_DSD  | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 4,450  |       |
| OVC_ACC_DSD  | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services  | 1,557  | 2,034 |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS   | 6,224  | 8,135 |

|                |  |       |  |
|----------------|--|-------|--|
| OVC_SERV_DSD   | Sex: Male  | 3,112 |  |
| OVC_SERV_DSD   | Sex: Female  | 3,112 |  |
| OVC_SERV_DSD   | Sum of Sex disaggregates   | 6,224 |  |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 1     |  |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment  | 1     |  |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points                                | 1     |  |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates   | 1     |  |
| FPINT_SITE_DSD | Service delivery type: Clinical  | 1     |  |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates   | 1     |  |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates   | 1     |  |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates   | 1     |  |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 10135</b>                 | <b>Mechanism Name: Clinical Services System Strengthening in Sofala, Manica and Tete (CHSS SMT)</b> |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement   |
| Prime Partner Name: Abt Associates         |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted  |
| TBD: No                                    | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |
| <b>Total All Funding Sources: 0</b>        |   |
| <b>Applied Pipeline Amount: 0</b>          |   |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 0              |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 10135   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | Clinical Services System Strengthening in Sofala, Manica and Tete |                |                |
| <b>Prime Partner Name:</b> | (CHSS SMT)  |                |                |
|                            | Abt Associates  |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HBHC  | 0              | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HKID  | 0              | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HVTB  | 0              | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | PDCS  | 0              | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |

|                       |                    |                       |                       |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention            | CIRC               | 0                     | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention            | HVCT               | 0                     | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention            | MTCT               | 0                     | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment             | HTXS               | 0                     | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment             | PDTX               | 0                     | 0                     |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015   | 2016   |
|------------------|--|--------|--------|
| PMTCT_ARV_DSD    | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 22,281 | 15,473 |
| PMTCT_ARV_DSD    | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 22,665 | 15,473 |
| PMTCT_ARV_DSD    | Life-long ART (including Option B+)  | 21,834 |        |
| PMTCT_ARV_DSD    | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 14,925 | 9,283  |
| PMTCT_ARV_DSD    | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 6,396  | 6,190  |
| PMTCT_ARV_DSD    | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and   | 446    |        |



|                |  |         |         |
|----------------|--|---------|---------|
|                | delivery)  |         |         |
| PMTCT_ARV_DSD  | Single-dose nevirapine (with or without tail)  | 0       | 0       |
| PMTCT_ARV_DSD  | Sum of Regimen Type disaggregates  | 22,280  | 0       |
| PMTCT_ARV_DSD  | Sum of New and Current disaggregates   | 21,321  | 15,473  |
| PMTCT_ARV_TA   | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 3,897   | 2,603   |
| PMTCT_ARV_TA   | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 3,965   | 1,044   |
| PMTCT_ARV_TA   | Life-long ART (including Option B+)  | 3,201   |         |
| PMTCT_ARV_TA   | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 2,602   | 1,559   |
| PMTCT_ARV_TA   | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 1,114   | 1,044   |
| PMTCT_ARV_TA   | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 697     |         |
| PMTCT_ARV_TA   | Sum of Regimen Type disaggregates  | 3,898   | 0       |
| PMTCT_ARV_TA   | Sum of New and Current disaggregates   | 3,716   | 2,603   |
| PMTCT_STAT_DSD | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                                     | 313,151 | 174,360 |
| PMTCT_STAT_DSD | Number of new ANC and L&D clients  | 313,151 | 166,060 |
| PMTCT_STAT_DSD | By: Known positives at entry   | 6,573   | 4,486   |
| PMTCT_STAT_DSD | By: Number of new positives identified   | 16,092  | 10,987  |
| PMTCT_STAT_DSD | Sum of Positives Status disaggregates  | 22,665  | 15,473  |
| PMTCT_STAT_TA  | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                                     | 66,161  | 60,078  |
| PMTCT_STAT_TA  | Number of new ANC and L&D clients  | 66,161  | 60,102  |
| PMTCT_STAT_TA  | By: Known positives at entry   | 1,150   | 301     |

|               |   |         |         |
|---------------|---|---------|---------|
| PMTCT_STAT_TA | By: Number of new positives identified  | 2,815   | 743     |
| PMTCT_STAT_TA | Sum of Positives Status disaggregates   | 3,965   | 1,044   |
| VMMC_CIRC_DSD | Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period                                    | 67,792  | 41,342  |
| VMMC_CIRC_DSD | By Age: <1  | 0       | 0       |
| VMMC_CIRC_DSD | By Age: 1-9   | 0       | 0       |
| VMMC_CIRC_DSD | By Age: 10-14   | 27,117  | 12,403  |
| VMMC_CIRC_DSD | By Age: 15-19   | 20,337  | 12,403  |
| VMMC_CIRC_DSD | By Age: 20-24   | 13,559  | 10,334  |
| VMMC_CIRC_DSD | By Age: 25-49   | 5,423   |         |
| VMMC_CIRC_DSD | By Age: 50+   | 1,355   | 0       |
| VMMC_CIRC_DSD | Sum of age disaggregates  | 67,791  | 35,140  |
| HTC_TST_DSD   | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 786,057 | 666,996 |
| HTC_TST_TA    | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 104,047 | 142,752 |
| GEND_GBV_DSD  | Number of people receiving post-GBV care  | 750     | 3,983   |
| CARE_CURR_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 215,437 | 239,687 |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 8,618   |         |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 84,021  |         |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 8,618   |         |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 114,182 |         |

|               |   |         |         |
|---------------|---|---------|---------|
| CARE_CURR_DSD | Sum of Aggregated Age/Sex disaggregates   | 215,439 |         |
| CARE_CURR_TA  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load   | 24,819  | 42,682  |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 992     |         |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 992     |         |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 13,154  |         |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 9,680   |         |
| CARE_CURR_TA  | Sum of Aggregated Age/Sex disaggregates   | 24,818  |         |
| CARE_NEW_DSD  | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 98,064  | 130,142 |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male  | 3,922   |         |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male  | 38,245  |         |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female  | 3,922   |         |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female  | 51,975  |         |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates   | 98,064  |         |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates   | 98,064  |         |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.   | 16,158  | 21,566  |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.  | 32,315  | 28,758  |
| TB_ART_DSD    | The number of registered new and relapse TB   | 4,938   | 7,481   |

|               |   |         |         |
|---------------|---|---------|---------|
|               | cases with documented HIV-positive status who are on ART during TB treatment during the reporting period                              |         |         |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period | 5,810   | 8,313   |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period                                  | 25,068  | 11,833  |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)  | 26,630  |         |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)  | 129,781 | 167,783 |
| TX_CURR_DSD   | Age/Sex: <1 Male  | 2,370   | 1,417   |
| TX_CURR_DSD   | Age/Sex: 1-4 Male   | 3,554   | 3,210   |
| TX_CURR_DSD   | Age/Sex: 5-14 Male  | 2,370   | 2,269   |
| TX_CURR_DSD   | Age/Sex: 15+ Male   | 32,728  |         |
| TX_CURR_DSD   | Age/Sex: <1 Female  | 2,709   | 1,417   |
| TX_CURR_DSD   | Age/Sex: 1-4 Female   | 3,554   | 3,210   |
| TX_CURR_DSD   | Age/Sex: 5-14 Female  | 2,370   | 2,269   |
| TX_CURR_DSD   | Age/Sex: 15+ Female   | 80,126  |         |
| TX_CURR_DSD   | Sum of age/sex disaggregates  | 16,927  | 13,792  |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Male  | 8,463   |         |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Male  | 32,728  |         |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Female  | 8,463   |         |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Female  | 80,126  |         |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex <15   | 16,926  |         |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex 15+   | 112,854 |         |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex disaggregates   | 129,780 |         |
| TX_CURR_TA    | Number of adults and children receiving   | 14,951  | 29,877  |

|            |  |        |        |
|------------|--|--------|--------|
|            | antiretroviral therapy (ART)   |        |        |
| TX_CURR_TA | Age/Sex: <1 Male   | 272    | 325    |
| TX_CURR_TA | Age/Sex: 1-4 Male  | 410    | 739    |
| TX_CURR_TA | Age/Sex: 5-14 Male   | 272    | 523    |
| TX_CURR_TA | Age/Sex: 15+ Male  | 3,770  |        |
| TX_CURR_TA | Age/Sex: <1 Female   | 312    | 325    |
| TX_CURR_TA | Age/Sex: 1-4 Female  | 410    | 739    |
| TX_CURR_TA | Age/Sex: 5-14 Female   | 272    | 523    |
| TX_CURR_TA | Age/Sex: 15+ Female  | 9,231  |        |
| TX_CURR_TA | Sum of Age/Sex disaggregations   | 1,948  | 3,174  |
| TX_CURR_TA | Aggregated Age/Sex: <15 Male   | 975    |        |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Male   | 3,770  |        |
| TX_CURR_TA | Aggregated Age/Sex: <15 Female   | 975    |        |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Female   | 9,231  |        |
| TX_CURR_TA | Sum of Aggregated Age/Sex <15  | 1,950  |        |
| TX_CURR_TA | Sum of Aggregated Age/Sex 15+  | 13,001 |        |
| TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates                                      | 14,951 |        |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 44,495 | 56,129 |
| TX_NEW_DSD | By Age/Sex: <1 Male  | 1,103  |        |
| TX_NEW_DSD | By Age/Sex: <1 Female  | 1,219  |        |
| TX_NEW_DSD | Sum of Age/Sex disaggregates   | 2,322  | 2,422  |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male  | 1,103  | 531    |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male                                     | 2,902  |        |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male                                     | 11,221 | 17,828 |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female                                    | 1,219  | 531    |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female                                   | 2,902  |        |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female                                   | 27,472 | 33,100 |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates                                      | 44,497 | 50,928 |
| TX_NEW_DSD | Pregnancy status   | 14,925 | 9,283  |

|                |   |        |        |
|----------------|---|--------|--------|
| TX_NEW_DSD     | Breastfeeding status  | 5,804  |        |
| TX_RET_DSD     | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 25,626 | 31,379 |
| TX_RET_DSD     | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 30,149 | 41,125 |
| LAB_CAP_DSD    | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 107    |        |
| LAB_CAP_DSD    | By site support type: Technical Assistance-only (TA)  | 107    |        |
| LAB_CAP_DSD    | Sum of Site Support Type disaggregates  | 107    |        |
| LAB_CAP_TA     | Sum of Site Support Type disaggregates  | 107    |        |
| HRH_PRE        | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre                        | 115    | 164    |
| HRH_PRE        | By Graduates: Nurses  | 55     | 82     |
| HRH_PRE        | By Graduates: Laboratory professionals  | 30     |        |
| HRH_PRE        | By Graduates: Other   | 30     | 82     |
| HRH_PRE        | Sum of Graduates disaggreagtes  | 115    | 194    |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 230    | 325    |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 741    | 325    |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points  | 230    |        |

|                |   |         |         |
|----------------|---|---------|---------|
|                | supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  |         |         |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 230     |         |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 741     |         |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 741     |         |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 741     |         |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 230     |         |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 206,819 |         |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 215,437 | 239,687 |
| TB_SCREEN_TA   | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 24,819  | 42,682  |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 10962</b>                    | <b>Mechanism Name: Prevention with Positives</b> |
| Funding Agency: DOD                           | Procurement Type: Grant                          |
| Prime Partner Name: University of Connecticut |  |
| Agreement Start Date: Redacted                | Agreement End Date: Redacted                     |
| TBD: No                                       | New Mechanism: No                                |
| Global Fund / Multilateral Engagement: N/A    |  |



|   |                       |
|---|-----------------------|
| G2G: No                                   | Managing Agency:      |
| <b>Total All Funding Sources: 173,093</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 173,093               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                           |                       |                       |
|----------------------------|---------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 10962                     |                       |                       |
| <b>Mechanism Name:</b>     | Prevention with Positives |                       |                       |
| <b>Prime Partner Name:</b> | University of Connecticut |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                      | 173,093               | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                            |  |
|----------------------------|--|
| <b>Mechanism ID: 10971</b> | <b>Mechanism Name: DOD HIV Program</b> |
|----------------------------|--|





|  |                              |
|--|------------------------------|
| Funding Agency: DOD                                      | Procurement Type: Grant      |
| Prime Partner Name: U.S. Department of Defense (Defense) |                              |
| Agreement Start Date: Redacted                           | Agreement End Date: Redacted |
| TBD: No  | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A               |                              |
| G2G: No  | Managing Agency:             |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                                      |                       |                       |
|----------------------------|--------------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 10971                                |                       |                       |
| <b>Mechanism Name:</b>     | DOD HIV Program                      |                       |                       |
| <b>Prime Partner Name:</b> | U.S. Department of Defense (Defense) |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                                 | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                   | <b>Planned Amount</b> | <b>On Hold Amount</b> |

|                        |                    |                       |                       |
|------------------------|--------------------|-----------------------|-----------------------|
| Governance and Systems | HVSI               | 0                     | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems | OHSS               | 0                     | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention             | CIRC               | 0                     | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention             | HMIN               | 0                     | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment              | HTXS               | 0                     | 0                     |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 3    |      |
| HRH_PRE          | By Graduates: Nurses   | 1    |      |
| HRH_PRE          | By Graduates: Midwives   | 2    |      |
| HRH_PRE          | Sum of Graduates disaggregates   | 3    |      |

### Implementing Mechanism Details

|                                      |  |
|--------------------------------------|--|
| <b>Mechanism ID: 11463</b>           | <b>Mechanism Name: United States Peace Corps/ Mozambique</b> |
| Funding Agency: PC                   | Procurement Type: USG Core                                   |
| Prime Partner Name: U.S. Peace Corps |  |



|  |                              |
|--|------------------------------|
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 420,905</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 420,905               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                                       |                       |                       |
|----------------------------|---------------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 11463                                 |                       |                       |
| <b>Mechanism Name:</b>     | United States Peace Corps/ Mozambique |                       |                       |
| <b>Prime Partner Name:</b> | U.S. Peace Corps                      |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                    | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID                                  | 112,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                    | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVOP                                  | 308,905               | 0                     |



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 11580</b>                 | <b>Mechanism Name: Comprehensive Approaches to Strengthening the Health System and HIV Response</b> |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement   |
| Prime Partner Name: JHPIEGO                |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted  |
| TBD: No                                    | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 26,022,759</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 26,022,759            |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                            |                   |
|----------------------------|-------------------|
| Gender: GBV                | 185,000           |
| Focus Area:                | GBV Prevention    |
| Sub Area:                  | Capacity building |
| Focus Area:                | Post GBV Care     |
| Motor Vehicles: Purchased  | 600,000           |
| Renovation                 | 180,000           |
| Human Resources for Health | 2,748,513         |
| Condom programming         | 348,754           |

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 11580   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | Comprehensive Approaches to Strengthening the Health System and |                |                |
| <b>Prime Partner Name:</b> | HIV Response  |                |                |
|                            | JHPIEGO   |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HVTB  | 632,614        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS  | 1,600,000      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | CIRC  | 19,297,333     | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | HVCT  | 2,007,968      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | HVOP  | 100,000        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | MTCT  | 337,000        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | HTXS  | 1,697,844      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |

|           |      |         |   |
|-----------|------|---------|---|
| Treatment | PDTX | 350,000 | 0 |
|-----------|------|---------|---|

## Implementing Mechanism Indicator Information

| Indicator Number  | Label  | 2015    | 2016    | Planning Budget Targets |
|-------------------|--|---------|---------|-------------------------|
| VMMC_CIRC_DS<br>D | Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period | 168,809 | 180,268 | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: <1   | 0       | 0       | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 1-9  | 0       | 0       | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 10-14  | 67,524  | 54,080  | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 15-19  | 50,643  | 54,080  | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 20-24  | 33,761  | 45,070  | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 25-49  | 13,505  |         | Redacted                |
| VMMC_CIRC_DS<br>D | By Age: 50+  | 3,377   | 0       | Redacted                |
| VMMC_CIRC_DS<br>D | Sum of age disaggregates   | 168,810 | 153,230 | Redacted                |
| HTC_TST_DSD       | Number of individuals who received T&C services for HIV and received their test results during the past 12 months                            | 361,730 | 292,612 | Redacted                |
| GEND_GBV_DSD      | Number of people receiving post-GBV  | 557     |         | Redacted                |

|         |  |       |  |          |
|---------|--|-------|--|----------|
|         | care   |       |  |          |
| HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 1,336 |  | Redacted |
| HRH_PRE | By Graduates: Nurses   | 1,336 |  | Redacted |
| HRH_PRE | Sum of Graduates disaggregates   | 1,336 |  | Redacted |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 12147</b>                 | <b>Mechanism Name: Maternal Child Health Integrated Program (MCHIP)</b> |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement                                 |
| Prime Partner Name: JHPIEGO                |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted  |
| TBD: No                                    | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 12147  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Maternal Child Health Integrated Program (MCHIP) |                |                |
| <b>Prime Partner Name:</b> | JHPIEGO  |                |                |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Care                       | HBHC   | 0              | 0              |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Prevention                 | MTCT   | 0              | 0              |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Treatment                  | HTXS   | 0              | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID:</b> 12148                   | <b>Mechanism Name:</b> SCIP Nampula     |
| Funding Agency: USAID                        | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Pathfinder International |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted            |
| TBD: No                                      | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A   |   |
| G2G: No                                      | Managing Agency:                        |

| <b>Total All Funding Sources:</b> 0 |                |
|-------------------------------------|----------------|
| <b>Applied Pipeline Amount:</b> 0   |                |
|                                     |                |
| Funding Source                      | Funding Amount |



|           |   |
|-----------|---|
| GHP-State | 0 |
|-----------|---|

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 12148                    |                |                |
|----------------------------|--------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | SCIP Nampula             |                |                |
| <b>Prime Partner Name:</b> | Pathfinder International |                |                |
| Strategic Area             | Budget Code              | Planned Amount | On Hold Amount |
| Care                       | HBHC                     | 0              | 0              |
| Strategic Area             | Budget Code              | Planned Amount | On Hold Amount |
| Care                       | HKID                     | 0              | 0              |
| Strategic Area             | Budget Code              | Planned Amount | On Hold Amount |
| Care                       | PDCS                     | 0              | 0              |
| Strategic Area             | Budget Code              | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS                     | 0              | 0              |
| Strategic Area             | Budget Code              | Planned Amount | On Hold Amount |
| Prevention                 | HVAB                     | 0              | 0              |

| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention     | HVCT        | 0              | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention     | HVOP        | 0              | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention     | MTCT        | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015   | 2016   |
|------------------|--|--------|--------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 9,750  |        |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 760    |        |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 1,170  |        |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 595    |        |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 517    |        |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 68     |        |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 1,901  |        |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 3,159  |        |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 1,414  |        |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 166    |        |
| PP_PREV_DSD      | Age/sex: 50+ Female  | 0      |        |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 9,750  |        |
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results during the past 12 months                                      | 80,726 | 10,846 |
| OVC_ACC_DSD      | Number of active beneficiaries receiving   | 8,138  |        |

|                |   |        |  |
|----------------|---|--------|--|
|                | support from PEPFAR OVC programs to access HIV services   |        |  |
| OVC_SERV_DSD   | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS   | 32,552 |  |
| OVC_SERV_DSD   | Sex: Male   | 16,276 |  |
| OVC_SERV_DSD   | Sex: Female   | 16,276 |  |
| OVC_SERV_DSD   | Sum of Sex disaggregates  | 32,552 |  |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 14     |  |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 14     |  |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 14     |  |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 14     |  |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 14     |  |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 14     |  |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 14     |  |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 14     |  |

### Implementing Mechanism Details

|                            |   |
|----------------------------|---|
| <b>Mechanism ID: 12149</b> | <b>Mechanism Name: SCIP Zambezia</b>    |
| Funding Agency: USAID      | Procurement Type: Cooperative Agreement |

|  |                              |
|--|------------------------------|
| Prime Partner Name: World Vision International |                              |
| Agreement Start Date: Redacted                 | Agreement End Date: Redacted |
| TBD: No  | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A     |                              |
| G2G: No  | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,938,437</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,938,437             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                         |  |
|-------------------------|--|
| Condom programming      | 122,839  |
| Gender: GBV             | 25,000   |
| Focus Area:             | GBV Prevention   |
| Sub Area:               | Collection and Use of Gender-related Strategic Information                               |
| Sub Area:               | Implementation   |
| Sub Area:               | Monitoring and Evaluation  |
| Gender: Gender Equality | 25,000   |
| Focus Area:             | Changing harmful gender norms and promoting positive gender norms                        |
| Sub Area:               | Collection and Use of Gender-related Strategic Information                               |
| Sub Area:               | Implementation   |
| Sub Area:               | Monitoring and Evaluation  |
| Focus Area:             | Increase gender-equitable access to income and productive resources, including education |



|                             |   |
|-----------------------------|---|
| Sub Area:                   | Collection and Use of Gender-related Strategic Information  |
| Sub Area:                   | Implementation  |
| Sub Area:                   | Monitoring and Evaluation   |
| Key Populations: MSM and TG | 100,000   |
| Focus Area:                 | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Key Populations: FSW        | 100,000   |
| Focus Area:                 | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention              |
| Economic Strengthening      | 100,000   |

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 12149                      |                |                |
|----------------------------|----------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | SCIP Zambezia              |                |                |
| <b>Prime Partner Name:</b> | World Vision International |                |                |
| Strategic Area             | Budget Code                | Planned Amount | On Hold Amount |
| Care                       | HBHC                       | 1,161,959      | 0              |
| Strategic Area             | Budget Code                | Planned Amount | On Hold Amount |
| Prevention                 | HVCT                       | 649,400        | 0              |
| Strategic Area             | Budget Code                | Planned Amount | On Hold Amount |
| Prevention                 | HVOP                       | 127,078        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015   | 2016   |
|------------------|---|--------|--------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.  | 9,750  |        |
| PP_PREV_DSD      | Age/sex: 10-14 Male   | 760    |        |
| PP_PREV_DSD      | Age/sex: 15-19 Male   | 1,170  |        |
| PP_PREV_DSD      | Age/sex: 20-24 Male   | 595    |        |
| PP_PREV_DSD      | Age/sex: 25-49 Male   | 517    |        |
| PP_PREV_DSD      | Age/sex: 50+ Male   | 68     |        |
| PP_PREV_DSD      | Age/sex: 10-14 Female   | 1,901  |        |
| PP_PREV_DSD      | Age/sex: 15-19 Female   | 3,159  |        |
| PP_PREV_DSD      | Age/sex: 20-24 Female   | 1,414  |        |
| PP_PREV_DSD      | Age/sex: 25-49 Female   | 166    |        |
| PP_PREV_DSD      | Age/sex: 50+ Female   | 0      |        |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates  | 9,750  |        |
| KP_PREV_DSD      | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required   | 647    |        |
| KP_PREV_DSD      | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 647    |        |
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 56,727 | 11,493 |
| OVC_ACC_DSD      | Number of active beneficiaries receiving  | 15,298 |        |

|                |   |        |        |
|----------------|---|--------|--------|
|                | support from PEPFAR OVC programs to access HIV services   |        |        |
| OVC_SERV_DSD   | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS   | 61,190 | 11,604 |
| OVC_SERV_DSD   | Sex: Male   | 30,595 |        |
| OVC_SERV_DSD   | Sex: Female   | 30,595 |        |
| OVC_SERV_DSD   | Sum of Sex disaggregates  | 61,190 |        |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 16     |        |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 16     |        |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 16     |        |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 16     |        |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 16     |        |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 16     |        |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 16     |        |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 16     |        |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 16     |        |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 16     |        |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 16     |        |



## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 12150</b>                         | <b>Mechanism Name: Systems for Improved Access to Pharmaceuticals and Services (SIAPS)</b> |
| Funding Agency: USAID                              | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Management Sciences for Health |  |
| Agreement Start Date: Redacted                     | Agreement End Date: Redacted   |
| TBD: No  | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A         |  |
| G2G: No  | Managing Agency:   |
| <b>Total All Funding Sources: 1,000,000</b>        |  |
| <b>Applied Pipeline Amount: 0</b>                  |  |
|  |  |
| <b>Funding Source</b>                              | <b>Funding Amount</b>  |
| GHP-State  | 1,000,000  |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |
|----------------------------|--|
| <b>Mechanism ID:</b>       | <b>12150</b>   |
| <b>Mechanism Name:</b>     | <b>Systems for Improved Access to Pharmaceuticals and Services (SIAPS)</b> |
| <b>Prime Partner Name:</b> | <b>Management Sciences for Health</b>                                      |



| Strategic Area         | Budget Code | Planned Amount | On Hold Amount |
|------------------------|-------------|----------------|----------------|
| Governance and Systems | OHSS        | 1,000,000      | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 12152</b>                 | <b>Mechanism Name: Regional Outreach Addressing AIDS Through Development Strategies (ROADS II)</b> |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: FHI 360                |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted   |
| TBD: No                                    | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:   |
| <b>Total All Funding Sources: 0</b>        |  |
| <b>Applied Pipeline Amount: 0</b>          |  |
|  |  |
| <b>Funding Source</b>                      | <b>Funding Amount</b>  |
| GHP-State                                  | 0  |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 12152  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Regional Outreach Addressing AIDS Through Development Strategies |                |                |
| <b>Prime Partner Name:</b> | (ROADS II)   |                |                |
|                            | FHI 360  |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HKID   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVCT   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Treatment                  | HTXS   | 0              | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015  | 2016 |
|------------------|--|-------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 3,081 |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 240   |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 370   |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 188   |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 163   |      |

|             |  |        |     |
|-------------|--|--------|-----|
| PP_PREV_DSD | Age/sex: 50+ Male  | 22     |     |
| PP_PREV_DSD | Age/sex: 10-14 Female  | 601    |     |
| PP_PREV_DSD | Age/sex: 15-19 Female  | 998    |     |
| PP_PREV_DSD | Age/sex: 20-24 Female  | 447    |     |
| PP_PREV_DSD | Age/sex: 25-49 Female  | 52     |     |
| PP_PREV_DSD | Age/sex: 50+ Female  | 0      |     |
| PP_PREV_DSD | Sum of Age/Sex disaggregates   | 3,081  |     |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required  | 24,208 |     |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)                        | 19,109 |     |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)  | 5,099  |     |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0      |     |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months  | 49,800 | 279 |

|                |   |   |  |
|----------------|---|---|--|
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 3 |  |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 3 |  |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 3 |  |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 3 |  |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 3 |  |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 3 |  |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 3 |  |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 3 |  |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 12159</b>                               | <b>Mechanism Name: Strengthening HIV and GBV Prevention within the Police</b> |
| Funding Agency: USAID                                    | Procurement Type: Cooperative Agreement                                       |
| Prime Partner Name: United Nations Development Programme |   |
| Agreement Start Date: Redacted                           | Agreement End Date: Redacted  |
| TBD: No  | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A               |   |
| G2G: No  | Managing Agency:  |
| <b>Total All Funding Sources: 0</b>                      |   |

|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Applied Pipeline Amount: 0</b> |                       |
|                                   |                       |
| <b>Funding Source</b>             | <b>Funding Amount</b> |
| GHP-State                         | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12159  |                       |                       |
| <b>Mechanism Name:</b>     | Strengthening HIV and GBV Prevention within the Police |                       |                       |
| <b>Prime Partner Name:</b> | United Nations Development Programme                   |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVAB   | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVOP   | 0                     | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                            |  |
|----------------------------|--|
| <b>Mechanism ID: 12165</b> | <b>Mechanism Name: Strategic Information</b> |
|----------------------------|--|



|   |   |
|---|---|
|   | <b>Improvement in Mozambique (SIIM) Project</b> |
| Funding Agency: USAID                             | Procurement Type: Grant                         |
| Prime Partner Name: Health Alliance International |   |
| Agreement Start Date: Redacted                    | Agreement End Date: Redacted                    |
| TBD: No   | New Mechanism: No                               |
| Global Fund / Multilateral Engagement: N/A        |   |
| G2G: No   | Managing Agency:                                |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 250,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 250,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12165  |                       |                       |
| <b>Mechanism Name:</b>     | Strategic Information Improvement in Mozambique (SIIM) Project |                       |                       |
| <b>Prime Partner Name:</b> | Health Alliance International                                  |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS   | 250,000               | 0                     |



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 12167</b>                                      | <b>Mechanism Name: CLSI</b>             |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Clinical and Laboratory Standards Institute |   |
| Agreement Start Date: Redacted                                  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                      |   |
| G2G: No   | Managing Agency:                        |
| <b>Total All Funding Sources: 0</b>                             |   |
| <b>Applied Pipeline Amount: 0</b>                               |   |
|   |   |
| <b>Funding Source</b>   | <b>Funding Amount</b>                   |
| GHP-State   | 0                                       |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                      |              |
|----------------------|--------------|
| <b>Mechanism ID:</b> | <b>12167</b> |
|----------------------|--------------|

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism Name:</b>     | <b>CLSI</b>  |                       |                       |
| <b>Prime Partner Name:</b> | <b>Clinical and Laboratory Standards Institute</b> |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                 | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HLAB   | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                 | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS   | 0                     | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 12168</b>                   | <b>Mechanism Name: Increasing access to HIV prevention care and treatment for Key Populations in Mozambique</b> |
| Funding Agency: HHS/CDC                      | Procurement Type: Cooperative Agreement   |
| Prime Partner Name: Pathfinder International |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted  |
| TBD: No                                      | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A   |   |
| G2G: No                                      | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 2,362,132</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 2,362,132             |

### Sub Partner Name(s)

(No data provided.)



### Cross-Cutting Budget Attribution(s)

|                             |   |
|-----------------------------|---|
| Gender: GBV                 | 68,718  |
| Focus Area:                 | GBV Prevention  |
| Sub Area:                   | Implementation  |
| Key Populations: FSW        | 1,488,883   |
| Focus Area:                 | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention              |
| Focus Area:                 | Training of health workers and community outreach workers   |
| Focus Area:                 | Collection and use of strategic information on SWs and clients  |
| Focus Area:                 | Monitoring and evaluation of SW programs  |
| Focus Area:                 | Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs                              |
| Key Populations: MSM and TG | 229,059   |
| Focus Area:                 | Training of health workers and community outreach workers   |
| Focus Area:                 | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area:                 | Collection and use of strategic information   |
| Focus Area:                 | Monitoring and evaluation of MSM/TG programs  |
| Focus Area:                 | Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG                           |
| Condom programming          | 96,715  |
| Motor Vehicles: Purchased   | 144,000   |

### Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 12168  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Increasing access to HIV prevention care and treatment for Key |                |                |
| <b>Prime Partner Name:</b> | Populations in Mozambique                                      |                |                |
|                            | Pathfinder International                                       |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVCT   | 181,000        | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 1,671,945      | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Treatment                  | HTXS   | 509,187        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015   | 2016 | Planning Budget Targets |
|------------------|--|--------|------|-------------------------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 28,175 |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 2,197  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 3,381  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 1,718  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 1,494  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 197    |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 5,494  |      | Redacted                |

|             |  |        |        |          |
|-------------|--|--------|--------|----------|
| PP_PREV_DSD | Age/sex: 15-19 Female  | 9,129  |        | Redacted |
| PP_PREV_DSD | Age/sex: 20-24 Female  | 4,083  |        | Redacted |
| PP_PREV_DSD | Age/sex: 25-49 Female  | 479    |        | Redacted |
| PP_PREV_DSD | Age/sex: 50+ Female  | 0      |        | Redacted |
| PP_PREV_DSD | Sum of Age/Sex disaggregates   | 28,172 |        | Redacted |
| KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required  | 9,354  | 16,060 | Redacted |
| KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)                        | 6,394  | 10,984 | Redacted |
| KP_PREV_DSD | By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)  | 2,960  | 5,076  | Redacted |
| KP_PREV_DSD | By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 0      |        | Redacted |
| HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their   | 22,812 | 24,621 | Redacted |

|                |   |    |  |          |
|----------------|---|----|--|----------|
|                | test results during the past 12 months  |    |  |          |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment | 22 |  | Redacted |

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 12169</b>                 | <b>Mechanism Name: Families Matter Program (FMP)</b> |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement              |
| Prime Partner Name: Samaritans Purse       |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                         |
| TBD: No                                    | New Mechanism: No                                    |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:                                     |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information



|                            |                               |                       |                       |
|----------------------------|-------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12169                         |                       |                       |
| <b>Mechanism Name:</b>     | Families Matter Program (FMP) |                       |                       |
| <b>Prime Partner Name:</b> | Samaritans Purse              |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>            | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID                          | 0                     | 0                     |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015   | 2016 | Planning Budget Targets |
|------------------|--|--------|------|-------------------------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 12,500 |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 975    |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 1,500  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 762    |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 662    |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 88     |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 2,438  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 4,050  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 1,812  |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 213    |      | Redacted                |
| PP_PREV_DSD      | Age/sex: 50+ Female  | 0      |      | Redacted                |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 12,500 |      | Redacted                |

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 12619</b>                              | <b>Mechanism Name: AAB</b>              |
| Funding Agency: HHS/CDC                                 | Procurement Type: Cooperative Agreement |
| Prime Partner Name: American Association of Blood Banks |   |



|  |                              |
|--|------------------------------|
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 250,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 250,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                                     |                       |                       |
|----------------------------|-------------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12619                               |                       |                       |
| <b>Mechanism Name:</b>     | AABB                                |                       |                       |
| <b>Prime Partner Name:</b> | American Association of Blood Banks |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HMBL                                | 250,000               | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)



## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 12624</b>                                | <b>Mechanism Name: FURJ</b>             |
| Funding Agency: HHS/CDC                                   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Fundacao Universitaria Jose Bonifacio |   |
| Agreement Start Date: Redacted                            | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                |   |
| G2G: No   | Managing Agency:                        |
| <b>Total All Funding Sources: 0</b>                       |   |
| <b>Applied Pipeline Amount: 0</b>                         |   |
|   |   |
| <b>Funding Source</b>                                     | <b>Funding Amount</b>                   |
| GHP-State   | 0                                       |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |                                       |                       |                       |
|----------------------------|---------------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12624                                 |                       |                       |
| <b>Mechanism Name:</b>     | FURJ                                  |                       |                       |
| <b>Prime Partner Name:</b> | Fundacao Universitaria Jose Bonifacio |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                    | <b>Planned Amount</b> | <b>On Hold Amount</b> |

|                        |      |   |   |
|------------------------|------|---|---|
| Governance and Systems | HLAB | 0 | 0 |
|------------------------|------|---|---|

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| LAB_ACC_TA       | Sum of Support Type disaggregates  | 10   |      | Redacted                |
| LAB_CAP_DSD      | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 1    |      | Redacted                |
| LAB_CAP_DSD      | By site support type: Technical Assistance-only (TA)   | 1    |      | Redacted                |
| LAB_CAP_DSD      | Sum of Site Support Type disaggregates   | 1    |      | Redacted                |
| LAB_CAP_TA       | Sum of Site Support Type disaggregates   | 1    |      | Redacted                |

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 12648</b>                     | <b>Mechanism Name: Promoting the Quality of Medicines (PQM)</b> |
| Funding Agency: USAID                          | Procurement Type: Contract                                      |
| Prime Partner Name: United States Pharmacopeia |   |
| Agreement Start Date: Redacted                 | Agreement End Date: Redacted                                    |
| TBD: No  | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A     |   |
| G2G: No  | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 300,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |





|           |         |
|-----------|---------|
| GHP-State | 300,000 |
|-----------|---------|

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 12648                                    |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Promoting the Quality of Medicines (PQM) |                |                |
| <b>Prime Partner Name:</b> | United States Pharmacopeia               |                |                |
| Strategic Area             | Budget Code                              | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS                                     | 300,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 12665</b>   | <b>Mechanism Name: DPS Cabo Delgado Province</b> |
| Funding Agency: HHS/CDC  | Procurement Type: Cooperative Agreement          |
| Prime Partner Name: Provincial Directorate of Health, Cabo Delgado |  |
| Agreement Start Date: Redacted                                     | Agreement End Date: Redacted                     |
| TBD: No  | New Mechanism: No                                |



|  |                          |
|--|--------------------------|
| Global Fund / Multilateral Engagement: N/A |                          |
| G2G: Yes                                   | Managing Agency: HHS/CDC |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 389,300</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 389,300               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|   |                    |                       |                       |
|---|--------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b> 12665  |                    |                       |                       |
| <b>Mechanism Name:</b> DPS Cabo Delgado Province                          |                    |                       |                       |
| <b>Prime Partner Name:</b> Provincial Directorate of Health, Cabo Delgado |                    |                       |                       |
| <b>Strategic Area</b>   | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment   | HTXS               | 311,440               | 0                     |
| <b>Strategic Area</b>   | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment   | PDTX               | 77,860                | 0                     |

### Implementing Mechanism Indicator Information



(No data provided.)

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 12681</b>                 | <b>Mechanism Name: JEMBI</b>            |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement |
| Prime Partner Name: JEMBI                  |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted            |
| TBD: No                                    | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,430,896</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,430,896             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                    |                       |                       |
|----------------------------|--------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 12681              |                       |                       |
| <b>Mechanism Name:</b>     | JEMBI              |                       |                       |
| <b>Prime Partner Name:</b> | JEMBI              |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |

| Governance and Systems | HVSI | 1,430,896 | 0 |
|------------------------|------|-----------|---|

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 12702</b>                                    | <b>Mechanism Name: UCSF SI Technical Assistance</b> |
| Funding Agency: HHS/CDC                                       | Procurement Type: Cooperative Agreement             |
| Prime Partner Name: University of California at San Francisco |   |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted                        |
| TBD: No   | New Mechanism: No                                   |
| Global Fund / Multilateral Engagement: N/A                    |   |
| G2G: No   | Managing Agency:                                    |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,850,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,850,000             |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)



## Budget Code Information

| <b>Mechanism ID:</b> 12702<br><b>Mechanism Name:</b> UCSF SI Technical Assistance<br><b>Prime Partner Name:</b> University of California at San Francisco |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems  | HVSI        | 950,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | MTCT        | 100,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Treatment   | HTXS        | 800,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID:</b> 12998                                   | <b>Mechanism Name:</b> DPS Maputo Province |
| Funding Agency: HHS/CDC                                      | Procurement Type: Cooperative Agreement    |
| Prime Partner Name: Provincial Directorate of Health, Maputo |  |
| Agreement Start Date: Redacted                               | Agreement End Date: Redacted               |
| TBD: No  | New Mechanism: No                          |
| Global Fund / Multilateral Engagement: N/A                   |  |
| G2G: Yes   | Managing Agency: HHS/CDC                   |

| <b>Total All Funding Sources:</b> 97,325 |                |
|--|----------------|
| <b>Applied Pipeline Amount:</b> 0        |                |
|  |                |
| Funding Source                           | Funding Amount |



|           |        |
|-----------|--------|
| GHP-State | 97,325 |
|-----------|--------|

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 12998                                    |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | DPS Maputo Province                      |                |                |
| <b>Prime Partner Name:</b> | Provincial Directorate of Health, Maputo |                |                |
| Strategic Area             | Budget Code                              | Planned Amount | On Hold Amount |
| Treatment                  | HTXS                                     | 77,860         | 0              |
| Strategic Area             | Budget Code                              | Planned Amount | On Hold Amount |
| Treatment                  | PDTX                                     | 19,465         | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                             |   |
|-----------------------------|---|
| <b>Mechanism ID: 13022</b>  | <b>Mechanism Name: Clinical Services System Strengthening (CHASS)</b> |
| Funding Agency: USAID       | Procurement Type: Cooperative Agreement                               |
| Prime Partner Name: FHI 360 |   |



|  |                              |
|--|------------------------------|
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 38,555,013</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 38,555,013            |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |  |
|----------------------------|--|
| Human Resources for Health | 520,000  |
| Condom programming         | 306,659  |
| Economic Strengthening     | 300,000  |
| Education                  | 200,000  |
| Gender: Gender Equality    | 300,000  |
| Focus Area:                | Promoting gender-related policies and laws that increase legal protection                |
| Sub Area:                  | Implementation   |
| Focus Area:                | Increase gender-equitable access to income and productive resources, including education |
| Focus Area:                | Equity in HIV prevention, care, treatment and support                                    |
| Motor Vehicles: Purchased  | 600,000  |

### Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 13022  |             |                |                |
|---|-------------|----------------|----------------|
| <b>Mechanism Name:</b> Clinical Services System Strengthening (CHASS) |             |                |                |
| <b>Prime Partner Name:</b> FHI 360                                    |             |                |                |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HBHC        | 5,475,148      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HVTB        | 877,239        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | PDCS        | 792,947        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems  | OHSS        | 520,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | CIRC        | 4,292,583      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | HVCT        | 2,193,696      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | HVOP        | 317,242        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | MTCT        | 4,737,042      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Treatment   | HTXS        | 17,512,606     | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |



| Treatment | PDTX | 1,836,510 | 0 |
|-----------|------|-----------|---|

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016  |
|------------------|--|------|-------|
| PMTCT_ARV_DSD    | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 612  |       |
| PMTCT_ARV_DSD    | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 623  |       |
| PMTCT_ARV_DSD    | Life-long ART (including Option B+)  | 600  |       |
| PMTCT_ARV_DSD    | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 407  |       |
| PMTCT_ARV_DSD    | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 175  |       |
| PMTCT_ARV_DSD    | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 12   |       |
| PMTCT_ARV_DSD    | Single-dose nevirapine (with or without tail)  | 0    |       |
| PMTCT_ARV_DSD    | Sum of Regimen Type disaggregates  | 612  |       |
| PMTCT_ARV_DSD    | Sum of New and Current disaggregates   | 582  |       |
| PMTCT_ARV_TA     | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 358  | 1,311 |
| PMTCT_ARV_TA     | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 365  | 525   |
| PMTCT_ARV_TA     | Life-long ART (including Option B+)  | 322  |       |

|                |   |         |         |
|----------------|---|---------|---------|
| PMTCT_ARV_TA   | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy                                       | 238     | 786     |
| PMTCT_ARV_TA   | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy                                  | 102     | 525     |
| PMTCT_ARV_TA   | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)  | 36      |         |
| PMTCT_ARV_TA   | Sum of Regimen Type disaggregates   | 358     | 0       |
| PMTCT_ARV_TA   | Sum of New and Current disaggregates  | 340     | 1,311   |
| PMTCT_STAT_DSD | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)          | 27,026  |         |
| PMTCT_STAT_DSD | Number of new ANC and L&D clients   | 27,026  |         |
| PMTCT_STAT_DSD | By: Known positives at entry  | 181     |         |
| PMTCT_STAT_DSD | By: Number of new positives identified  | 442     |         |
| PMTCT_STAT_DSD | Sum of Positives Status disaggregates   | 623     |         |
| PMTCT_STAT_TA  | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)          | 15,822  | 41,146  |
| PMTCT_STAT_TA  | Number of new ANC and L&D clients   | 15,822  | 40,160  |
| PMTCT_STAT_TA  | By: Known positives at entry  | 106     | 154     |
| PMTCT_STAT_TA  | By: Number of new positives identified  | 259     | 371     |
| PMTCT_STAT_TA  | Sum of Positives Status disaggregates   | 365     | 525     |
| HTC_TST_DSD    | Number of individuals who received T&C services for HIV and received their test results during the past 12 months           | 133,502 |         |
| HTC_TST_TA     | Number of individuals who received T&C services for HIV and received their test results during the past 12 months           | 31,074  | 114,547 |
| GEND_GBV_DSD   | Number of people receiving post-GBV care  | 1,000   | 1,390   |
| CARE_CURR_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical | 14,160  |         |

|               |  |        |        |
|---------------|--|--------|--------|
|               | assessment (WHO staging) OR CD4 count<br>OR viral load   |        |        |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Male  | 566    |        |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Male  | 5,523  |        |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Female  | 566    |        |
| CARE_CURR_DSD | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Female  | 7,505  |        |
| CARE_CURR_DSD | Sum of Aggregated Age/Sex disaggregates  | 14,160 |        |
| CARE_CURR_TA  | Number of HIV positive adults and children<br>who received at least one of the following<br>during the reporting period: clinical<br>assessment (WHO staging) OR CD4 count<br>OR viral load  | 12,474 | 17,279 |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Male  | 499    |        |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Male  | 4,865  |        |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Female  | 499    |        |
| CARE_CURR_TA  | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Female  | 6,611  |        |
| CARE_CURR_TA  | Sum of Aggregated Age/Sex disaggregates  | 12,474 |        |
| CARE_NEW_DSD  | Number of HIV-infected adults and children<br>newly enrolled in clinical care during the<br>reporting period and received at least one of<br>the following at enrollment: clinical<br>assessment (WHO staging) OR CD4 count<br>OR viral load | 6,516  |        |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male   | 225    |        |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male   | 2,190  |        |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female   | 225    |        |

|               |  |       |       |
|---------------|--|-------|-------|
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female   | 2,976 |       |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates  | 5,616 |       |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates  | 5,616 |       |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.                              | 1,062 |       |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.   | 2,124 |       |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 523   |       |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period                | 615   |       |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period   | 938   | 1,335 |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)                 | 988   |       |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 8,530 |       |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 156   |       |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 234   |       |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 156   |       |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 2,151 |       |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 178   |       |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 234   |       |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 156   |       |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 5,267 |       |

|             |  |       |        |
|-------------|--|-------|--------|
| TX_CURR_DSD | Sum of age/sex disaggregates   | 1,114 |        |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male   | 556   |        |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male   | 2,151 |        |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female   | 556   |        |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Female   | 5,267 |        |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15  | 1,112 |        |
| TX_CURR_DSD | Sum of Aggregated Age/Sex 15+  | 7,418 |        |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates                                      | 8,530 |        |
| TX_CURR_TA  | Number of adults and children receiving antiretroviral therapy (ART)         | 7,514 | 12,095 |
| TX_CURR_TA  | Age/Sex: <1 Male   | 137   | 90     |
| TX_CURR_TA  | Age/Sex: 1-4 Male  | 206   | 207    |
| TX_CURR_TA  | Age/Sex: 5-14 Male   | 137   | 146    |
| TX_CURR_TA  | Age/Sex: 15+ Male  | 1,895 |        |
| TX_CURR_TA  | Age/Sex: <1 Female   | 157   | 90     |
| TX_CURR_TA  | Age/Sex: 1-4 Female  | 206   | 207    |
| TX_CURR_TA  | Age/Sex: 5-14 Female   | 137   | 146    |
| TX_CURR_TA  | Age/Sex: 15+ Female  | 4,639 |        |
| TX_CURR_TA  | Sum of Age/Sex disaggregations   | 980   | 886    |
| TX_CURR_TA  | Aggregated Age/Sex: <1 Male  | 137   |        |
| TX_CURR_TA  | Aggregated Age/Sex: <1 Female  | 157   |        |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Male   | 490   |        |
| TX_CURR_TA  | Aggregated Age/Sex: 15+ Male   | 1,895 |        |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Female   | 490   |        |
| TX_CURR_TA  | Aggregated Age/Sex: 15+ Female   | 4,639 |        |
| TX_CURR_TA  | Sum of Aggregated Age/Sex <15  | 980   |        |
| TX_CURR_TA  | Sum of Aggregated Age/Sex 15+  | 6,534 |        |
| TX_CURR_TA  | Sum of Aggregated Age/Sex disaggregates                                      | 7,514 |        |
| TX_CURR_TA  | Sum of Aggregated Age/Sex (<1 and 1-14) <15                                  | 294   |        |
| TX_NEW_DSD  | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 2,925 |        |

|                |   |       |    |
|----------------|---|-------|----|
| TX_NEW_DSD     | Aggregated Grouping by Age: <1 Male   | 73    |    |
| TX_NEW_DSD     | Aggregated Grouping by Age/Sex: <15 Male  | 191   |    |
| TX_NEW_DSD     | Aggregated Grouping by Age/Sex: 15+ Male  | 738   |    |
| TX_NEW_DSD     | Aggregated Grouping by Age/Sex: <1 Female   | 80    |    |
| TX_NEW_DSD     | Aggregated Grouping by Age/Sex: <15 Female  | 191   |    |
| TX_NEW_DSD     | Aggregated Grouping by Age/Sex: 15+ Female  | 1,806 |    |
| TX_NEW_DSD     | Sum of Aggregated Age/Sex disaggregates   | 2,926 |    |
| TX_NEW_DSD     | Pregnancy status  | 407   |    |
| TX_NEW_DSD     | Breastfeeding status  | 382   |    |
| TX_RET_DSD     | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 2,151 |    |
| TX_RET_DSD     | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 2,531 |    |
| LAB_CAP_DSD    | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 22    |    |
| LAB_CAP_DSD    | By site support type: Technical Assistance-only (TA)  | 22    |    |
| LAB_CAP_DSD    | Sum of Site Support Type disaggregates  | 22    |    |
| LAB_CAP_TA     | Sum of Site Support Type disaggregates  | 22    |    |
| HRH_PRE        | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre                        | 30    | 36 |
| HRH_PRE        | By Graduates: Nurses  | 30    | 18 |
| HRH_PRE        | Sum of Graduates disaggreagtes  | 30    | 66 |
| FPINT_SITE_DSD | Number of service delivery points supported   | 77    |    |

|                |   |        |        |
|----------------|---|--------|--------|
|                | by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  |        |        |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 225    |        |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 77     |        |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 77     |        |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 225    |        |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 225    |        |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 77     |        |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 77     |        |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 225    |        |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 77     |        |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 77     |        |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 13,594 |        |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load                       | 14,160 |        |
| TB_SCREEN_TA   | Number of HIV positive adults and children who received at least one of the following   | 12,474 | 17,279 |



|  |   |  |  |
|--|---|--|--|
|  | during the reporting period: clinical<br>assessment (WHO staging) OR CD4 count<br>OR viral load |  |  |
|--|---|--|--|

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13065</b>  | <b>Mechanism Name: ICAP HQ</b>          |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Columbia University Mailman School of Public Health |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                              |   |
| G2G: No   | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,000,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,000,000             |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |
|----------------------------|--|
| <b>Mechanism ID: 13065</b> |  |
|----------------------------|--|





|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism Name:</b>     | ICAP HQ   |                       |                       |
| <b>Prime Partner Name:</b> | Columbia University Mailman School of Public Health |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVCT  | 250,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | MTCT  | 250,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS  | 500,000               | 0                     |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 13160</b>                                     | <b>Mechanism Name: DPS Zambezia Province</b> |
| Funding Agency: HHS/CDC  | Procurement Type: Cooperative Agreement      |
| Prime Partner Name: Provincial Directorate of Health, Zambezia |  |
| Agreement Start Date: Redacted                                 | Agreement End Date: Redacted                 |
| TBD: No  | New Mechanism: No                            |
| Global Fund / Multilateral Engagement: N/A                     |  |
| G2G: Yes   | Managing Agency: HHS/CDC                     |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 875,926</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 875,926               |

## Sub Partner Name(s)

(No data provided.)



## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 13160                                      |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | DPS Zambezia Province                      |                |                |
| <b>Prime Partner Name:</b> | Provincial Directorate of Health, Zambezia |                |                |
| Strategic Area             | Budget Code                                | Planned Amount | On Hold Amount |
| Treatment                  | HTXS                                       | 700,741        | 0              |
| Strategic Area             | Budget Code                                | Planned Amount | On Hold Amount |
| Treatment                  | PDTX                                       | 175,185        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13194</b>                                    | <b>Mechanism Name: UCSF PP</b>          |
| Funding Agency: HHS/CDC                                       | Procurement Type: Cooperative Agreement |
| Prime Partner Name: University of California at San Francisco |   |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                    |   |
| G2G: No   | Managing Agency:                        |
| <b>Total All Funding Sources: 0</b>                           |   |



|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Applied Pipeline Amount: 0</b> |                       |
|                                   |                       |
| <b>Funding Source</b>             | <b>Funding Amount</b> |
| GHP-State                         | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13194                                     |                       |                       |
| <b>Mechanism Name:</b>     | UCSF PP                                   |                       |                       |
| <b>Prime Partner Name:</b> | University of California at San Francisco |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                                      | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | MTCT                                      | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS                                      | 0                     | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)



## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 13206</b>                                     | <b>Mechanism Name: EGPAF CB</b>         |
| Funding Agency: HHS/CDC  | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation |   |
| Agreement Start Date: Redacted                                 | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                     |   |
| G2G: No  | Managing Agency:                        |
| <b>Total All Funding Sources: 0</b>                            |   |
| <b>Applied Pipeline Amount: 0</b>                              |   |
|  |   |
| <b>Funding Source</b>  | <b>Funding Amount</b>                   |
| GHP-State  | 0                                       |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13206                                      |                       |                       |
| <b>Mechanism Name:</b>     | EGPAF CB                                   |                       |                       |
| <b>Prime Partner Name:</b> | Elizabeth Glaser Pediatric AIDS Foundation |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                         | <b>Planned Amount</b> | <b>On Hold Amount</b> |



|           |      |   |   |
|-----------|------|---|---|
| Treatment | HTXS | 0 | 0 |
|-----------|------|---|---|

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13212</b>                  | <b>Mechanism Name: HIVQUAL</b>          |
| Funding Agency: HHS/HRSA                    | Procurement Type: Cooperative Agreement |
| Prime Partner Name: New York AIDS Institute |   |
| Agreement Start Date: Redacted              | Agreement End Date: Redacted            |
| TBD: No                                     | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A  |   |
| G2G: No                                     | Managing Agency:                        |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |                         |                       |                       |
|----------------------------|-------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13212                   |                       |                       |
| <b>Mechanism Name:</b>     | HIVQUAL                 |                       |                       |
| <b>Prime Partner Name:</b> | New York AIDS Institute |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>      | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS                    | 0                     | 0                     |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID:</b> 13214                      | <b>Mechanism Name:</b> Fortalecimento dos Sistemas de Saúde e Acção Social (FORSSAS) |
| Funding Agency: USAID                           | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Deloitte Consulting Limited |  |
| Agreement Start Date: Redacted                  | Agreement End Date: Redacted   |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A      |  |
| G2G: No   | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources:</b> 0 |                       |
| <b>Applied Pipeline Amount:</b> 0   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 13214  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Fortalecimento dos Sistemas de Saúde e Ação Social (FORSSAS) |                |                |
| <b>Prime Partner Name:</b> | Deloitte Consulting Limited                                  |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HKID   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS   | 0              | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 90   |      |
| HRH_PRE          | By Graduates: Social service workers   | 90   |      |
| HRH_PRE          | By Graduates: Other  | 0    |      |
| HRH_PRE          | Sum of Graduates disaggreagtes   | 90   |      |

## Implementing Mechanism Details

|                              |  |
|------------------------------|--|
| <b>Mechanism ID:</b> 13255   | <b>Mechanism Name:</b> Community Clinical Health Services Strengthening (COMCHASS) |
| <b>Funding Agency:</b> USAID | <b>Procurement Type:</b> Contract  |



|  |                              |
|--|------------------------------|
| Prime Partner Name: FHI 360                |                              |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13255   |                       |                       |
| <b>Mechanism Name:</b>     | Community Clinical Health Services Strengthening (COMCHASS) |                       |                       |
| <b>Prime Partner Name:</b> | FHI 360   |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC  | 0                     | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID  | 0                     | 0                     |



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Care           | PDCS        | 0              | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention     | MTCT        | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015   | 2016   |
|------------------|---|--------|--------|
| OVC_ACC_DSD      | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services            | 23,538 | 4,751  |
| OVC_SERV_DSD     | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 94,149 | 19,000 |
| OVC_SERV_DSD     | Sex: Male   | 47,074 |        |
| OVC_SERV_DSD     | Sex: Female   | 47,074 |        |
| OVC_SERV_DSD     | Sum of Sex disaggregates  | 94,148 |        |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 13271</b>   | <b>Mechanism Name: Prevenção e Comunicação para Todos (PACTO)</b> |
| Funding Agency: USAID  | Procurement Type: Cooperative Agreement                           |
| Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health |   |
| Agreement Start Date: Redacted   | Agreement End Date: Redacted                                      |
| TBD: No  | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A                                     |   |
| G2G: No  | Managing Agency:  |
| <b>Total All Funding Sources: 0</b>  |   |
| <b>Applied Pipeline Amount: 0</b>  |   |
|  |   |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 0              |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 13271  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Prevenção e Comunicação para Todos (PACTO)                 |                |                |
| <b>Prime Partner Name:</b> | Johns Hopkins University Bloomberg School of Public Health |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Governance and Systems     | HVSI   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | CIRC   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVCT   | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label | 2015 | 2016 |
|------------------|-------|------|------|
|------------------|-------|------|------|

|             |  |        |  |
|-------------|--|--------|--|
| PP_PREV_DSD | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 15,756 |  |
| PP_PREV_DSD | Age/sex: 10-14 Male  | 1,229  |  |
| PP_PREV_DSD | Age/sex: 15-19 Male  | 1,891  |  |
| PP_PREV_DSD | Age/sex: 20-24 Male  | 961    |  |
| PP_PREV_DSD | Age/sex: 25-49 Male  | 835    |  |
| PP_PREV_DSD | Age/sex: 50+ Male  | 110    |  |
| PP_PREV_DSD | Age/sex: 10-14 Female  | 3,073  |  |
| PP_PREV_DSD | Age/sex: 15-19 Female  | 5,105  |  |
| PP_PREV_DSD | Age/sex: 20-24 Female  | 2,285  |  |
| PP_PREV_DSD | Age/sex: 25-49 Female  | 268    |  |
| PP_PREV_DSD | Age/sex: 50+ Female  | 0      |  |
| PP_PREV_DSD | Sum of Age/Sex disaggregates   | 15,757 |  |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 13275</b>  | <b>Mechanism Name: ICAP Capacity Building<br/>Zambezia</b> |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement                    |
| Prime Partner Name: Columbia University Mailman School of Public Health |  |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted                               |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A                              |  |
| G2G: No   | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 13275<br><b>Mechanism Name:</b> ICAP Capacity Building Zambezia<br><b>Prime Partner Name:</b> Columbia University Mailman School of Public Health |             |                |                |
|--|-------------|----------------|----------------|
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | HBHC        | 0              | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | HVTB        | 0              | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Care   | PDCS        | 0              | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems   | OHSS        | 0              | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Prevention   | CIRC        | 0              | 0              |
| Strategic Area   | Budget Code | Planned Amount | On Hold Amount |
| Prevention   | HVCT        | 0              | 0              |

| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention     | MTCT        | 0              | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | HTXS        | 0              | 0              |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | PDTX        | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number  | Label  | 2015  | 2016  | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS<br>D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 7,950 | 6,280 | Redacted                |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 8,086 | 6,280 | Redacted                |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 7,791 |       | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 5,385 | 3,768 | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 2,308 | 2,512 | Redacted                |
| PMTCT_ARV_DS<br>D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 159   |       | Redacted                |

|                    |  |         |        |          |
|--------------------|--|---------|--------|----------|
| PMTCT_ARV_DS<br>D  | Single-dose nevirapine (with or without tail)  | 0       | 0      | Redacted |
| PMTCT_ARV_DS<br>D  | Sum of Regimen Type disaggregates  | 7,950   | 0      | Redacted |
| PMTCT_ARV_DS<br>D  | Sum of New and Current disaggregates   | 7,693   | 6,280  | Redacted |
| PMTCT_ARV_TA       | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 826     | 1,375  | Redacted |
| PMTCT_ARV_TA       | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 841     | 550    | Redacted |
| PMTCT_ARV_TA       | Life-long ART (including Option B+)  | 703     |        | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 560     | 825    | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 240     | 550    | Redacted |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 124     |        | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates  | 827     | 0      | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates   | 800     | 1,375  | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                                     | 100,685 | 55,919 | Redacted |
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients  | 100,685 | 53,261 | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry   | 2,345   | 1,820  | Redacted |

|                    |  |         |         |          |
|--------------------|--|---------|---------|----------|
| PMTCT_STAT_DS<br>D | By: Number of new positives identified   | 5,741   | 4,460   | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates  | 8,086   | 6,280   | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                           | 10,468  | 33,434  | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients  | 10,468  | 29,334  | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry   | 244     | 158     | Redacted |
| PMTCT_STAT_TA      | By: Number of new positives identified   | 597     | 392     | Redacted |
| PMTCT_STAT_TA      | Sum of Positives Status disaggregates  | 841     | 550     | Redacted |
| VMMC_CIRC_DS<br>D  | Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period | 34,073  |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: <1   | 0       |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 1-9  | 0       |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 10-14  | 13,629  |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 15-19  | 10,222  |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 20-24  | 6,815   |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 25-49  | 2,726   |         | Redacted |
| VMMC_CIRC_DS<br>D  | By Age: 50+  | 681     |         | Redacted |
| VMMC_CIRC_DS<br>D  | Sum of age disaggregates   | 34,073  |         | Redacted |
| HTC_TST_DSD        | Number of individuals who received   | 316,748 | 175,560 | Redacted |

|                   |   |        |        |          |
|-------------------|---|--------|--------|----------|
|                   | T&C services for HIV and received their test results during the past 12 months  |        |        |          |
| HTC_TST_TA        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 19,150 | 64,468 | Redacted |
| GEND_GBV_DSD      | Number of people receiving post-GBV care  | 1,000  |        | Redacted |
| CARE_CURR_DS<br>D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 77,332 | 68,576 | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 3,093  |        | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 30,160 |        | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 3,093  |        | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 40,986 |        | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex disaggregates   | 77,332 |        | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 1,625  | 15,729 | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 65     |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 634    |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 65     |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 861    |        | Redacted |



|               |   |        |        |          |
|---------------|---|--------|--------|----------|
| CARE_CURR_TA  | Sum of Aggregated Age/Sex disaggregates   | 1,625  |        | Redacted |
| CARE_NEW_DSD  | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 40,451 | 45,979 | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male  | 1,618  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male  | 15,776 |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female  | 1,618  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female  | 21,439 |        | Redacted |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates   | 40,451 |        | Redacted |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates   | 40,451 |        | Redacted |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.   | 5,800  | 6,178  | Redacted |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.  | 11,600 | 8,232  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period  | 2,716  | 2,542  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period   | 3,195  | 2,825  | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period  | 8,513  | 4,392  | Redacted |

|               |  |        |        |          |
|---------------|--|--------|--------|----------|
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 8,927  |        | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 46,586 | 48,003 | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 851    | 644    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 1,276  | 1,467  | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 851    | 1,035  | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 11,748 |        | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 972    | 644    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 1,276  | 1,467  | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 851    | 1,035  | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 28,762 |        | Redacted |
| TX_CURR_DSD   | Sum of age/sex disaggregates   | 6,077  | 6,292  | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Male   | 3,038  |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Female   | 3,038  |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex <15  | 6,076  |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex disaggregates  | 6,076  |        | Redacted |
| TX_CURR_TA    | Number of adults and children receiving antiretroviral therapy (ART)   | 979    | 11,010 | Redacted |
| TX_CURR_TA    | Age/Sex: <1 Male   | 18     | 145    | Redacted |
| TX_CURR_TA    | Age/Sex: 1-4 Male  | 27     | 332    | Redacted |
| TX_CURR_TA    | Age/Sex: 5-14 Male   | 18     | 234    | Redacted |
| TX_CURR_TA    | Age/Sex: 15+ Male  | 247    |        | Redacted |
| TX_CURR_TA    | Age/Sex: <1 Female   | 20     | 145    | Redacted |
| TX_CURR_TA    | Age/Sex: 1-4 Female  | 27     | 332    | Redacted |
| TX_CURR_TA    | Age/Sex: 5-14 Female   | 18     | 234    | Redacted |
| TX_CURR_TA    | Age/Sex: 15+ Female  | 604    |        | Redacted |
| TX_CURR_TA    | Sum of Age/Sex disaggregations   | 128    | 1,422  | Redacted |
| TX_CURR_TA    | Aggregated Age/Sex: <15 Male   | 64     |        | Redacted |
| TX_CURR_TA    | Aggregated Age/Sex: <15 Female   | 64     |        | Redacted |

|            |   |        |        |          |
|------------|---|--------|--------|----------|
| TX_CURR_TA | Sum of Aggregated Age/Sex <15   | 128    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates   | 128    |        | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART)  | 17,764 | 21,614 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male   | 847    |        | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female   | 937    |        | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates  | 1,784  | 936    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male   | 440    | 207    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male  | 1,159  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male  | 4,480  | 6,859  | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female   | 487    | 207    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female  | 1,159  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female  | 10,967 | 12,741 | Redacted |
| TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates   | 17,765 | 19,600 | Redacted |
| TX_NEW_DSD | Pregnancy status  | 5,385  | 3,768  | Redacted |
| TX_NEW_DSD | Breastfeeding status  | 2,317  |        | Redacted |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 11,560 | 12,392 | Redacted |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 13,600 | 17,690 | Redacted |
| HRH_PRE    | Number of new HCW who graduated from a pre-service training institution or  | 30     |        | Redacted |

|                |   |     |     |          |
|----------------|---|-----|-----|----------|
|                | program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre   |     |     |          |
| HRH_PRE        | By Graduates: Nurses  | 30  | 30  | Redacted |
| HRH_PRE        | Sum of Graduates disaggregates  | 30  | 83  | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 70  | 117 | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 222 | 117 | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 70  |     | Redacted |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 70  |     | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 222 |     | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 222 |     | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 70  |     | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 70  |     | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 222 |     | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 70  |     | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type  | 70  |     | Redacted |

|               |   |        |        |          |
|---------------|---|--------|--------|----------|
|               | disaggregates   |        |        |          |
| TB_SCREEN_DSD | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 74,239 |        | Redacted |
| TB_SCREEN_DSD | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 77,332 | 68,576 | Redacted |
| TB_SCREEN_TA  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 1,625  | 15,729 | Redacted |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 13313</b>  | <b>Mechanism Name: National Public Health Reference Laboratory</b> |
| Funding Agency: State/AF  | Procurement Type: USG Core   |
| Prime Partner Name: Regional Procurement Support Office/Frankfurt |  |
| Agreement Start Date: Redacted                                    | Agreement End Date: Redacted                                       |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A                        |  |
| G2G: No   | Managing Agency:   |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,600,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,600,000             |

### Sub Partner Name(s)

(No data provided.)



## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 13313   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | National Public Health Reference Laboratory   |                |                |
| <b>Prime Partner Name:</b> | Regional Procurement Support Office/Frankfurt |                |                |
| Strategic Area             | Budget Code                                   | Planned Amount | On Hold Amount |
| Governance and Systems     | HLAB  | 1,600,000      | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID:</b> 13413                         | <b>Mechanism Name:</b> Youth:Work       |
| Funding Agency: USAID                              | Procurement Type: Cooperative Agreement |
| Prime Partner Name: International Youth Foundation |   |
| Agreement Start Date: Redacted                     | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A         |   |
| G2G: No  | Managing Agency:                        |
| <b>Total All Funding Sources:</b> 0                |   |
| <b>Applied Pipeline Amount:</b> 0                  |   |
|  |   |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 0              |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 13413                          |                |                |
|----------------------------|--------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | Youth:Work                     |                |                |
| <b>Prime Partner Name:</b> | International Youth Foundation |                |                |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Care                       | HBHC                           | 0              | 0              |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Care                       | HKID                           | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| OVC_ACC_DSD      | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services | 0    |      |
| OVC_SERV_DSD     | Number of active beneficiaries served by   | 0    |      |



|              |  |   |  |
|--------------|--|---|--|
|              | PEPFAR OVC programs for children and families affected by HIV/AIDS |   |  |
| OVC_SERV_DSD | Sex: Male  | 0 |  |
| OVC_SERV_DSD | Sex: Female  | 0 |  |
| OVC_SERV_DSD | Sum of Sex disaggregates   | 0 |  |

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 13510</b>                       | <b>Mechanism Name: HIV Prevention for Most-at-Risk Populations (MARPS) - GHC</b> |
| Funding Agency: HHS/CDC                          | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Global Health Communications |  |
| Agreement Start Date: Redacted                   | Agreement End Date: Redacted   |
| TBD: No  | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A       |  |
| G2G: No  | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)



### Budget Code Information

| <b>Mechanism ID:</b>       | <b>13510</b>   |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | <b>HIV Prevention for Most-at-Risk Populations (MARPS) - GHC</b> |                |                |
| <b>Prime Partner Name:</b> | <b>Global Health Communications</b>                              |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Treatment                  | HTXS   | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015  | 2016 | Planning Budget Targets |
|------------------|---|-------|------|-------------------------|
| KP_PREV_DSD      | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required   | 1,748 |      | Redacted                |
| KP_PREV_DSD      | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,598 |      | Redacted                |
| KP_PREV_DSD      | By key population type: Males who inject drugs ( Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the                  | 135   |      | Redacted                |

|             |  |    |  |          |
|-------------|--|----|--|----------|
|             | minimum standards required)  |    |  |          |
| KP_PREV_DSD | By key population type: Females who inject drugs (Female PWID)<br>(Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 15 |  | Redacted |

### Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13583</b>  | <b>Mechanism Name: ICAP TA</b>          |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Columbia University Mailman School of Public Health |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                              |   |
| G2G: No   | Managing Agency:                        |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 27,667,525</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 27,667,525            |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                           |         |
|---------------------------|---------|
| Motor Vehicles: Purchased | 406,896 |
|---------------------------|---------|

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 13583   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | ICAP TA   |                |                |
| <b>Prime Partner Name:</b> | Columbia University Mailman School of Public Health |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HBHC  | 3,683,670      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HVTB  | 637,769        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | PDCS  | 818,625        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | CIRC  | 250,000        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | HVCT  | 1,826,540      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | MTCT  | 2,477,716      | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | HTXS  | 15,782,483     | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | PDTX  | 2,190,722      | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number  | Label  | 2015  | 2016  | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS<br>D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 5,760 | 2,943 | Redacted                |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 5,859 | 2,943 | Redacted                |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 5,644 |       | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 3,820 | 1,766 | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 1,637 | 1,177 | Redacted                |
| PMTCT_ARV_DS<br>D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 115   |       | Redacted                |
| PMTCT_ARV_DS<br>D | Single-dose nevirapine (with or without tail)  | 0     | 0     | Redacted                |
| PMTCT_ARV_DS<br>D | Sum of Regimen Type disaggregates  | 5,759 | 0     | Redacted                |
| PMTCT_ARV_DS<br>D | Sum of New and Current disaggregates   | 5,457 | 2,943 | Redacted                |
| PMTCT_ARV_TA      | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,926 | 4,015 | Redacted                |
| PMTCT_ARV_TA      | Number of HIV- positive pregnant   | 1,960 | 1,610 | Redacted                |

|                    |   |         |        |          |
|--------------------|---|---------|--------|----------|
|                    | women identified in the reporting period<br>(including known HIV-positive at entry)   |         |        |          |
| PMTCT_ARV_TA       | Life-long ART (including Option B+)   | 1,637   |        | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Newly<br>initiated on treatment during the current<br>pregnancy                                 | 1,278   | 2,405  | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Already on<br>treatment at the beginning of the<br>current pregnancy                            | 548     | 1,610  | Redacted |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component<br>of WHO Option A during pregnancy<br>and delivery)                                    | 289     |        | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates   | 1,926   | 0      | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates  | 1,826   | 4,015  | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known<br>HIV status (includes women who were<br>tested for HIV and received their<br>results) | 145,745 | 36,213 | Redacted |
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients   | 145,745 | 34,489 | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry  | 1,699   | 852    | Redacted |
| PMTCT_STAT_DS<br>D | By: Number of new positives identified  | 4,160   | 2,091  | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates   | 5,859   | 2,943  | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known<br>HIV status (includes women who were<br>tested for HIV and received their<br>results) | 48,747  | 94,381 | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients   | 48,747  | 90,845 | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry  | 568     | 463    | Redacted |
| PMTCT_STAT_TA      | By: Number of new positives identified  | 1,391   | 1,147  | Redacted |
| PMTCT_STAT_TA      | Sum of Positives Status disaggregates   | 1,959   | 1,610  | Redacted |

|                   |   |         |         |          |
|-------------------|---|---------|---------|----------|
| HTC_TST_DSD       | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 457,582 | 274,957 | Redacted |
| HTC_TST_TA        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 109,746 | 217,773 | Redacted |
| GEND_GBV_DSD      | Number of people receiving post-GBV care  | 500     | 2,495   | Redacted |
| CARE_CURR_DS<br>D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 74,594  | 43,390  | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 2,984   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 29,092  |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 2,984   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 39,535  |         | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex disaggregates   | 74,595  |         | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 17,204  | 31,137  | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 688     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 6,709   |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 688     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 9,118   |         | Redacted |

|               |   |        |        |          |
|---------------|---|--------|--------|----------|
|               | PERMISSION ONLY: 15+ Female   |        |        |          |
| CARE_CURR_TA  | Sum of Aggregated Age/Sex disaggregates   | 17,203 |        | Redacted |
| CARE_NEW_DSD  | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 34,662 | 15,416 | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male  | 1,386  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male  | 13,518 |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female  | 1,386  |        | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female  | 18,371 |        | Redacted |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates   | 34,661 |        | Redacted |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates   | 34,661 |        | Redacted |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.   | 5,595  | 3,905  | Redacted |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.  | 11,189 | 5,209  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period  | 3,133  | 1,196  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period   | 3,686  | 1,327  | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth  | 7,416  | 3,642  | Redacted |

|               |  |        |        |          |
|---------------|--|--------|--------|----------|
|               | during the reporting period  |        |        |          |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 7,819  |        | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 44,936 | 30,377 | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 821    | 263    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 1,231  | 603    | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 821    | 425    | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 11,332 |        | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 938    | 263    | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 1,231  | 603    | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 821    | 425    | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 27,743 |        | Redacted |
| TX_CURR_DSD   | Sum of age/sex disaggregates   | 5,863  | 2,582  | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Male  | 821    |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Female  | 938    |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Male   | 2,931  |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Male   | 11,332 |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Female   | 2,931  |        | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Female   | 27,743 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex <15  | 5,862  |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex 15+  | 39,075 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex disaggregates  | 44,937 |        | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex (<1 and 1-14) <15  | 1,759  |        | Redacted |
| TX_CURR_TA    | Number of adults and children receiving antiretroviral therapy (ART)   | 10,364 | 21,796 | Redacted |
| TX_CURR_TA    | Age/Sex: <1 Male   | 189    | 295    | Redacted |
| TX_CURR_TA    | Age/Sex: 1-4 Male  | 284    | 674    | Redacted |
| TX_CURR_TA    | Age/Sex: 5-14 Male   | 189    | 471    | Redacted |



|            |  |        |        |          |
|------------|--|--------|--------|----------|
| TX_CURR_TA | Age/Sex: 15+ Male  | 2,613  |        | Redacted |
| TX_CURR_TA | Age/Sex: <1 Female   | 216    | 295    | Redacted |
| TX_CURR_TA | Age/Sex: 1-4 Female  | 284    | 674    | Redacted |
| TX_CURR_TA | Age/Sex: 5-14 Female   | 189    | 471    | Redacted |
| TX_CURR_TA | Age/Sex: 15+ Female  | 6,398  |        | Redacted |
| TX_CURR_TA | Sum of Age/Sex disaggregations   | 1,351  | 2,880  | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Male  | 189    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Female  | 216    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Male   | 676    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Male   | 2,613  |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Female   | 676    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Female   | 6,398  |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex <15  | 1,352  |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex 15+  | 9,011  |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates                                      | 10,363 |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex (<1 and 1-14) <15                                  | 405    |        | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 17,372 | 17,542 | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Male  | 431    |        | Redacted |
| TX_NEW_DSD | By Age/Sex: <1 Female  | 476    |        | Redacted |
| TX_NEW_DSD | Sum of Age/Sex disaggregates   | 907    | 460    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male  | 431    | 101    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male                                     | 1,133  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male                                     | 4,381  | 5,797  | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female                                    | 476    | 101    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female                                   | 1,133  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+  | 10,725 | 10,762 | Redacted |

|                |   |        |        |          |
|----------------|---|--------|--------|----------|
|                | Female  |        |        |          |
| TX_NEW_DSD     | Sum of Aggregated Age/Sex disaggregates   | 17,372 | 16,559 | Redacted |
| TX_NEW_DSD     | Pregnancy status  | 3,820  | 1,766  | Redacted |
| TX_NEW_DSD     | Breastfeeding status  | 2,266  |        | Redacted |
| TX_RET_DSD     | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 9,968  | 5,677  | Redacted |
| TX_RET_DSD     | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 11,727 | 8,119  | Redacted |
| LAB_CAP_DSD    | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 82     |        | Redacted |
| LAB_CAP_DSD    | By site support type: Technical Assistance-only (TA)  | 82     |        | Redacted |
| LAB_CAP_DSD    | Sum of Site Support Type disaggregates  | 82     |        | Redacted |
| LAB_CAP_TA     | Sum of Site Support Type disaggregates  | 82     |        | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 155    | 72     | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 412    | 72     | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family                           | 155    |        | Redacted |

|                |   |        |        |          |
|----------------|---|--------|--------|----------|
|                | planning services   |        |        |          |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 155    |        | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 412    |        | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 412    |        | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 155    |        | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 155    |        | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 412    |        | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 155    |        | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 155    |        | Redacted |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 71,610 |        | Redacted |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 74,594 | 43,390 | Redacted |
| TB_SCREEN_TA   | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 17,204 | 31,137 | Redacted |

### Implementing Mechanism Details

|                            |                            |
|----------------------------|----------------------------|
| <b>Mechanism ID: 13654</b> | <b>Mechanism Name: UCM</b> |
|----------------------------|----------------------------|



|   |   |
|---|---|
| Funding Agency: HHS/CDC                               | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Catholic University of Mozambique |   |
| Agreement Start Date: Redacted                        | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A            |   |
| G2G: No   | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 300,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 300,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 282,384 |
|----------------------------|---------|

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                                   |                       |                       |
|----------------------------|-----------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13654                             |                       |                       |
| <b>Mechanism Name:</b>     | UCM                               |                       |                       |
| <b>Prime Partner Name:</b> | Catholic University of Mozambique |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS                              | 300,000               | 0                     |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 40   |      | Redacted                |
| HRH_PRE          | By Graduates: Doctors  | 40   |      | Redacted                |
| HRH_PRE          | Sum of Graduates disaggreagtes   | 40   |      | Redacted                |

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13661</b>                                    | <b>Mechanism Name: CISM - Manhica Research Center</b> |
| Funding Agency: HHS/CDC                                       | Procurement Type: Cooperative Agreement               |
| Prime Partner Name: Barcelona Centre for International Health |   |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted                          |
| TBD: No   | New Mechanism: No                                     |
| Global Fund / Multilateral Engagement: N/A                    |   |
| G2G: No   | Managing Agency:                                      |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 540,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 540,000               |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | <b>13661</b>                                     |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | <b>CISM - Manhica Research Center</b>            |                |                |
| <b>Prime Partner Name:</b> | <b>Barcelona Centre for International Health</b> |                |                |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Governance and Systems     | HVSI   | 240,000        | 0              |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Prevention                 | MTCT   | 300,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13668</b>                                  | <b>Mechanism Name: ARIEL</b>            |
| Funding Agency: HHS/CDC                                     | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Fundacao ARIEL Contra a SIDA Pediatrica |   |
| Agreement Start Date: Redacted                              | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                  |   |
| G2G: No   | Managing Agency:                        |
| <b>Total All Funding Sources: 25,768,800</b>                |   |



|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Applied Pipeline Amount: 0</b> |                       |
|                                   |                       |
| <b>Funding Source</b>             | <b>Funding Amount</b> |
| GHP-State                         | 25,768,800            |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 773,720 |
| Motor Vehicles: Purchased  | 315,205 |

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 13668                                  |                       |                       |
| <b>Mechanism Name:</b>     | ARIEL                                  |                       |                       |
| <b>Prime Partner Name:</b> | Fundacao ARIEL Contra a SIDA Pediatrca |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                                   | 3,602,686             | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HVTB                                   | 643,295               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | PDCS                                   | 882,099               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |

| Governance and Systems | OHSS        | 450,000        | 0              |
|------------------------|-------------|----------------|----------------|
| Strategic Area         | Budget Code | Planned Amount | On Hold Amount |
| Prevention             | HVCT        | 3,294,806      | 0              |
| Strategic Area         | Budget Code | Planned Amount | On Hold Amount |
| Prevention             | MTCT        | 2,543,472      | 0              |
| Strategic Area         | Budget Code | Planned Amount | On Hold Amount |
| Treatment              | HTXS        | 12,272,236     | 0              |
| Strategic Area         | Budget Code | Planned Amount | On Hold Amount |
| Treatment              | PDTX        | 2,080,206      | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number  | Label  | 2015   | 2016   | Planning Budget Targets |
|-------------------|--|--------|--------|-------------------------|
| PMTCT_ARV_DS<br>D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 9,262  | 11,762 | Redacted                |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 10,085 | 11,762 | Redacted                |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 9,077  |        | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 6,094  | 7,060  | Redacted                |
| PMTCT_ARV_DS      | Sub-Disag of Life-long ART: Already on   | 2,612  | 4,702  | Redacted                |



|                    |  |         |        |          |
|--------------------|--|---------|--------|----------|
| D                  | treatment at the beginning of the current pregnancy  |         |        |          |
| PMTCT_ARV_DS<br>D  | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 185     |        | Redacted |
| PMTCT_ARV_DS<br>D  | Single-dose nevirapine (with or without tail)  | 0       | 0      | Redacted |
| PMTCT_ARV_DS<br>D  | Sum of Regimen Type disaggregates  | 9,262   | 0      | Redacted |
| PMTCT_ARV_DS<br>D  | Sum of New and Current disaggregates   | 8,706   | 11,762 | Redacted |
| PMTCT_ARV_TA       | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 1,724   | 2,202  | Redacted |
| PMTCT_ARV_TA       | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 2,079   | 881    | Redacted |
| PMTCT_ARV_TA       | Life-long ART (including Option B+)  | 1,219   |        | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 1,114   | 1,321  | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 477     | 881    | Redacted |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 504     |        | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates  | 1,723   | 0      | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates   | 1,591   | 2,202  | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)                                     | 104,949 | 98,686 | Redacted |

|                    |   |         |         |          |
|--------------------|---|---------|---------|----------|
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients   | 104,949 | 93,993  | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry  | 2,924   | 3,410   | Redacted |
| PMTCT_STAT_DS<br>D | By: Number of new positives identified  | 7,161   | 8,352   | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates   | 10,085  | 11,762  | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)  | 26,284  | 39,068  | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients   | 26,284  | 37,199  | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry  | 603     | 255     | Redacted |
| PMTCT_STAT_TA      | By: Number of new positives identified  | 1,477   | 626     | Redacted |
| PMTCT_STAT_TA      | Sum of Positives Status disaggregates   | 2,080   | 881     | Redacted |
| HTC_TST_DSD        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 579,280 | 836,748 | Redacted |
| HTC_TST_TA         | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 160,887 | 132,715 | Redacted |
| GEND_GBV_DSD       | Number of people receiving post-GBV care  | 336     | 2,271   | Redacted |
| CARE_CURR_DS<br>D  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 226,919 | 219,293 | Redacted |
| CARE_CURR_DS<br>D  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 9,076   |         | Redacted |
| CARE_CURR_DS<br>D  | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 88,499  |         | Redacted |
| CARE_CURR_DS       | Aggregated Age/sex - USE WITH HQ  | 9,076   |         | Redacted |

|                   |  |         |        |          |
|-------------------|--|---------|--------|----------|
| D                 | PERMISSION ONLY: <15 Female  |         |        |          |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Female  | 120,267 |        | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex<br>disaggregates   | 226,918 |        | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and<br>children who received at least one of<br>the following during the reporting<br>period: clinical assessment (WHO<br>staging) OR CD4 count OR viral load  | 13,230  | 17,500 | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Male  | 529     |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Male  | 5,160   |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: <15 Female  | 529     |        | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ<br>PERMISSION ONLY: 15+ Female  | 7,012   |        | Redacted |
| CARE_CURR_TA      | Sum of Aggregated Age/Sex<br>disaggregates   | 13,230  |        | Redacted |
| CARE_NEW_DSD      | Number of HIV-infected adults and<br>children newly enrolled in clinical care<br>during the reporting period and<br>received at least one of the following at<br>enrollment: clinical assessment (WHO<br>staging) OR CD4 count OR viral load | 99,461  | 74,087 | Redacted |
| CARE_NEW_DSD      | Aggregated Age/sex: <15 Male   | 3,978   |        | Redacted |
| CARE_NEW_DSD      | Aggregated Age/sex: 15+ Male   | 38,789  |        | Redacted |
| CARE_NEW_DSD      | Aggregated Age/sex: <15 Female   | 3,978   |        | Redacted |
| CARE_NEW_DSD      | Aggregated Age/sex: 15+ Female   | 52,715  |        | Redacted |
| CARE_NEW_DSD      | Sum of Aggregated Age/sex<br>disaggregates   | 99,460  |        | Redacted |
| CARE_NEW_TA       | Sum of Aggregated Age/sex<br>disaggregates   | 99,460  |        | Redacted |

|               |  |         |         |          |
|---------------|--|---------|---------|----------|
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.                              | 17,019  | 19,737  | Redacted |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.   | 34,038  | 26,315  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 4,294   | 5,652   | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period                | 5,051   | 6,281   | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period   | 11,396  | 7,861   | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)                 | 12,166  |         | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 136,699 | 153,508 | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 2,496   | 1,689   | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 3,745   | 3,840   | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 2,496   | 2,712   | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 34,471  |         | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 2,853   | 1,689   | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 3,745   | 3,840   | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 2,496   | 2,712   | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 84,397  |         | Redacted |
| TX_CURR_DSD   | Sum of age/sex disaggregates   | 17,831  | 16,482  | Redacted |

|             |  |        |        |          |
|-------------|--|--------|--------|----------|
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male   | 8,915  |        | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female   | 8,915  |        | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15  | 17,830 |        | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates                                      | 17,830 |        | Redacted |
| TX_CURR_TA  | Number of adults and children receiving antiretroviral therapy (ART)         | 7,970  | 12,249 | Redacted |
| TX_CURR_TA  | Age/Sex: <1 Male   | 146    | 194    | Redacted |
| TX_CURR_TA  | Age/Sex: 1-4 Male  | 218    | 440    | Redacted |
| TX_CURR_TA  | Age/Sex: 5-14 Male   | 146    | 308    | Redacted |
| TX_CURR_TA  | Age/Sex: 15+ Male  | 2,010  |        | Redacted |
| TX_CURR_TA  | Age/Sex: <1 Female   | 166    | 194    | Redacted |
| TX_CURR_TA  | Age/Sex: 1-4 Female  | 218    | 440    | Redacted |
| TX_CURR_TA  | Age/Sex: 5-14 Female   | 146    | 308    | Redacted |
| TX_CURR_TA  | Age/Sex: 15+ Female  | 4,921  |        | Redacted |
| TX_CURR_TA  | Sum of Age/Sex disaggregations   | 1,040  | 1,884  | Redacted |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Male   | 520    |        | Redacted |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Female   | 520    |        | Redacted |
| TX_CURR_TA  | Sum of Aggregated Age/Sex <15  | 1,040  |        | Redacted |
| TX_CURR_TA  | Sum of Aggregated Age/Sex disaggregates                                      | 1,040  |        | Redacted |
| TX_NEW_DSD  | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 52,940 | 68,317 | Redacted |
| TX_NEW_DSD  | By Age/Sex: <1 Male  | 1,312  |        | Redacted |
| TX_NEW_DSD  | By Age/Sex: <1 Female  | 1,450  |        | Redacted |
| TX_NEW_DSD  | Sum of Age/Sex disaggregates   | 2,762  | 2,908  | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age: <1 Male  | 1,312  | 638    | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <15 Male                                     | 3,452  |        | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: 15+ Male                                     | 13,350 | 21,721 | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <1 Female                                    | 1,450  | 638    | Redacted |

|             |   |        |        |          |
|-------------|---|--------|--------|----------|
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <15 Female  | 3,452  |        | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: 15+ Female  | 32,685 | 40,338 | Redacted |
| TX_NEW_DSD  | Sum of Aggregated Age/Sex disaggregates   | 52,939 | 62,059 | Redacted |
| TX_NEW_DSD  | Pregnancy status  | 6,094  | 7,060  | Redacted |
| TX_NEW_DSD  | Breastfeeding status  | 6,905  |        | Redacted |
| TX_RET_DSD  | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 20,343 | 24,191 | Redacted |
| TX_RET_DSD  | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 23,932 | 31,993 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 66     |        | Redacted |
| LAB_CAP_DSD | By site support type: Technical Assistance-only (TA)  | 66     |        | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates  | 66     |        | Redacted |
| LAB_CAP_TA  | Sum of Site Support Type disaggregates  | 66     |        | Redacted |
| HRH_PRE     | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre                        | 30     | 203    | Redacted |
| HRH_PRE     | By Graduates: Nurses  | 30     | 132    | Redacted |
| HRH_PRE     | Sum of Graduates disaggreagtes  | 30     | 203    | Redacted |

|                |   |         |         |          |
|----------------|---|---------|---------|----------|
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 184     | 227     | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 505     | 227     | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 184     |         | Redacted |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 184     |         | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 505     |         | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 505     |         | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 184     |         | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 184     |         | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 505     |         | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 184     |         | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 184     |         | Redacted |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 217,842 |         | Redacted |
| TB_SCREEN_DSD  | Number of HIV positive adults and   | 226,919 | 219,293 | Redacted |



|              |   |        |        |          |
|--------------|---|--------|--------|----------|
|              | children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load                                   |        |        |          |
| TB_SCREEN_TA | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 13,230 | 17,500 | Redacted |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 13776</b>                             | <b>Mechanism Name: CCS</b>              |
| Funding Agency: HHS/CDC                                | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Center for Collaboration in Health |   |
| Agreement Start Date: Redacted                         | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A             |   |
| G2G: No  | Managing Agency:                        |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 18,699,218</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 18,699,218            |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 759,838 |
| Motor Vehicles: Purchased  | 163,224 |



## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 13776<br><b>Mechanism Name:</b> CCS<br><b>Prime Partner Name:</b> Center for Collaboration in Health |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HBHC        | 2,898,977      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | HVTB        | 861,859        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Care  | PDCS        | 453,500        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems  | OHSS        | 600,000        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | HVCT        | 967,701        | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Prevention  | MTCT        | 2,052,114      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Treatment   | HTXS        | 9,640,487      | 0              |
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Treatment   | PDTX        | 1,224,580      | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number  | Label  | 2015  | 2016  | Planning Budget Targets |
|-------------------|--|-------|-------|-------------------------|
| PMTCT_ARV_DS<br>D | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 6,193 | 7,833 | Redacted                |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 5,633 | 7,833 | Redacted                |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 6,069 |       | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 4,019 | 4,704 | Redacted                |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 1,723 | 3,129 | Redacted                |
| PMTCT_ARV_DS<br>D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 124   |       | Redacted                |
| PMTCT_ARV_DS<br>D | Single-dose nevirapine (with or without tail)  | 0     | 0     | Redacted                |
| PMTCT_ARV_DS<br>D | Sum of Regimen Type disaggregates  | 6,193 | 0     | Redacted                |
| PMTCT_ARV_DS<br>D | Sum of New and Current disaggregates   | 5,742 | 7,833 | Redacted                |
| PMTCT_ARV_TA      | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT)                               | 859   | 1,613 | Redacted                |

|                    |  |        |        |          |
|--------------------|--|--------|--------|----------|
|                    | during pregnancy and delivery  |        |        |          |
| PMTCT_ARV_TA       | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)  | 676    | 646    | Redacted |
| PMTCT_ARV_TA       | Life-long ART (including Option B+)  | 430    |        | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy                              | 530    | 967    | Redacted |
| PMTCT_ARV_TA       | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy                         | 227    | 646    | Redacted |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)                                 | 430    |        | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates  | 860    | 0      | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates   | 757    | 1,613  | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 58,269 | 80,273 | Redacted |
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients  | 58,269 | 76,450 | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry   | 1,633  | 2,274  | Redacted |
| PMTCT_STAT_DS<br>D | By: Number of new positives identified   | 3,999  | 5,559  | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates  | 5,632  | 7,833  | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 11,358 | 26,266 | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients  | 11,358 | 24,928 | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry   | 197    | 188    | Redacted |

|                   |   |         |         |          |
|-------------------|---|---------|---------|----------|
| PMTCT_STAT_TA     | By: Number of new positives identified  | 480     | 458     | Redacted |
| PMTCT_STAT_TA     | Sum of Positives Status disaggregates   | 677     | 646     | Redacted |
| HTC_TST_DSD       | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 309,262 | 308,855 | Redacted |
| HTC_TST_TA        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 29,363  | 90,562  | Redacted |
| GEND_GBV_DSD      | Number of people receiving post-GBV care  | 1,000   | 3,114   | Redacted |
| CARE_CURR_DS<br>D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 166,981 | 202,425 | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 6,679   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 65,122  |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 6,679   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 88,500  |         | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex disaggregates   | 166,980 |         | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 2,661   | 23,612  | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 107     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 1,038   |         | Redacted |

|              |   |        |        |          |
|--------------|---|--------|--------|----------|
| CARE_CURR_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 107    |        | Redacted |
| CARE_CURR_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 1,410  |        | Redacted |
| CARE_CURR_TA | Sum of Aggregated Age/Sex disaggregates   | 2,662  |        | Redacted |
| CARE_NEW_DSD | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load | 59,489 | 63,675 | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: <15 Male  | 2,379  |        | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Male  | 23,201 |        | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: <15 Female  | 2,379  |        | Redacted |
| CARE_NEW_DSD | Aggregated Age/sex: 15+ Female  | 31,529 |        | Redacted |
| CARE_NEW_DSD | Sum of Aggregated Age/sex disaggregates   | 59,488 |        | Redacted |
| CARE_NEW_TA  | Sum of Aggregated Age/sex disaggregates   | 59,488 |        | Redacted |
| FN_THER_DSD  | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.   | 12,524 | 18,218 | Redacted |
| FN_THER_DSD  | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.  | 25,047 | 24,289 | Redacted |
| TB_ART_DSD   | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period  | 3,688  | 5,932  | Redacted |
| TB_ART_DSD   | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment   | 4,338  | 6,590  | Redacted |

|               |  |         |         |          |
|---------------|--|---------|---------|----------|
|               | during the reporting period  |         |         |          |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period                                 | 5,980   | 11,261  | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) | 6,309   |         | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving antiretroviral therapy (ART)   | 100,591 | 141,697 | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Male   | 1,837   | 1,189   | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Male  | 2,755   | 2,704   | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Male   | 1,837   | 1,910   | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Male  | 25,366  |         | Redacted |
| TX_CURR_DSD   | Age/Sex: <1 Female   | 2,099   | 1,189   | Redacted |
| TX_CURR_DSD   | Age/Sex: 1-4 Female  | 2,755   | 2,704   | Redacted |
| TX_CURR_DSD   | Age/Sex: 5-14 Female   | 1,837   | 1,910   | Redacted |
| TX_CURR_DSD   | Age/Sex: 15+ Female  | 62,104  |         | Redacted |
| TX_CURR_DSD   | Sum of age/sex disaggregates   | 13,120  | 11,606  | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Male  | 1,837   |         | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <1 Female  | 2,099   |         | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Male   | 6,560   |         | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Male   | 25,366  |         | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: <15 Female   | 6,560   |         | Redacted |
| TX_CURR_DSD   | Aggregated Age/Sex: 15+ Female   | 62,104  |         | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex <15  | 13,120  |         | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex 15+  | 87,470  |         | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex disaggregates  | 100,590 |         | Redacted |
| TX_CURR_DSD   | Sum of Aggregated Age/Sex (<1 and 1-14) <15  | 3,936   |         | Redacted |
| TX_CURR_TA    | Number of adults and children receiving antiretroviral therapy (ART)   | 1,603   | 16,528  | Redacted |

|            |  |        |        |          |
|------------|--|--------|--------|----------|
| TX_CURR_TA | Age/Sex: <1 Male   | 29     | 208    | Redacted |
| TX_CURR_TA | Age/Sex: 1-4 Male  | 44     | 475    | Redacted |
| TX_CURR_TA | Age/Sex: 5-14 Male   | 29     | 336    | Redacted |
| TX_CURR_TA | Age/Sex: 15+ Male  | 404    |        | Redacted |
| TX_CURR_TA | Age/Sex: <1 Female   | 33     | 208    | Redacted |
| TX_CURR_TA | Age/Sex: 1-4 Female  | 44     | 475    | Redacted |
| TX_CURR_TA | Age/Sex: 5-14 Female   | 29     | 336    | Redacted |
| TX_CURR_TA | Age/Sex: 15+ Female  | 989    |        | Redacted |
| TX_CURR_TA | Sum of Age/Sex disaggregations   | 208    | 2,038  | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Male  | 29     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <1 Female  | 33     |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Male   | 105    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Male   | 404    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: <15 Female   | 105    |        | Redacted |
| TX_CURR_TA | Aggregated Age/Sex: 15+ Female   | 989    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex <15  | 210    |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex 15+  | 1,393  |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates                                      | 1,603  |        | Redacted |
| TX_CURR_TA | Sum of Aggregated Age/Sex (<1 and 1-14) <15                                  | 62     |        | Redacted |
| TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 32,084 | 51,454 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age: <1 Male  | 795    | 376    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male                                     | 2,093  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male                                     | 8,091  | 16,720 | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <1 Female                                    | 879    | 376    | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female                                   | 2,093  |        | Redacted |
| TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+  | 19,808 | 31,059 | Redacted |

|                |   |        |        |          |
|----------------|---|--------|--------|----------|
|                | Female  |        |        |          |
| TX_NEW_DSD     | Sum of Aggregated Age/Sex disaggregates   | 32,085 | 47,779 | Redacted |
| TX_NEW_DSD     | Pregnancy status  | 4,019  | 4,704  | Redacted |
| TX_NEW_DSD     | Breastfeeding status  | 4,185  |        | Redacted |
| TX_RET_DSD     | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 13,704 | 13,574 | Redacted |
| TX_RET_DSD     | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 16,122 | 18,271 | Redacted |
| LAB_CAP_DSD    | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 58     |        | Redacted |
| LAB_CAP_DSD    | By site support type: Technical Assistance-only (TA)  | 58     |        | Redacted |
| LAB_CAP_DSD    | Sum of Site Support Type disaggregates  | 58     |        | Redacted |
| LAB_CAP_TA     | Sum of Site Support Type disaggregates  | 58     |        | Redacted |
| HRH_PRE        | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre                        | 60     | 79     | Redacted |
| HRH_PRE        | By Graduates: Nurses  | 60     | 49     | Redacted |
| HRH_PRE        | Sum of Graduates disaggreagtes  | 60     | 139    | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 112    | 136    | Redacted |



|                |   |         |         |          |
|----------------|---|---------|---------|----------|
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 344     | 136     | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 112     |         | Redacted |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates  | 112     |         | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points   | 344     |         | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 344     |         | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 112     |         | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 112     |         | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 344     |         | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 112     |         | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 112     |         | Redacted |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 160,301 |         | Redacted |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load                       | 166,981 | 202,425 | Redacted |

|              |   |       |        |          |
|--------------|---|-------|--------|----------|
| TB_SCREEN_TA | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 2,661 | 23,612 | Redacted |
|--------------|---|-------|--------|----------|

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 13782</b>   | <b>Mechanism Name: Improved Reproductive Health and Rights Services for Most at Risk Populations in Tete</b> |
| Funding Agency: USAID  | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: International Center for Reproductive Health, Mozambique |  |
| Agreement Start Date: Redacted   | Agreement End Date: Redacted   |
| TBD: No  | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A                                   |  |
| G2G: No  | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 13782   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | Improved Reproductive Health and Rights Services for Most at Risk |                |                |
| <b>Prime Partner Name:</b> | Populations in Tete   |                |                |
|                            | International Center for Reproductive Health, Mozambique          |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | HVCT  | 0              | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Prevention                 | HVOP  | 0              | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 0    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 50+ Female  | 0    |      |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 0    |      |
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results  | 0    |      |

|             |  |     |  |
|-------------|--|-----|--|
|             | during the past 12 months                |     |  |
| GEND_GBVDSD | Number of people receiving post-GBV care | 100 |  |
| GEND_GBVDSD | Sex: Male                                | 0   |  |
| GEND_GBVDSD | Sex: Female                              | 0   |  |
| GEND_GBVDSD | Sum of Sex disaggregates                 | 0   |  |

### Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 13784</b>                      | <b>Mechanism Name: INS</b>              |
| Funding Agency: HHS/CDC                         | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Instituto Nacional de Saúde |   |
| Agreement Start Date: Redacted                  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A      |   |
| G2G: Yes  | Managing Agency: HHS/CDC                |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 3,965,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 3,965,000             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

Custom

Page 244 of 311

FACTS Info v3.8.17.0

2015-11-25 12:28 EST

| <b>Mechanism ID:</b>       | 13784                       |                |                |
|----------------------------|-----------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | INS                         |                |                |
| <b>Prime Partner Name:</b> | Instituto Nacional de Saúde |                |                |
| Strategic Area             | Budget Code                 | Planned Amount | On Hold Amount |
| Governance and Systems     | HLAB                        | 1,350,000      | 0              |
| Strategic Area             | Budget Code                 | Planned Amount | On Hold Amount |
| Governance and Systems     | HVSI                        | 1,900,000      | 0              |
| Strategic Area             | Budget Code                 | Planned Amount | On Hold Amount |
| Prevention                 | HVCT                        | 100,000        | 0              |
| Strategic Area             | Budget Code                 | Planned Amount | On Hold Amount |
| Prevention                 | MTCT                        | 290,000        | 0              |
| Strategic Area             | Budget Code                 | Planned Amount | On Hold Amount |
| Treatment                  | HTXS                        | 325,000        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label                             | 2015 | 2016 | Planning Budget Targets |
|------------------|-----------------------------------|------|------|-------------------------|
| LAB_ACC_TA       | Sum of Support Type disaggregates | 10   |      | Redacted                |

## Implementing Mechanism Details

|                                |                                   |
|--------------------------------|-----------------------------------|
| <b>Mechanism ID:</b> 14597     | <b>Mechanism Name:</b> DevResults |
| Funding Agency: USAID          | Procurement Type: Contract        |
| Prime Partner Name: DevResults |                                   |
| Agreement Start Date: Redacted | Agreement End Date: Redacted      |



|  |                       |
|--|-----------------------|
| TBD: No                                    | New Mechanism: No     |
| Global Fund / Multilateral Engagement: N/A |                       |
| G2G: No                                    | Managing Agency:      |
| Total All Funding Sources: 76,000          |                       |
| Applied Pipeline Amount: 0                 |                       |
|  |                       |
| <b>Funding Source</b>                      | <b>Funding Amount</b> |
| GHP-State                                  | 76,000                |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                    |                       |                       |
|----------------------------|--------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14597              |                       |                       |
| <b>Mechanism Name:</b>     | DevResults         |                       |                       |
| <b>Prime Partner Name:</b> | DevResults         |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HVSI               | 76,000                | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)



## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 14598</b>                 | <b>Mechanism Name: Health Policy Project (HPP)</b> |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement            |
| Prime Partner Name: Futures Group          |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                       |
| TBD: No                                    | New Mechanism: No                                  |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:                                   |
| <b>Total All Funding Sources: 240,000</b>  |  |
| <b>Applied Pipeline Amount: 0</b>          |  |
|  |  |
| <b>Funding Source</b>                      | <b>Funding Amount</b>                              |
| GHP-State                                  | 240,000  |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |                             |                       |                       |
|----------------------------|-----------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14598                       |                       |                       |
| <b>Mechanism Name:</b>     | Health Policy Project (HPP) |                       |                       |
| <b>Prime Partner Name:</b> | Futures Group               |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>          | <b>Planned Amount</b> | <b>On Hold Amount</b> |



|                        |      |         |   |
|------------------------|------|---------|---|
| Governance and Systems | HVSI | 240,000 | 0 |
|------------------------|------|---------|---|

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 14639</b>                 | <b>Mechanism Name: Capacity Building Providers to LCD</b> |
| Funding Agency: USAID                      | Procurement Type: Contract                                |
| Prime Partner Name: New Partner            |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                              |
| TBD: No                                    | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 400,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 400,000               |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)





### Budget Code Information

| <b>Mechanism ID:</b>       | 14639                              |                |                |
|----------------------------|------------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | Capacity Building Providers to LCD |                |                |
| <b>Prime Partner Name:</b> | New Partner                        |                |                |
| Strategic Area             | Budget Code                        | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS                               | 400,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID:</b> 14652  | <b>Mechanism Name:</b> Health Management Twinning |
| Funding Agency: USAID   | Procurement Type: Cooperative Agreement           |
| Prime Partner Name: Columbia University Mailman School of Public Health |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted                      |
| TBD: No   | New Mechanism: No                                 |
| Global Fund / Multilateral Engagement: N/A                              |   |
| G2G: No   | Managing Agency:                                  |

| <b>Total All Funding Sources:</b> 200,000 |                |
|---|----------------|
| <b>Applied Pipeline Amount:</b> 0         |                |
| Funding Source                            | Funding Amount |
| GHP-State                                 | 200,000        |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)



|                            |         |
|----------------------------|---------|
| Human Resources for Health | 193,430 |
|----------------------------|---------|

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b> 14652<br><b>Mechanism Name:</b> Health Management Twinning<br><b>Prime Partner Name:</b> Columbia University Mailman School of Public Health |             |                |                |
|---|-------------|----------------|----------------|
| Strategic Area  | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems  | OHSS        | 200,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID:</b> 14670   | <b>Mechanism Name:</b> Strengthening Health and Social Service System |
| Funding Agency: USAID  | Procurement Type: Cooperative Agreement                               |
| Prime Partner Name: Foundation for Community Development, Mozambique |   |
| Agreement Start Date: Redacted                                       | Agreement End Date: Redacted  |
| TBD: No  | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A                           |   |
| G2G: No  | Managing Agency:  |
| <b>Total All Funding Sources:</b> 1,063,551                          |   |
| <b>Applied Pipeline Amount:</b> 0                                    |   |
|  |   |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 1,063,551      |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                    |        |
|--------------------|--------|
| Condom programming | 55,844 |
|--------------------|--------|

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 14670  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Strengthening Health and Social Service System   |                |                |
| <b>Prime Partner Name:</b> | Foundation for Community Development, Mozambique |                |                |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Care                       | HBHC   | 528,240        | 0              |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Care                       | HKID   | 477,540        | 0              |
| Strategic Area             | Budget Code                                      | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 57,771         | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label | 2015 | 2016 |
|------------------|-------|------|------|
|------------------|-------|------|------|



|              |   |       |       |
|--------------|---|-------|-------|
| OVC_ACC_DSD  | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services            | 1,500 | 887   |
| OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 6,000 | 3,544 |
| OVC_SERV_DSD | Sex: Male   | 3,000 |       |
| OVC_SERV_DSD | Sex: Female   | 3,000 |       |
| OVC_SERV_DSD | Sum of Sex disaggregates  | 6,000 |       |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 14719</b>  | <b>Mechanism Name: Evaluations QI and Viral Load</b> |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement              |
| Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC) |  |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted                         |
| TBD: No   | New Mechanism: No                                    |
| Global Fund / Multilateral Engagement: N/A  |  |
| G2G: No   | Managing Agency:                                     |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 500,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 500,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 14719   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | Evaluations QI and Viral Load   |                |                |
| <b>Prime Partner Name:</b> | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC) |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | HTXS  | 500,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

| <b>Mechanism ID: 14732</b>                 | <b>Mechanism Name: (ASPIRES) Accelerating Strategies for Practical Innovation &amp; Research in Economic Strengthening</b> |
|--|--|
| Funding Agency: USAID                      | Procurement Type: Contract   |
| Prime Partner Name: FHI 360                |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted   |
| TBD: No                                    | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:   |
| <b>Total All Funding Sources: 350,000</b>  |  |
| <b>Applied Pipeline Amount: 0</b>          |  |
| Funding Source                             | Funding Amount   |
| GHP-State                                  | 350,000  |



### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                         |  |
|-------------------------|--|
| Economic Strengthening  | 100,000  |
| Gender: Gender Equality | 50,000   |
| Focus Area:             | Increase gender-equitable access to income and productive resources, including education |
| Sub Area:               | Collection and Use of Gender-related Strategic Information                               |

### Key Issues

(No data provided.)

### Budget Code Information

| Mechanism ID:       | 14732       | (ASPIRES) Accelerating Strategies for Practical Innovation & Research in Economic Strengthening |                |
|---------------------|-------------|---|----------------|
| Mechanism Name:     |             |   |                |
| Prime Partner Name: | FHI 360     |   |                |
| Strategic Area      | Budget Code | Planned Amount  | On Hold Amount |
| Care                | HKID        | 350,000   | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                     |          |
|---------------------|----------|
| Mechanism ID: 14739 | TBD: Yes |
| REDACTED            |          |



## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID:</b> 14748                         | <b>Mechanism Name:</b> UNICEF Umbrella Grant |
| Funding Agency: USAID                              | Procurement Type: Grant                      |
| Prime Partner Name: United Nations Children's Fund |  |
| Agreement Start Date: Redacted                     | Agreement End Date: Redacted                 |
| TBD: No  | New Mechanism: No                            |
| Global Fund / Multilateral Engagement: N/A         |  |
| G2G: No  | Managing Agency:                             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources:</b> 1,060,000 |                       |
| <b>Applied Pipeline Amount:</b> 0           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,060,000             |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|   |                    |                       |                       |
|---|--------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b> 14748<br><b>Mechanism Name:</b> UNICEF Umbrella Grant<br><b>Prime Partner Name:</b> United Nations Children's Fund |                    |                       |                       |
| <b>Strategic Area</b>   | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |

| Care           | HBHC        | 560,000        | 0              |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care           | HKID        | 500,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 14751</b>                  | <b>Mechanism Name: Ecohealth Project</b> |
| Funding Agency: USAID                       | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Gorongosa National Park |  |
| Agreement Start Date: Redacted              | Agreement End Date: Redacted             |
| TBD: No                                     | New Mechanism: No                        |
| Global Fund / Multilateral Engagement: N/A  |  |
| G2G: No                                     | Managing Agency:                         |

| <b>Total All Funding Sources: 0</b> |                |
|-------------------------------------|----------------|
| <b>Applied Pipeline Amount: 0</b>   |                |
|                                     |                |
| Funding Source                      | Funding Amount |
| GHP-State                           | 0              |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues



(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 14751                   |                |                |
|----------------------------|-------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | Ecohealth Project       |                |                |
| <b>Prime Partner Name:</b> | Gorongosa National Park |                |                |
| Strategic Area             | Budget Code             | Planned Amount | On Hold Amount |
| Care                       | HKID                    | 0              | 0              |
| Strategic Area             | Budget Code             | Planned Amount | On Hold Amount |
| Prevention                 | HVAB                    | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 |
|------------------|--|------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 0    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 0    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 0    |      |
| PP_PREV_DSD      | Age/sex: 50+ Female  | 0    |      |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 0    |      |



## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 14789</b>                                     | <b>Mechanism Name: EGPAF TA</b>         |
| Funding Agency: HHS/CDC  | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation |   |
| Agreement Start Date: Redacted                                 | Agreement End Date: Redacted            |
| TBD: No  | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                     |   |
| G2G: No  | Managing Agency:                        |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 22,563,096</b> |                       |
| <b>Applied Pipeline Amount: 0</b>            |                       |
|  |                       |
| <b>Funding Source</b>                        | <b>Funding Amount</b> |
| GHP-State                                    | 22,563,096            |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 490,970 |
| Motor Vehicles: Purchased  | 250,000 |

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14789                                      |                       |                       |
| <b>Mechanism Name:</b>     | EGPAF TA                                   |                       |                       |
| <b>Prime Partner Name:</b> | Elizabeth Glaser Pediatric AIDS Foundation |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                         | <b>Planned Amount</b> | <b>On Hold Amount</b> |

|                        |                    |                       |                       |
|------------------------|--------------------|-----------------------|-----------------------|
| Care                   | HBHC               | 3,215,566             | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                   | HVTB               | 968,767               | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                   | PDCS               | 635,905               | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems | OHSS               | 400,000               | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention             | HVCT               | 1,971,746             | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention             | MTCT               | 1,768,754             | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment              | HTXS               | 11,904,751            | 0                     |
| <b>Strategic Area</b>  | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment              | PDTX               | 1,697,607             | 0                     |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015  | 2016   | Planning Budget Targets |
|------------------|--|-------|--------|-------------------------|
| PMTCT_ARV_DS D   | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) | 6,284 | 10,526 | Redacted                |

|                   |  |       |        |          |
|-------------------|--|-------|--------|----------|
|                   | during pregnancy and delivery  |       |        |          |
| PMTCT_ARV_DS<br>D | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 6,392 | 10,526 | Redacted |
| PMTCT_ARV_DS<br>D | Life-long ART (including Option B+)  | 6,158 |        | Redacted |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 4,067 | 6,317  | Redacted |
| PMTCT_ARV_DS<br>D | Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy   | 1,743 | 4,209  | Redacted |
| PMTCT_ARV_DS<br>D | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)   | 126   |        | Redacted |
| PMTCT_ARV_DS<br>D | Single-dose nevirapine (with or without tail)  | 0     | 0      | Redacted |
| PMTCT_ARV_DS<br>D | Sum of Regimen Type disaggregates  | 6,284 | 0      | Redacted |
| PMTCT_ARV_DS<br>D | Sum of New and Current disaggregates   | 5,810 | 10,526 | Redacted |
| PMTCT_ARV_TA      | Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery | 820   | 64     | Redacted |
| PMTCT_ARV_TA      | Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)                                      | 835   | 26     | Redacted |
| PMTCT_ARV_TA      | Life-long ART (including Option B+)  | 410   |        | Redacted |
| PMTCT_ARV_TA      | Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy  | 531   | 38     | Redacted |
| PMTCT_ARV_TA      | Sub-Disag of Life-long ART: Already on treatment at the beginning of the   | 228   | 26     | Redacted |

|                    |  |         |         |          |
|--------------------|--|---------|---------|----------|
|                    | current pregnancy  |         |         |          |
| PMTCT_ARV_TA       | Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)                                 | 410     |         | Redacted |
| PMTCT_ARV_TA       | Single-dose nevirapine (with or without tail)  | 0       | 0       | Redacted |
| PMTCT_ARV_TA       | Sum of Regimen Type disaggregates  | 820     | 0       | Redacted |
| PMTCT_ARV_TA       | Sum of New and Current disaggregates   | 759     | 64      | Redacted |
| PMTCT_STAT_DS<br>D | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 37,237  | 62,942  | Redacted |
| PMTCT_STAT_DS<br>D | Number of new ANC and L&D clients  | 37,237  | 59,946  | Redacted |
| PMTCT_STAT_DS<br>D | By: Known positives at entry   | 1,854   | 3,057   | Redacted |
| PMTCT_STAT_DS<br>D | By: Number of new positives identified   | 4,538   | 7,469   | Redacted |
| PMTCT_STAT_DS<br>D | Sum of Positives Status disaggregates  | 6,392   | 10,526  | Redacted |
| PMTCT_STAT_TA      | Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) | 4,862   | 565     | Redacted |
| PMTCT_STAT_TA      | Number of new ANC and L&D clients  | 4,862   | 524     | Redacted |
| PMTCT_STAT_TA      | By: Known positives at entry   | 242     | 8       | Redacted |
| PMTCT_STAT_TA      | By: Number of new positives identified   | 593     | 18      | Redacted |
| PMTCT_STAT_TA      | Sum of Positives Status disaggregates  | 835     | 26      | Redacted |
| HTC_TST_DSD        | Number of individuals who received T&C services for HIV and received their test results during the past 12 months  | 220,577 | 398,918 | Redacted |
| HTC_TST_TA         | Number of individuals who received T&C services for HIV and received their test results during the past 12 months  | 17,270  | 2,370   | Redacted |

|                   |   |         |         |          |
|-------------------|---|---------|---------|----------|
| GEND_GBVDSD       | Number of people receiving post-GBV care  | 290     | 2,111   | Redacted |
| CARE_CURR_DS<br>D | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 148,528 | 176,138 | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 5,941   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 57,926  |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 5,941   |         | Redacted |
| CARE_CURR_DS<br>D | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 78,720  |         | Redacted |
| CARE_CURR_DS<br>D | Sum of Aggregated Age/Sex disaggregates   | 148,528 |         | Redacted |
| CARE_CURR_TA      | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 2,446   | 1,127   | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male  | 98      |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male  | 954     |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female  | 98      |         | Redacted |
| CARE_CURR_TA      | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female  | 1,296   |         | Redacted |
| CARE_CURR_TA      | Sum of Aggregated Age/Sex disaggregates   | 2,446   |         | Redacted |
| CARE_NEW_DSD      | Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and  | 64,251  | 61,301  | Redacted |

|               |  |        |         |          |
|---------------|--|--------|---------|----------|
|               | received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load                                   |        |         |          |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Male   | 2,570  |         | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Male   | 25,058 |         | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: <15 Female   | 2,570  |         | Redacted |
| CARE_NEW_DSD  | Aggregated Age/sex: 15+ Female   | 34,053 |         | Redacted |
| CARE_NEW_DSD  | Sum of Aggregated Age/sex disaggregates  | 64,251 |         | Redacted |
| CARE_NEW_TA   | Sum of Aggregated Age/sex disaggregates  | 64,251 |         | Redacted |
| FN_THER_DSD   | Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.                              | 11,140 | 15,852  | Redacted |
| FN_THER_DSD   | Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.   | 22,279 | 21,135  | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period | 2,713  | 4,862   | Redacted |
| TB_ART_DSD    | The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period                | 3,191  | 5,403   | Redacted |
| PMTCT_EID_DSD | Number of infants who had a virologic HIV test within 12 months of birth during the reporting period   | 6,848  | 5,769   | Redacted |
| PMTCT_EID_DSD | Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)                 | 7,226  |         | Redacted |
| TX_CURR_DSD   | Number of adults and children receiving  | 89,475 | 123,297 | Redacted |

|             |  |        |        |          |
|-------------|--|--------|--------|----------|
|             | antiretroviral therapy (ART)   |        |        |          |
| TX_CURR_DSD | Age/Sex: <1 Male   | 1,634  | 1,231  | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Male  | 2,451  | 2,804  | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Male   | 1,634  | 1,975  | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Male  | 22,563 |        | Redacted |
| TX_CURR_DSD | Age/Sex: <1 Female   | 1,867  | 1,231  | Redacted |
| TX_CURR_DSD | Age/Sex: 1-4 Female  | 2,451  | 2,804  | Redacted |
| TX_CURR_DSD | Age/Sex: 5-14 Female   | 1,634  | 1,975  | Redacted |
| TX_CURR_DSD | Age/Sex: 15+ Female  | 55,241 |        | Redacted |
| TX_CURR_DSD | Sum of age/sex disaggregates   | 11,671 | 12,020 | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Male   | 5,835  |        | Redacted |
| TX_CURR_DSD | Aggregated Age/Sex: <15 Female                                       | 5,835  |        | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15  | 11,670 |        | Redacted |
| TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates                              | 11,670 |        | Redacted |
| TX_CURR_TA  | Number of adults and children receiving antiretroviral therapy (ART) | 1,473  | 789    | Redacted |
| TX_CURR_TA  | Age/Sex: <1 Male   | 27     | 15     | Redacted |
| TX_CURR_TA  | Age/Sex: 1-4 Male  | 40     | 34     | Redacted |
| TX_CURR_TA  | Age/Sex: 5-14 Male   | 27     | 24     | Redacted |
| TX_CURR_TA  | Age/Sex: 15+ Male  | 372    |        | Redacted |
| TX_CURR_TA  | Age/Sex: <1 Female   | 31     | 15     | Redacted |
| TX_CURR_TA  | Age/Sex: 1-4 Female  | 40     | 34     | Redacted |
| TX_CURR_TA  | Age/Sex: 5-14 Female   | 27     | 24     | Redacted |
| TX_CURR_TA  | Age/Sex: 15+ Female  | 910    |        | Redacted |
| TX_CURR_TA  | Sum of Age/Sex disaggregations                                       | 192    | 146    | Redacted |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Male   | 96     |        | Redacted |
| TX_CURR_TA  | Aggregated Age/Sex: <15 Female                                       | 96     |        | Redacted |
| TX_CURR_TA  | Sum of Aggregated Age/Sex <15  | 192    |        | Redacted |
| TX_CURR_TA  | Sum of Aggregated Age/Sex disaggregates                              | 192    |        | Redacted |
| TX_NEW_DSD  | Number of adults and children newly                                  | 34,087 | 48,736 | Redacted |



|             |   |        |        |          |
|-------------|---|--------|--------|----------|
|             | enrolled on antiretroviral therapy (ART)  |        |        |          |
| TX_NEW_DSD  | Aggregated Grouping by Age: <1 Male   | 845    | 467    | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <15 Male  | 2,223  |        | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: 15+ Male  | 8,596  | 15,462 | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <1 Female   | 934    | 467    | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: <15 Female  | 2,223  |        | Redacted |
| TX_NEW_DSD  | Aggregated Grouping by Age/Sex: 15+ Female  | 21,045 | 28,712 | Redacted |
| TX_NEW_DSD  | Sum of Aggregated Age/Sex disaggregates   | 34,087 | 44,174 | Redacted |
| TX_NEW_DSD  | Pregnancy status  | 4,067  | 6,317  | Redacted |
| TX_NEW_DSD  | Breastfeeding status  | 4,446  |        | Redacted |
| TX_RET_DSD  | Number of adults and children who are still alive and on treatment at 12 months after initiating ART  | 19,651 | 22,693 | Redacted |
| TX_RET_DSD  | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 23,119 | 29,910 | Redacted |
| LAB_CAP_DSD | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests  | 85     |        | Redacted |
| LAB_CAP_DSD | By site support type: Technical Assistance-only (TA)  | 85     |        | Redacted |
| LAB_CAP_DSD | Sum of Site Support Type disaggregates  | 85     |        | Redacted |
| LAB_CAP_TA  | Sum of Site Support Type disaggregates  | 85     |        | Redacted |

|                |  |     |     |          |
|----------------|--|-----|-----|----------|
| HRH_PRE        | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre                 | 200 | 96  | Redacted |
| HRH_PRE        | By Graduates: Nurses   | 0   | 30  | Redacted |
| HRH_PRE        | By Graduates: Laboratory professionals   | 50  | 30  | Redacted |
| HRH_PRE        | By Graduates: Other  | 150 | 91  | Redacted |
| HRH_PRE        | Sum of Graduates disaggregates   | 200 | 151 | Redacted |
| FPINT_SITE_DSD | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services   | 293 | 276 | Redacted |
| FPINT_SITE_DSD | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment  | 812 | 276 | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 138 |     | Redacted |
| FPINT_SITE_DSD | By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 155 |     | Redacted |
| FPINT_SITE_DSD | Sum of Numerator Site Support Type disaggregates   | 293 |     | Redacted |
| FPINT_SITE_DSD | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points  | 400 |     | Redacted |

|                |   |         |         |          |
|----------------|---|---------|---------|----------|
| FPINT_SITE_DSD | By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points  | 412     |         | Redacted |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates  | 812     |         | Redacted |
| FPINT_SITE_DSD | Service delivery type: Clinical   | 293     |         | Redacted |
| FPINT_SITE_DSD | Sum of Service Delivery Type disaggregates  | 293     |         | Redacted |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates  | 812     |         | Redacted |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates  | 293     |         | Redacted |
| FPINT_SITE_TA  | Sum of Service Delivery Type disaggregates  | 293     |         | Redacted |
| TB_SCREEN_DSD  | The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period  | 142,587 |         | Redacted |
| TB_SCREEN_DSD  | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 148,528 | 176,138 | Redacted |
| TB_SCREEN_TA   | Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load | 2,446   | 1,127   | Redacted |

### Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 14792</b>  | <b>Mechanism Name: ISCISA</b>           |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: ISCISA- Superior Institution of Health Sciences |   |
| Agreement Start Date: Redacted                                      | Agreement End Date: Redacted            |



|  |                       |
|--|-----------------------|
| TBD: No                                    | New Mechanism: No     |
| Global Fund / Multilateral Engagement: N/A |                       |
| G2G: No                                    | Managing Agency:      |
| Total All Funding Sources: 400,000         |                       |
| Applied Pipeline Amount: 0                 |                       |
|  |                       |
| <b>Funding Source</b>                      | <b>Funding Amount</b> |
| GHP-State                                  | 400,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 378,582 |
|----------------------------|---------|

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14792   |                       |                       |
| <b>Mechanism Name:</b>     | ISCISA  |                       |                       |
| <b>Prime Partner Name:</b> | ISCISA- Superior Institution of Health Sciences |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                              | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVCT  | 40,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                              | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | MTCT  | 40,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                              | <b>Planned Amount</b> | <b>On Hold Amount</b> |



| Treatment      | HTXS        | 160,000        | 0              |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | PDTX        | 160,000        | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 0    |      | Redacted                |
| HRH_PRE          | By Graduates: Nurses   | 0    |      | Redacted                |
| HRH_PRE          | By Graduates: Other  | 0    |      | Redacted                |
| HRH_PRE          | Sum of Graduates disaggregates   | 0    |      | Redacted                |

## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 14794</b>                             | <b>Mechanism Name: Blood Donor Association</b> |
| Funding Agency: HHS/CDC                                | Procurement Type: Cooperative Agreement        |
| Prime Partner Name: Mozambique Blood Donor Association |  |
| Agreement Start Date: Redacted                         | Agreement End Date: Redacted                   |
| TBD: No  | New Mechanism: No                              |
| Global Fund / Multilateral Engagement: N/A             |  |
| G2G: No  | Managing Agency:                               |

| <b>Total All Funding Sources: 0</b> |                |
|-------------------------------------|----------------|
| <b>Applied Pipeline Amount: 0</b>   |                |
|                                     |                |
| Funding Source                      | Funding Amount |



|           |   |
|-----------|---|
| GHP-State | 0 |
|-----------|---|

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 14794                              |                |                |
|----------------------------|------------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | Blood Donor Association            |                |                |
| <b>Prime Partner Name:</b> | Mozambique Blood Donor Association |                |                |
| Strategic Area             | Budget Code                        | Planned Amount | On Hold Amount |
| Prevention                 | HMBL                               | 0              | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 14806</b>                   | <b>Mechanism Name: P/E Quick Impact Program</b> |
| Funding Agency: State/AF                     | Procurement Type: Grant                         |
| Prime Partner Name: U.S. Department of State |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted                    |
| TBD: No                                      | New Mechanism: No                               |
| Global Fund / Multilateral Engagement: N/A   |   |



|   |                       |
|---|-----------------------|
| G2G: No                                   | Managing Agency:      |
| <b>Total All Funding Sources: 375,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 375,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                          |                       |                       |
|----------------------------|--------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14806                    |                       |                       |
| <b>Mechanism Name:</b>     | P/E Quick Impact Program |                       |                       |
| <b>Prime Partner Name:</b> | U.S. Department of State |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                     | 50,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID                     | 260,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | OHSS                     | 15,000                | 0                     |

| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|----------------|-------------|----------------|----------------|
| Prevention     | HVAB        | 50,000         | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015  | 2016 |
|------------------|--|-------|------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period. | 2,078 |      |
| PP_PREV_DSD      | Age/sex: 10-14 Male  | 162   |      |
| PP_PREV_DSD      | Age/sex: 15-19 Male  | 249   |      |
| PP_PREV_DSD      | Age/sex: 20-24 Male  | 127   |      |
| PP_PREV_DSD      | Age/sex: 25-49 Male  | 110   |      |
| PP_PREV_DSD      | Age/sex: 50+ Male  | 15    |      |
| PP_PREV_DSD      | Age/sex: 10-14 Female  | 405   |      |
| PP_PREV_DSD      | Age/sex: 15-19 Female  | 673   |      |
| PP_PREV_DSD      | Age/sex: 20-24 Female  | 301   |      |
| PP_PREV_DSD      | Age/sex: 25-49 Female  | 35    |      |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates   | 2,077 |      |
| OVC_ACC_DSD      | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services   | 2,286 |      |
| OVC_SERV_DSD     | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS  | 9,143 |      |
| OVC_SERV_DSD     | Sex: Male  | 4,571 |      |
| OVC_SERV_DSD     | Sex: Female  | 4,571 |      |
| OVC_SERV_DSD     | Sum of Sex disaggregates   | 9,142 |      |
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a  | 52    |      |



|         |  |    |  |
|---------|--|----|--|
|         | result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre |    |  |
| HRH_PRE | By Graduates: Doctors  | 24 |  |
| HRH_PRE | By Graduates: Nurses   | 20 |  |
| HRH_PRE | By Graduates: Other  | 8  |  |
| HRH_PRE | Sum of Graduates disaggreagtes   | 52 |  |

### Implementing Mechanism Details

|   |  |
|---|--|
| <b>Mechanism ID: 14807</b>                            | <b>Mechanism Name: Support the Mozambican Armed Forces in the Fight Against HIV/AIDS</b> |
| Funding Agency: DOD                                   | Procurement Type: Grant  |
| Prime Partner Name: Population Services International |  |
| Agreement Start Date: Redacted                        | Agreement End Date: Redacted   |
| TBD: No   | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A            |  |
| G2G: No   | Managing Agency:   |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | <b>14807</b>   |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | <b>Support the Mozambican Armed Forces in the Fight Against HIV/AIDS</b> |                |                |
| <b>Prime Partner Name:</b> | <b>Population Services International</b>                                 |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | CIRC   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVCT   | 0              | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 0              | 0              |

### Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015   | 2016   |
|------------------|---|--------|--------|
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 25,929 | 21,097 |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 14822</b>                   | <b>Mechanism Name: ITECH</b>            |
| Funding Agency: HHS/HRSA                     | Procurement Type: Cooperative Agreement |
| Prime Partner Name: University of Washington |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted            |
| TBD: No                                      | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A   |   |
| G2G: No                                      | Managing Agency:                        |
| <b>Total All Funding Sources: 3,208,333</b>  |   |



|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Applied Pipeline Amount: 0</b> |                       |
|                                   |                       |
| <b>Funding Source</b>             | <b>Funding Amount</b> |
| GHP-State                         | 3,208,333             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 531,932 |
| Condom programming         | 23,532  |

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                          |                       |                       |
|----------------------------|--------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 14822                    |                       |                       |
| <b>Mechanism Name:</b>     | ITECH                    |                       |                       |
| <b>Prime Partner Name:</b> | University of Washington |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and Systems     | HLAB                     | 200,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | CIRC                     | 350,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVCT                     | 230,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>       | <b>Planned Amount</b> | <b>On Hold Amount</b> |

|                       |                    |                       |                       |
|-----------------------|--------------------|-----------------------|-----------------------|
| Prevention            | MTCT               | 230,000               | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment             | HTXS               | 1,278,333             | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment             | PDTX               | 920,000               | 0                     |

### Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| HRH_PRE          | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 262  |      | Redacted                |
| HRH_PRE          | By Graduates: Other  | 262  |      | Redacted                |
| HRH_PRE          | Sum of Graduates disaggreagtes   | 262  |      | Redacted                |

### Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 16052</b>                                    | <b>Mechanism Name: UCSF-HQ -COAG</b>    |
| Funding Agency: HHS/CDC                                       | Procurement Type: Cooperative Agreement |
| Prime Partner Name: University of California at San Francisco |   |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                    |   |
| G2G: No   | Managing Agency:                        |

|   |  |
|---|--|
| <b>Total All Funding Sources: 900,000</b> |  |
| <b>Applied Pipeline Amount: 0</b>         |  |
|   |  |



| Funding Source | Funding Amount |
|----------------|----------------|
| GHP-State      | 900,000        |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 16052                                     |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | UCSF-HQ -COAG                             |                |                |
| <b>Prime Partner Name:</b> | University of California at San Francisco |                |                |
| Strategic Area             | Budget Code                               | Planned Amount | On Hold Amount |
| Prevention                 | MTCT                                      | 400,000        | 0              |
| Strategic Area             | Budget Code                               | Planned Amount | On Hold Amount |
| Treatment                  | PDTX                                      | 500,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                                |  |
|--------------------------------|--|
| <b>Mechanism ID:</b> 16671     | <b>Mechanism Name:</b> Foundation for Innovative New Diagnostics |
| <b>Funding Agency:</b> HHS/CDC | <b>Procurement Type:</b> Cooperative Agreement                   |



|   |                              |
|---|------------------------------|
| Prime Partner Name: Foundation for Innovative New Diagnostics |                              |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted |
| TBD: No   | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A                    |                              |
| G2G: No   | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 755,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 755,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 16671                                     |                       |                       |
| <b>Mechanism Name:</b>     | Foundation for Innovative New Diagnostics |                       |                       |
| <b>Prime Partner Name:</b> | Foundation for Innovative New Diagnostics |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HVTB                                      | 275,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and             | HLAB                                      | 480,000               | 0                     |

|         |  |  |  |
|---------|--|--|--|
| Systems |  |  |  |
|---------|--|--|--|

## Implementing Mechanism Indicator Information

| Indicator Number | Label  | 2015 | 2016 | Planning Budget Targets |
|------------------|--|------|------|-------------------------|
| LAB_ACC_TA       | Sum of Support Type disaggregates  | 10   |      | Redacted                |
| LAB_CAP_DSD      | Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests | 3    |      | Redacted                |
| LAB_CAP_DSD      | By site support type: Technical Assistance-only (TA)   | 3    |      | Redacted                |
| LAB_CAP_DSD      | Sum of Site Support Type disaggregates   | 3    |      | Redacted                |
| LAB_CAP_TA       | Sum of Site Support Type disaggregates   | 3    |      | Redacted                |

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 16802</b>                                      | <b>Mechanism Name: DPS Inhambane Province</b> |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement       |
| Prime Partner Name: Provincial Directorate of Health, Inhambane |   |
| Agreement Start Date: Redacted                                  | Agreement End Date: Redacted                  |
| TBD: No   | New Mechanism: No                             |
| Global Fund / Multilateral Engagement: N/A                      |   |
| G2G: Yes  | Managing Agency: HHS/CDC                      |

|  |                       |
|--|-----------------------|
| <b>Total All Funding Sources: 97,325</b> |                       |
| <b>Applied Pipeline Amount: 0</b>        |                       |
|  |                       |
| <b>Funding Source</b>                    | <b>Funding Amount</b> |
| GHP-State                                | 97,325                |



### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 16802                                       |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | DPS Inhambane Province                      |                |                |
| <b>Prime Partner Name:</b> | Provincial Directorate of Health, Inhambane |                |                |
| Strategic Area             | Budget Code                                 | Planned Amount | On Hold Amount |
| Treatment                  | HTXS  | 77,860         | 0              |
| Strategic Area             | Budget Code                                 | Planned Amount | On Hold Amount |
| Treatment                  | PDTX  | 19,465         | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 16879</b>                 | <b>Mechanism Name: World Food Program</b> |
| Funding Agency: USAID                      | Procurement Type: Grant                   |
| Prime Partner Name: World Food Program     |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted              |
| TBD: No                                    | New Mechanism: No                         |
| Global Fund / Multilateral Engagement: N/A |   |





|   |                       |
|---|-----------------------|
| G2G: No                                     | Managing Agency:      |
| <b>Total All Funding Sources: 4,252,526</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 4,252,526             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |                           |                       |                       |
|----------------------------|---------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | <b>16879</b>              |                       |                       |
| <b>Mechanism Name:</b>     | <b>World Food Program</b> |                       |                       |
| <b>Prime Partner Name:</b> | <b>World Food Program</b> |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                      | 3,252,526             | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>        | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID                      | 1,000,000             | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)



## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 16998</b>                                 | <b>Mechanism Name: DPS Gaza Province</b> |
| Funding Agency: HHS/CDC                                    | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: Provincial Directorate of Health, Gaza |  |
| Agreement Start Date: Redacted                             | Agreement End Date: Redacted             |
| TBD: No  | New Mechanism: No                        |
| Global Fund / Multilateral Engagement: N/A                 |  |
| G2G: Yes   | Managing Agency: HHS/CDC                 |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 439,300</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 439,300               |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                    |        |
|--------------------|--------|
| Condom programming | 47,064 |
|--------------------|--------|

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 16998                                  |                       |                       |
| <b>Mechanism Name:</b>     | DPS Gaza Province                      |                       |                       |
| <b>Prime Partner Name:</b> | Provincial Directorate of Health, Gaza |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                     | <b>Planned Amount</b> | <b>On Hold Amount</b> |



| Treatment      | HTXS        | 361,440        | 0              |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | PDTX        | 77,860         | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

| <b>Mechanism ID: 16999</b>                                    | <b>Mechanism Name: DPS Nampula Province</b> |
|---|---|
| Funding Agency: HHS/CDC                                       | Procurement Type: Cooperative Agreement     |
| Prime Partner Name: Provincial Directorate of Health, Nampula |   |
| Agreement Start Date: Redacted                                | Agreement End Date: Redacted                |
| TBD: No   | New Mechanism: No                           |
| Global Fund / Multilateral Engagement: N/A                    |   |
| G2G: Yes  | Managing Agency: HHS/CDC                    |
| <b>Total All Funding Sources: 97,325</b>                      |   |
| <b>Applied Pipeline Amount: 0</b>                             |   |
|   |   |
| Funding Source  | Funding Amount                              |
| GHP-State   | 97,325                                      |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)



## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 16999                                     |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | DPS Nampula Province                      |                |                |
| <b>Prime Partner Name:</b> | Provincial Directorate of Health, Nampula |                |                |
| Strategic Area             | Budget Code                               | Planned Amount | On Hold Amount |
| Treatment                  | HTXS                                      | 77,860         | 0              |
| Strategic Area             | Budget Code                               | Planned Amount | On Hold Amount |
| Treatment                  | PDTX                                      | 19,465         | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 17044</b>                         | <b>Mechanism Name: Ministry of Health (MISAU)</b> |
| Funding Agency: HHS/CDC                            | Procurement Type: Cooperative Agreement           |
| Prime Partner Name: Ministry of Health, Mozambique |   |
| Agreement Start Date: Redacted                     | Agreement End Date: Redacted                      |
| TBD: No  | New Mechanism: No                                 |
| Global Fund / Multilateral Engagement: N/A         |   |
| G2G: Yes   | Managing Agency: HHS/CDC                          |

| <b>Total All Funding Sources: 1,374,000</b> |                |
|---|----------------|
| <b>Applied Pipeline Amount: 0</b>           |                |
| Funding Source                              | Funding Amount |
| GHP-State                                   | 1,374,000      |



### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 17044                          |                |                |
|----------------------------|--------------------------------|----------------|----------------|
| <b>Mechanism Name:</b>     | Ministry of Health (MISAU)     |                |                |
| <b>Prime Partner Name:</b> | Ministry of Health, Mozambique |                |                |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Governance and Systems     | HLAB                           | 600,000        | 0              |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Prevention                 | MTCT                           | 200,000        | 0              |
| Strategic Area             | Budget Code                    | Planned Amount | On Hold Amount |
| Treatment                  | HTXS                           | 574,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                            |   |
|----------------------------|---|
| <b>Mechanism ID:</b> 17169 | <b>Mechanism Name:</b> Mozambique Strategic Information Program (M-SIP) |
|----------------------------|---|



|  |                              |
|--|------------------------------|
| Funding Agency: USAID                      | Procurement Type: Contract   |
| Prime Partner Name: John Snow Inc (JSI)    |                              |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted |
| TBD: No                                    | New Mechanism: No            |
| Global Fund / Multilateral Engagement: N/A |                              |
| G2G: No                                    | Managing Agency:             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 875,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 875,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 17169  |                       |                       |
| <b>Mechanism Name:</b>     | Mozambique Strategic Information Program (M-SIP) |                       |                       |
| <b>Prime Partner Name:</b> | John Snow Inc (JSI)                              |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                               | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HKID   | 225,000               | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>                               | <b>Planned Amount</b> | <b>On Hold Amount</b> |

| Prevention     | MTCT        | 100,000        | 0              |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment      | HTXS        | 550,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 17171</b>                          | <b>Mechanism Name: N"weti - Strengthening Civil Society Engagement to Improve Sexual and Reproductive Health and Service Delivery for Youth</b> |
| Funding Agency: USAID                               | Procurement Type: Contract  |
| Prime Partner Name: N'WETI - Comunicação para Saúde |   |
| Agreement Start Date: Redacted                      | Agreement End Date: Redacted  |
| TBD: No   | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A          |   |
| G2G: No   | Managing Agency:  |

| <b>Total All Funding Sources: 1,104,424</b> |                |
|---|----------------|
| <b>Applied Pipeline Amount: 0</b>           |                |
|   |                |
| Funding Source                              | Funding Amount |
| GHP-State                                   | 1,104,424      |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|                    |         |
|--------------------|---------|
| Condom programming | 105,202 |
| Gender: GBV        | 400,000 |

|                         |   |
|-------------------------|---|
| Focus Area:             | GBV Prevention  |
| Sub Area:               | Implementation  |
| Gender: Gender Equality | 400,000   |
| Focus Area:             | Changing harmful gender norms and promoting positive gender norms         |
| Sub Area:               | Monitoring and Evaluation   |
| Focus Area:             | Promoting gender-related policies and laws that increase legal protection |
| Sub Area:               | Implementation  |
| Focus Area:             | Equity in HIV prevention, care, treatment and support                     |
| Sub Area:               | Monitoring and Evaluation   |

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 17171  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | N"weti - Strengthening Civil Society Engagement to Improve Sexual and Reproductive Health and Service Delivery for Youth |                |                |
| <b>Prime Partner Name:</b> | N'WETI - Comunicação para Saúde  |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HBHC   | 995,591        | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 108,833        | 0              |

## Implementing Mechanism Indicator Information



| Indicator Number | Label   | 2015  | 2016  |
|------------------|---|-------|-------|
| PP_PREV_DSD      | Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.  | 5,699 |       |
| PP_PREV_DSD      | Age/sex: 10-14 Male   | 445   |       |
| PP_PREV_DSD      | Age/sex: 15-19 Male   | 684   |       |
| PP_PREV_DSD      | Age/sex: 20-24 Male   | 347   |       |
| PP_PREV_DSD      | Age/sex: 25-49 Male   | 302   |       |
| PP_PREV_DSD      | Age/sex: 50+ Male   | 40    |       |
| PP_PREV_DSD      | Age/sex: 10-14 Female   | 1,112 |       |
| PP_PREV_DSD      | Age/sex: 15-19 Female   | 1,847 |       |
| PP_PREV_DSD      | Age/sex: 20-24 Female   | 826   |       |
| PP_PREV_DSD      | Age/sex: 25-49 Female   | 96    |       |
| PP_PREV_DSD      | Sum of Age/Sex disaggregates  | 5,699 |       |
| HTC_TST_DSD      | Number of individuals who received T&C services for HIV and received their test results during the past 12 months   | 1,000 | 7,599 |
| FPINT_SITE_DSD   | Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services  | 2     |       |
| FPINT_SITE_DSD   | Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment   | 2     |       |
| FPINT_SITE_DSD   | By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services | 2     |       |
| FPINT_SITE_DSD   | Sum of Numerator Site Support Type disaggregates  | 2     |       |
| FPINT_SITE_DSD   | By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported   | 2     |       |

|                |  |   |  |
|----------------|--|---|--|
|                | HIV service delivery points                        |   |  |
| FPINT_SITE_DSD | Sum of Denominator Site Support Type disaggregates | 2 |  |
| FPINT_SITE_TA  | Sum of Denominator Site Support Type disaggregates | 2 |  |
| FPINT_SITE_TA  | Sum of Numerator Site Support Type disaggregates   | 2 |  |

### Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 17259</b>                 | <b>Mechanism Name: Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS</b> |
| Funding Agency: USAID                      | Procurement Type: Grant   |
| Prime Partner Name: JEMBI                  |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted  |
| TBD: No                                    | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 17259  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Fortalecimento do Sistema de Monitoria e Avaliacao do MMAS |                |                |
| <b>Prime Partner Name:</b> | JEMBI  |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HKID   | 0              | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID:</b> 17260   | <b>Mechanism Name:</b> Esperança de Vida |
| Funding Agency: USAID  | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã |  |
| Agreement Start Date: Redacted   | Agreement End Date: Redacted             |
| TBD: No  | New Mechanism: No                        |
| Global Fund / Multilateral Engagement: N/A   |  |
| G2G: No  | Managing Agency:                         |

| <b>Total All Funding Sources:</b> 502,004 |                |
|---|----------------|
| <b>Applied Pipeline Amount:</b> 0         |                |
| Funding Source                            | Funding Amount |
| GHP-State                                 | 502,004        |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                         |  |
|-------------------------|--|
| Condom procurement      | 32,694   |
| Economic Strengthening  | 70,000   |
| Education               | 80,000   |
| Gender: Gender Equality | 50,000   |
| Focus Area:             | Promoting gender-related policies and laws that increase legal protection                |
| Sub Area:               | Implementation   |
| Focus Area:             | Increase gender-equitable access to income and productive resources, including education |
| Focus Area:             | Equity in HIV prevention, care, treatment and support                                    |

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 17260  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Esperança de Vida  |                |                |
| <b>Prime Partner Name:</b> | REENCONTRO - Associação Moçambicana Para Apoio e Desenvolvimento da Criança Orfã |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HBHC   | 309,259        | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HKID   | 158,923        | 0              |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Prevention                 | HVOP   | 33,822         | 0              |

## Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015  | 2016  |
|------------------|---|-------|-------|
| OVC_ACC_DSD      | Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services            | 1,273 | 1,577 |
| OVC_SERV_DSD     | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 5,093 | 6,306 |
| OVC_SERV_DSD     | Sex: Male   | 2,546 |       |
| OVC_SERV_DSD     | Sex: Female   | 2,546 |       |
| OVC_SERV_DSD     | Sum of Sex disaggregates  | 5,092 |       |

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 17261</b>  | <b>Mechanism Name: Improving Integrated HIV Homecare Services</b> |
| Funding Agency: USAID   | Procurement Type: Grant   |
| Prime Partner Name: Associacao Nacional dos Enfermeiros de Mocambique (ANEMO) |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted                                      |
| TBD: No   | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A                                    |   |
| G2G: No   | Managing Agency:  |

|                                     |                       |
|-------------------------------------|-----------------------|
| <b>Total All Funding Sources: 0</b> |                       |
| <b>Applied Pipeline Amount: 0</b>   |                       |
|                                     |                       |
| <b>Funding Source</b>               | <b>Funding Amount</b> |
| GHP-State                           | 0                     |

## Sub Partner Name(s)

(No data provided.)



## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 17261   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | Improving Integrated HIV Homecare Services                |                |                |
| <b>Prime Partner Name:</b> | Associacao Nacional dos Enfermeiros de Mocambique (ANEMO) |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Care                       | HBHC  | 0              | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|   |   |
|---|---|
| <b>Mechanism ID: 17567</b>  | <b>Mechanism Name: NASTAD</b>           |
| Funding Agency: HHS/CDC   | Procurement Type: Cooperative Agreement |
| Prime Partner Name: National Alliance of State and Territorial AIDS Directors |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                                    |   |
| G2G: No   | Managing Agency:                        |

| <b>Total All Funding Sources: 890,370</b> |                |
|---|----------------|
| <b>Applied Pipeline Amount: 0</b>         |                |
| Funding Source                            | Funding Amount |
| GHP-State                                 | 890,370        |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

(No data provided.)

### Key Issues

(No data provided.)

### Budget Code Information

| <b>Mechanism ID:</b>       | 17567   |                |                |
|----------------------------|---|----------------|----------------|
| <b>Mechanism Name:</b>     | NASTAD  |                |                |
| <b>Prime Partner Name:</b> | National Alliance of State and Territorial AIDS Directors |                |                |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Governance and Systems     | OHSS  | 180,000        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | HTXS  | 350,370        | 0              |
| Strategic Area             | Budget Code   | Planned Amount | On Hold Amount |
| Treatment                  | PDTX  | 360,000        | 0              |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                            |  |
|----------------------------|--|
| <b>Mechanism ID:</b> 17571 | <b>Mechanism Name:</b> Nursing Capacity Building |
|----------------------------|--|



|   |   |
|---|---|
|   | <b>Program</b>                          |
| Funding Agency: HHS/HRSA  | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Columbia University Mailman School of Public Health |   |
| Agreement Start Date: Redacted  | Agreement End Date: Redacted            |
| TBD: No   | New Mechanism: No                       |
| Global Fund / Multilateral Engagement: N/A                              |   |
| G2G: No   | Managing Agency:                        |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 100,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 100,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |         |
|----------------------------|---------|
| Human Resources for Health | 100,000 |
|----------------------------|---------|

### Key Issues

(No data provided.)

### Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 17571   |                       |                       |
| <b>Mechanism Name:</b>     | Nursing Capacity Building Program                   |                       |                       |
| <b>Prime Partner Name:</b> | Columbia University Mailman School of Public Health |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                                  | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Governance and             | OHSS  | 100,000               | 0                     |





|         |  |  |  |
|---------|--|--|--|
| Systems |  |  |  |
|---------|--|--|--|

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 17591</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 17652</b>                   | <b>Mechanism Name: Food Security Innovation Lab: Collaborative Research on Assets and Market Access</b> |
| Funding Agency: USAID                        | Procurement Type: Cooperative Agreement   |
| Prime Partner Name: University of California |   |
| Agreement Start Date: Redacted               | Agreement End Date: Redacted  |
| TBD: No                                      | New Mechanism: No   |
| Global Fund / Multilateral Engagement: N/A   |   |
| G2G: No                                      | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 250,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 250,000               |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

|           |        |
|-----------|--------|
| Education | 50,000 |
|-----------|--------|



|                         |  |
|-------------------------|--|
| Economic Strengthening  | 50,000   |
| Gender: Gender Equality | 50,000   |
| Focus Area:             | Increase gender-equitable access to income and productive resources, including education |
| Sub Area:               | Monitoring and Evaluation  |

## Key Issues

(No data provided.)

## Budget Code Information

| <b>Mechanism ID:</b>       | 17652  |                |                |
|----------------------------|--|----------------|----------------|
| <b>Mechanism Name:</b>     | Food Security Innovation Lab: Collaborative Research on Assets and |                |                |
| <b>Prime Partner Name:</b> | Market Access  |                |                |
|                            | University of California   |                |                |
| Strategic Area             | Budget Code  | Planned Amount | On Hold Amount |
| Care                       | HKID   | 250,000        | 0              |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 17723</b>                 | <b>Mechanism Name: Support for the Mozambican Armed Forces in the Fight against HIV/AIDS</b> |
| Funding Agency: DOD                        | Procurement Type: Cooperative Agreement  |
| Prime Partner Name: JHPIEGO                |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted   |
| TBD: No                                    | New Mechanism: No  |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:   |



|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 2,462,147</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 2,462,147             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                           |         |
|---------------------------|---------|
| Motor Vehicles: Purchased | 600,000 |
|---------------------------|---------|

### Key Issues

(No data provided.)

### Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 17723  |                       |                       |
| <b>Mechanism Name:</b>     | Support for the Mozambican Armed Forces in the Fight against |                       |                       |
| <b>Prime Partner Name:</b> | HIV/AIDS   |                       |                       |
|                            | JHPIEGO  |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>   | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | CIRC   | 2,462,147             | 0                     |

### Implementing Mechanism Indicator Information

| Indicator Number | Label   | 2015   | 2016 |
|------------------|---|--------|------|
| VMMC_CIRC_DSD    | Number of males circumcised as part of the voluntary medical male circumcision (VMMC) | 25,624 |      |

|               |   |        |  |
|---------------|---|--------|--|
|               | for HIV prevention program within the reporting period  |        |  |
| VMMC_CIRC_DSD | By Age: 10-14   | 10,250 |  |
| VMMC_CIRC_DSD | By Age: 15-19   | 7,687  |  |
| VMMC_CIRC_DSD | By Age: 20-24   | 5,125  |  |
| VMMC_CIRC_DSD | By Age: 25-49   | 2,050  |  |
| VMMC_CIRC_DSD | By Age: 50+   | 512    |  |
| VMMC_CIRC_DSD | Sum of age disaggregates  | 25,624 |  |
| HTC_TST_DSD   | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 38,390 |  |

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 18099</b>                 | <b>Mechanism Name: Linkages Across the Continuum of HIV Services for Key Populations</b> |
| Funding Agency: USAID                      | Procurement Type: Contract   |
| Prime Partner Name: FHI 360                |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted   |
| TBD: No                                    | New Mechanism: Yes   |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:   |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 1,555,770</b> |                       |
| <b>Applied Pipeline Amount: 0</b>           |                       |
|   |                       |
| <b>Funding Source</b>                       | <b>Funding Amount</b> |
| GHP-State                                   | 1,555,770             |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                    |        |
|--------------------|--------|
| Condom programming | 96,664 |
|--------------------|--------|



|                             |   |
|-----------------------------|---|
| Key Populations: FSW        | 780,000   |
| Focus Area:                 | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention              |
| Focus Area:                 | Training of health workers and community outreach workers   |
| Focus Area:                 | Collection and use of strategic information on SWs and clients  |
| Focus Area:                 | Monitoring and evaluation of SW programs  |
| Focus Area:                 | Procurement of condoms, lubricants, and other commodities essential to core HIV services for SWs                              |
| Key Populations: MSM and TG | 520,000   |
| Focus Area:                 | Training of health workers and community outreach workers   |
| Focus Area:                 | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area:                 | Collection and use of strategic information   |
| Focus Area:                 | Monitoring and evaluation of MSM/TG programs  |
| Focus Area:                 | Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG                           |

## Key Issues

(No data provided.)

## Budget Code Information

|                            |   |                       |                       |
|----------------------------|---|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 18099   |                       |                       |
| <b>Mechanism Name:</b>     | Linkages Across the Continuum of HIV Services for Key Populations |                       |                       |
| <b>Prime Partner Name:</b> | FHI 360   |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>  | <b>Planned Amount</b> | <b>On Hold Amount</b> |

|                       |                    |                       |                       |
|-----------------------|--------------------|-----------------------|-----------------------|
|                       |                    |                       |                       |
| Prevention            | HVOP               | 1,155,343             | 0                     |
| <b>Strategic Area</b> | <b>Budget Code</b> | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment             | HTXS               | 400,427               | 0                     |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18100</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |

## Implementing Mechanism Details

|  |   |
|--|---|
| <b>Mechanism ID: 18101</b>                 | <b>Mechanism Name: Maternal and Child Survival Program (MCSP)</b> |
| Funding Agency: USAID                      | Procurement Type: Cooperative Agreement                           |
| Prime Partner Name: JHPIEGO                |   |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                                      |
| TBD: No                                    | New Mechanism: Yes  |
| Global Fund / Multilateral Engagement: N/A |   |
| G2G: No                                    | Managing Agency:  |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 500,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 500,000               |

## Sub Partner Name(s)

(No data provided.)



## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |  |                       |                       |
|----------------------------|--|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | 18101                                      |                       |                       |
| <b>Mechanism Name:</b>     | Maternal and Child Survival Program (MCSP) |                       |                       |
| <b>Prime Partner Name:</b> | JHPIEGO                                    |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>                         | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Care                       | HBHC                                       | 500,000               | 0                     |

## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18102</b> | <b>TBD: Yes</b> |
| REDACTED                   |                 |

## Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18103</b> | <b>TBD: Yes</b> |
| REDACTED                   |                 |

## Implementing Mechanism Details



|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18104</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |

### Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18108</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |

### Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID: 18110</b>                 | <b>Mechanism Name: ARC - Nursing Council</b> |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement      |
| Prime Partner Name: New Partner            |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                 |
| TBD: No                                    | New Mechanism: Yes                           |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:                             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources: 100,000</b> |                       |
| <b>Applied Pipeline Amount: 0</b>         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 100,000               |

### Sub Partner Name(s)

(No data provided.)

### Cross-Cutting Budget Attribution(s)

|                            |        |
|----------------------------|--------|
| Human Resources for Health | 94,644 |
|----------------------------|--------|

### Key Issues



(No data provided.)

### Budget Code Information

|                            |                              |                       |                       |
|----------------------------|------------------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b>       | <b>18110</b>                 |                       |                       |
| <b>Mechanism Name:</b>     | <b>ARC - Nursing Council</b> |                       |                       |
| <b>Prime Partner Name:</b> | <b>New Partner</b>           |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>           | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | HVCT                         | 10,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>           | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Prevention                 | MTCT                         | 10,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>           | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS                         | 40,000                | 0                     |
| <b>Strategic Area</b>      | <b>Budget Code</b>           | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | PDTX                         | 40,000                | 0                     |

### Implementing Mechanism Indicator Information

(No data provided.)

### Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18112</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |

### Implementing Mechanism Details

|                            |                 |
|----------------------------|-----------------|
| <b>Mechanism ID: 18120</b> | <b>TBD: Yes</b> |
| <b>REDACTED</b>            |                 |



## Implementing Mechanism Details

|  |  |
|--|--|
| <b>Mechanism ID:</b> 18121                 | <b>Mechanism Name:</b> Transition Monitoring |
| Funding Agency: HHS/CDC                    | Procurement Type: Cooperative Agreement      |
| Prime Partner Name: ICF Macro              |  |
| Agreement Start Date: Redacted             | Agreement End Date: Redacted                 |
| TBD: No                                    | New Mechanism: Yes                           |
| Global Fund / Multilateral Engagement: N/A |  |
| G2G: No                                    | Managing Agency:                             |

|   |                       |
|---|-----------------------|
| <b>Total All Funding Sources:</b> 410,000 |                       |
| <b>Applied Pipeline Amount:</b> 0         |                       |
|   |                       |
| <b>Funding Source</b>                     | <b>Funding Amount</b> |
| GHP-State                                 | 410,000               |

## Sub Partner Name(s)

(No data provided.)

## Cross-Cutting Budget Attribution(s)

(No data provided.)

## Key Issues

(No data provided.)

## Budget Code Information

|                            |                       |                       |                       |
|----------------------------|-----------------------|-----------------------|-----------------------|
| <b>Mechanism ID:</b> 18121 |                       |                       |                       |
| <b>Mechanism Name:</b>     | Transition Monitoring |                       |                       |
| <b>Prime Partner Name:</b> | ICF Macro             |                       |                       |
| <b>Strategic Area</b>      | <b>Budget Code</b>    | <b>Planned Amount</b> | <b>On Hold Amount</b> |
| Treatment                  | HTXS                  | 410,000               | 0                     |



## Implementing Mechanism Indicator Information

(No data provided.)

## Implementing Mechanism Details

|                     |          |
|---------------------|----------|
| Mechanism ID: 18122 | TBD: Yes |
| REDACTED            |          |

## Implementing Mechanism Details

|                     |          |
|---------------------|----------|
| Mechanism ID: 18123 | TBD: Yes |
| REDACTED            |          |

## Agency Information - Costs of Doing Business

### U.S. Agency for International Development

| Agency Cost of Doing Business                | GAP      | GHP-State        | GHP-USAID | Cost of Doing Business Category Total | Applied Pipeline |
|--|----------|------------------|-----------|---------------------------------------|------------------|
| Computers/IT Services                        |          | 0                |           | 0                                     | 256,951          |
| ICASS  |          | 1,347,593        |           | 1,347,593                             | 643,451          |
| Indirect Costs                               |          | 0                |           | 0                                     | 0                |
| Institutional Contractors                    |          | 0                |           | 0                                     | 573,412          |
| Management Meetings/Professional Development |          | 0                |           | 0                                     | 96,324           |
| Non-ICASS Administrative Costs               |          | 0                |           | 0                                     | 124,520          |
| Staff Program Travel                         |          | 0                |           | 0                                     | 634,567          |
| USG Staff Salaries and Benefits              |          | 0                |           | 0                                     | 4,223,182        |
| <b>Total</b>                                 | <b>0</b> | <b>1,347,593</b> | <b>0</b>  | <b>1,347,593</b>                      | <b>6,552,407</b> |

### U.S. Department of Defense

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Cost of Doing Business Category Total | Applied Pipeline |
|-------------------------------|-----|-----------|-----------|---------------------------------------|------------------|
| ICASS                         |     | 74,451    |           | 74,451                                | 0                |
| Management                    |     | 17,944    |           | 17,944                                | 0                |



|                                   |          |                |          |                |          |
|-----------------------------------|----------|----------------|----------|----------------|----------|
| Meetings/Professional Development |          |                |          |                |          |
| Non-ICASS Administrative Costs    |          | 10,351         |          | 10,351         | 0        |
| Staff Program Travel              |          | 40,976         |          | 40,976         | 0        |
| USG Staff Salaries and Benefits   |          | 125,653        |          | 125,653        | 0        |
| <b>Total</b>                      | <b>0</b> | <b>269,375</b> | <b>0</b> | <b>269,375</b> | <b>0</b> |

#### U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

| Agency Cost of Doing Business   | GAP              | GHP-State         | GHP-USAID | Cost of Doing Business Category Total | Applied Pipeline |
|---------------------------------|------------------|-------------------|-----------|---------------------------------------|------------------|
| Capital Security Cost Sharing   |                  | 532,812           |           | 532,812                               | 0                |
| Computers/IT Services           |                  | 657,505           |           | 657,505                               | 0                |
| ICASS                           |                  | 2,686,414         |           | 2,686,414                             | 0                |
| Non-ICASS Administrative Costs  |                  | 2,024,145         |           | 2,024,145                             | 0                |
| Staff Program Travel            |                  | 1,424,770         |           | 1,424,770                             | 0                |
| USG Staff Salaries and Benefits | 3,075,000        | 4,325,042         |           | 7,400,042                             | 0                |
| <b>Total</b>                    | <b>3,075,000</b> | <b>11,650,688</b> | <b>0</b>  | <b>14,725,688</b>                     | <b>0</b>         |

### U.S. Department of State

| Agency Cost of Doing Business                | GAP      | GHP-State        | GHP-USAID | Cost of Doing Business Category Total | Applied Pipeline |
|--|----------|------------------|-----------|---------------------------------------|------------------|
| Computers/IT Services                        |          | 10,915           |           | 10,915                                | 0                |
| ICASS  |          | 268,510          |           | 268,510                               | 0                |
| Indirect Costs                               |          | 12,360           |           | 12,360                                | 0                |
| Management Meetings/Professional Development |          | 40,308           |           | 40,308                                | 0                |
| Non-ICASS Administrative Costs               |          | 60,720           |           | 60,720                                | 0                |
| Staff Program Travel                         |          | 180,950          |           | 180,950                               | 0                |
| USG Staff Salaries and Benefits              |          | 1,121,827        |           | 1,121,827                             | 0                |
| <b>Total</b>                                 | <b>0</b> | <b>1,695,590</b> | <b>0</b>  | <b>1,695,590</b>                      | <b>0</b>         |

### U.S. Peace Corps

| Agency Cost of Doing Business  | GAP | GHP-State | GHP-USAID | Cost of Doing Business Category Total | Applied Pipeline |
|--------------------------------|-----|-----------|-----------|---------------------------------------|------------------|
| Non-ICASS Administrative Costs |     | 324,017   |           | 324,017                               | 0                |
| Peace Corps Volunteer Costs    |     | 1,747,914 |           | 1,747,914                             | 0                |
| Staff Program Travel           |     | 107,588   |           | 107,588                               | 0                |
| USG Staff Salaries             |     | 498,034   |           | 498,034                               | 0                |



|              |          |                  |          |                  |          |
|--------------|----------|------------------|----------|------------------|----------|
| and Benefits |          |                  |          |                  |          |
| <b>Total</b> | <b>0</b> | <b>2,677,553</b> | <b>0</b> | <b>2,677,553</b> | <b>0</b> |